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The APOPEC3 family of cytidine deaminases play an important role in host mediated 
antiviral defence against retroelements, including HIV-1. Although much has been 
discerned regarding the anti-viral nature of these proteins, their cellular function, as well 
as mechanisms of functional regulation and cellular co-factors, remains poorly defined. 
To address this, several cellular proteins that interact with APOBEC3G (A3G) have 
now been identified. The most intriguing of these are the Argonaute proteins, as the 
interaction is at least partially resistant to RNase treatment.  The Argonautes are integral 
components of RISC, which is involved in miRNA mediated translational repression 
and mRNA decay. Components of this pathway, as well as A3G and silenced mRNAs 
have been shown to localise to discrete cytoplasmic foci termed mRNA Processing (P) 
Bodies. These foci have very recently been implicated in influencing viral life cycles. 
However, the functional relevance of the interaction with the Argonaute proteins and 
localisation to P-bodies, to APOBEC3 anti-viral and cellular activity is currently 
unknown and therefore was investigated in more detail. 
It has been found that the ability of the APOBEC3 proteins to interact with Argonaute 2 
does not closely correlate with their anti-viral phenotypes. Further, knockdown of 
Argonaute 2 did not impact upon APOBEC3 mediated viral inhibition, suggesting that 
this cellular protein is not required for this process. Conversely, the role of APOBEC3 
proteins in the regulation of cellular RNA was also examined. However, the APOBEC3 
proteins did not specifically affect the post-transcriptional regulatory pathways of 
miRNA mediated repression, siRNA mediated silencing or ARE mediated decay. 
Localisation of APOBEC3 proteins to mRNA Processing bodies, on the other hand, 
does correlate with their anti-viral activities, implying that subcellular localisation may 
be important for viral inhibition. However, depletion of P-bodies through knockdown of 
DDX6 and Lsm1, did not affect APOBEC3 restriction of HIV-1 or replication of HIV-1 
in general. In sum, P-body associated proteins do not appear to regulate APOBEC3 
anti-viral activity and thus may be more relevant to an as yet unidentified cellular 
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1.1 Introduction to retroelements 
1.1.1 Retroviruses 
Human immunodeficiency virus type-1 (HIV-1) is a lentivirus belonging to the 
retrovirus family. Retroviruses are distinguished by two unique steps in their life cycle. 
Firstly, the reverse transcription of their RNA genome into a DNA copy and secondly, 
the integration of this DNA into the genome of the infected host cell, thus establishing a 
provirus which enables the production of viral RNA and proteins. There are seven 
genera of retroviruses (alpha, beta, gamma, delta, epsilon, lenti and spuma viruses), 
classified according to several criteria including core morphology, genome organisation 
and site of viral assembly. Gammaviruses, such as murine leukaemia virus (MLV), are 
considered simple retroviruses as they only encode the gag, pol and env genes, whereas 
complex retroviruses, such as lentiviruses, harbour additional genes encoding accessory 
proteins that are essential for viral replication (Goff, 2001).  
1.1.2 Retrotransposons 
In addition to exogenous retroviruses, endogenous retroelements are also present in the 
genomes of eukaryotes. These are host encoded DNA sequences that are able to convert 
their DNA into an RNA intermediate, which is reverse transcribed, and thus duplicated 
before re-integration back into the genome.  
Two main classes of retroelements have been delineated, containing either long terminal 
repeats (LTRs) at their 3’ and 5’ ends (LTR retrotransposons) or not (non-LTR 
retrotransposons). Examples of the former include the Ty elements in yeast, the 
intracisternal A particles (IAPs) and MusD elements in mice and the human endogenous 
retroviruses (HERVs) in humans. These retrotransposons are similar in structure to 
retroviruses as they encode a viral particle coat protein (Gag) as well as the enzymes 
necessary for reverse transcription (RT) and integration (IN) to facilitate autonomous 
retrotransposition. However they lack a functional envelope protein, which restricts 
their intercellular movement and means retrotransposition events are limited to the 
genome from which they originate.  
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The most well known non-LTR retroelements are the autonomous long interspersed 
nucleotide elements-1 (LINE-1s). LINE-1s contain two open reading frames, both of 
which are required for successful retrotransposition (Ostertag and Kazazian, 2001). The 
first of these, ORF1p (open reading frame-1p), encodes a nucleic acid binding protein 
which is able to form ribonucleoprotein complexes in both human and mouse cells 
(Doucet et al., 2010; Kulpa and Moran, 2005). It also possesses nucleic acid chaperone 
activity (Martin et al., 2005). The second, ORF2p (open reading frame-2p), has both 
endonuclease and reverse transcriptase enzymatic activity (Feng et al., 1996a; Moran et 
al., 1996). These elements retrotranspose through a process termed target primed 
reverse transcription (TPRT) whereby the nuclear genomic DNA is nicked by the 
ORF2p endonuclease, exposing a free 3’ hydroxyl end. This is then used as the primer, 
and the RNA as the template, for reverse transcriptase to generate a cDNA copy of the 
LINE-1 transcript directly on the DNA. One strand is first integrated before it is used as 
the template for generation of the second strand. The LINE-1 elements have cis 
preference wherein they will preferentially act on the RNA which encodes them. 
However the non-autonomous SINE (short interspersed nucleotide elements) 
retrotransposons are able to hijack the LINE-1 machinery to promote their own 
replication which demonstrates that LINE elements are also able to work on sequences 
in trans. This has ensured the survival and success of SINEs as the human Alu element, 
originally derived from 7SL RNA, is believed to comprise up to 11% of the human 
genome (Kazazian, 2004).  
LINE-1s are thought to comprise approximately 17% of the human genome, yet only 80 
- 100 of these elements are currently active (Sassaman et al., 1997). The potential for 
retrotransposition to cause serious genetic mutation via these gene insertion events is 
immense and potentially problematic for the stability of the genome. Disease induced 
mutations, including cancers, have been documented, (Boissinot et al., 2001; Kazazian, 
2004) and Alu retrotransposition events account for almost 0.3% of all human genetic 
diseases [reviewed in (Cordaux and Batzer, 2009)]. In defence, cellular control 
mechanisms have been established to limit the deleterious effects of these mobile 
elements. Transcriptional inactivation by DNA methylation is one such mechanism 
(Hata and Sakaki, 1997), as is utilisation of the RNAi pathway whereby small 
interfering RNAs produced from bi-directional transcription are used to silence the 
encoded transcripts. Knockdown of Dicer, the enzyme responsible for biogenesis of 
  
  22 
these small non-coding RNAs, leads to an increase in retrotransposition events in both 
human cultured cells and mouse embryos (Svoboda et al., 2004; Yang and Kazazian, 
2006). Finally, cellular proteins may also mediate suppression of retrotransposon 
activity. One such group of proteins are the APOBEC3 family of cytidine deaminases 
whose members have been implicated in the inhibition of both LINE-1 and Alu 
retrotransposition [reviewed in (Chiu and Greene, 2008)]. The inhibitory effect of these 
proteins can be extended to other retroelements, as well as other viruses and this will be 
discussed in greater depth in subsequent sections.  
 
1.2 Introduction to HIV-1 
1.2.1 Origin of HIV-1 
In 1983, HIV-1 was isolated and a year later identified as the causative agent of 
acquired immunodeficiency syndrome (AIDS) (Barre-Sinoussi et al., 1983; Gallo et al., 
1984). Worldwide, HIV-1 has caused approximately 25 million deaths and in 2008 33 
million people were estimated to be infected, with the majority of the disease burden in 
sub-saharan Africa (UNAIDS, 2009). HIV-1 arose as a result of a cross-species 
zoonosis, transmitted from chimpanzees to humans on three separate occasions, giving 
rise to the three different HIV-1 lineages, M (cause of the global AIDS pandemic), N 
(which is restricted to Cameroon) and O (restricted to central-west Africa) (Gao et al., 
1999; Keele et al., 2006; Van Heuverswyn et al., 2006). A fourth subtype, designated P, 
has also been reported and appears to be more closely related to simian 
immunodeficiency virus (SIV) from gorillas (SIVgor), which may also be the source of 
group O (Van Heuverswyn et al., 2006). A related yet distinct virus, termed HIV-2, 
primarily found circulating in West Africa gives a similar disease phenotype to HIV-1 
but with slower progression (Clavel et al., 1986). This virus is thought to have arisen in 
humans from multiple cross species transmission events of SIV from sooty mangabeys 
(SIVsm). In general, SIVs do not cause disease in their natural hosts, but it has recently 
been shown that infected wild chimpanzees may be subject to increased mortality and 





1.2.2 HIV-1 pathogenesis 
HIV-1 disease and progression to AIDS is characterised by a severe depletion of 
activated CD4+ T cells, which are the primary targets of productive HIV-1 infection in 
vivo. Specifically it is mucosal CD4+ memory T cells which are primarily targeted and 
the virus is then able to spread as these cells migrate through lymphoid tissues. Viral 
dissemination is also facilitated by dendritic cells. Although these cells cannot be 
productively infected, due to an inherent block to viral replication, they do express CD4 
and can capture virus on their surface and present it to CD4+ T cells. This is reflected in 
the fact that lymph nodes contain 5 – 10 fold more infected cells than the peripheral 
blood. The acute stage of HIV-1 infection is also associated with very high viral loads 
(Cohen and Fauci, 2001).  
However, direct infection of CD4+ T cells does not appear to be the predominant cause 
of the depletion of these cells and progression to AIDS. A major contributory factor 
may in fact be general immune activation, which is associated with early HIV-1 
infection. This results in increased frequencies of T cells displaying activating and 
memory markers, as well as increased pro-inflammatory cytokines and increased 
turnover of a number of other immune related cell types. This therefore provides a fresh 
pool of HIV-1 target cells to maintain the infection [reviewed in (Grossman et al., 
2006)]. 
Following the initial or acute stages of infection, the viral load appears to stabilise and 
virus production is also levelled through rapid clearance by CD8+ cytotoxic T 
lymphocytes (CTLs). However the slow but steady decline of the CD4+ T cell 
population continues and after a number of years eventually falls below a critical 
threshold required for efficient cell mediated immune responses. This signifies the onset 
of AIDS and infected individuals are highly susceptible to infections by opportunistic 
pathogens, which often prove fatal (Cohen and Fauci, 2001).  
The persistence of latently infected cells, those that harbour provirus but do not express 
viral proteins as they are in a resting state, represents a significant barrier to the 






1.2.3 HIV-1 therapeutics 
There is currently no cure for HIV-1 and although there has been considerable 
investment in the development of a protective vaccine, this has so far proved an elusive 
goal. However, the virus can be controlled for an extended period of time through the 
use of combined antiviral drugs, referred to as highly active antiretroviral therapy 
(HAART). These drugs target different viral proteins, namely reverse transcriptase and 
protease, in combination, in an attempt to reduce the potential for the emergence of drug 
resistant strains. They also act to reduce viral loads thereby minimising the chances of 
generating resistance mutations. However, the mutagenic capacity of HIV-1 is immense 
due to the error prone nature of the reverse transcriptase enzyme, which causes 3.4 x 10-
5 nucleotide changes per site per replication cycle, and its ability to induce 
recombination of the viral genome (Freed and Martin, 2001). Thus the identification of 
new drug targets is an area of intense research and drugs that interfere with viral entry 
and integration have also now been developed. However, targeting cellular proteins may 
be a more attractive route since they are less likely to mutate and thus contribute to drug 
resistance. Two types of cellular proteins may make ideal drug targets. Firstly those that 
are utilised by the virus in order to complete its life cycle and thus are necessary for 
virus replication. Numerous examples have now been documented, such as Cyclin T, 
LEDGF and the ESCRT proteins and these will be discussed in more detail in the 
ensuing sections. The second class of proteins are those that act to inhibit virus 
replication, so called restriction factors, that form part of the innate (or intrinsic) 
immune defence system (see section 1.6). Mechanisms to enhance or mimic the activity 
of these proteins may significantly aid natural immune responses to viral infection. 
Therefore the need to thoroughly understand the relevance of these proteins for viral 
replication and more importantly, how perturbing these proteins may affect cellular 
functioning is paramount and will dramatically contribute to future attempts to control 







1.3 HIV-1 genome organisation 
HIV-1 has a diploid genome, comprised of two 9 kb long positive sense, single stranded 
RNA molecules. Akin to most cellular mRNAs, these RNAs are both capped at their 5’ 
end and polyadenylated at their 3’end. 
The RNA genome contains several cis acting elements that are essential for the 
successful replication of the virus and production of infectious progeny virions (Figure 
1.1A). These include the Ψ packaging signal for virion incorporation, the primer 
binding site (PBS) for initiation of reverse transcription, the polypurine tract (PPT) for 
plus strand DNA synthesis, the Rev response element (RRE) involved in nuclear export 
and the transactivating response region (TAR) involved in transcription elongation 
(Freed and Martin, 2001). 
The resulting mRNA transcript encodes for fifteen proteins produced from nine open 
reading frames. The group specific antigen (gag), polymerase (pol) and envelope (env) 
genes are common to all retroviruses (Figure 1B). However, being a complex retrovirus, 
HIV-1 also encodes six additional genes, for the regulatory proteins Tat and Rev and the 
accessory proteins, Vif, Vpr, Vpu and Nef [reviewed in (Swanson and Malim, 2008)] 
(Figure 1C). The varying and essential functions of these genes will be outlined in the 
following sections.   
The genomic RNA is used as the template for reverse transcription, whereby a DNA 
copy is produced that is subsequently integrated into the host genome, termed the 
provirus. This provirus is transcribed by host cellular machinery to produce RNA 
transcripts that are either translated to produce viral proteins or else packaged into 
nascent virions, thus initiating the next round of infection. The establishment of the 
provirus confers several advantages to HIV-1 and other retroviruses to secure their 
successful propagation. It not only ensures that viral gene products are continually 
produced throughout the lifetime of the cell but also allows for vertical transmission of 




Figure 1.1: Genetic organisation of HIV-1 and MLV. 
A. Schematic diagram of the HIV-1 RNA genome, displaying several cis acting elements including the 
transactivating response (TAR) stem loop structure, the primer binding site (PBS), the Ψ packaging signal, 
the Rev response element (RRE) and the polypurine tract (PPT), as well as an additional central PPT 
(cPPT). Adapted from (Freed and Martin, 2001). B. The genome of the simple gammaretrovirus, murine 
leukaemia virus (MLV), encodes the Gag, Pol and Env proteins. Adapted from (Freed and Martin, 2001). 
C. The complex retrovirus, HIV-1, additionally encodes the accessory proteins Vif, Vpr, Vpu, and Nef 
and the regulatory proteins Tat and Rev. The Gag polyprotein is cleaved to generate the Matrix (MA), 
Capsid (CA), spacer protein 2 (p2), Nucleocapsid (NC), spacer peptide 1 (p1) and p6. Pol is synthesised 
as a Gag-Pol polyprotein by ribosomal frameshift and is cleaved to generate the viral Protease (PR), 
Reverse transcriptase (RT) and Integrase (IN) proteins. The Env protein contains an N-terminal signal 
peptide sequence and is cleaved to generate the gp120/Subunit (SU) and gp41/Transmembrane (TU) 





1.4 HIV-1 life cycle 
1.4.1 Overview 
To ensure the production of infectious progeny virions, HIV-1 must first successfully 
complete its life cycle within the host cell. There are numerous steps involved in this 
pathway, starting with attachment and entry into the target cell, followed by uncoating 
of the viral core, reverse transcription of the RNA genome into a DNA form, integration, 
transcription, nuclear export of the mRNA, translation in the cytoplasm, assembly of 
viral particles, budding and release (Figure 1.2). Along this pathway, HIV-1, like all 
obligate intracellular pathogens, will encounter numerous host proteins. The limited 
genetic repertoire of the virus means that it is dependent on some of these cellular 
proteins to facilitate its propagation. Although several of these factors have been 
independently identified and characterised, recent whole genome screens, based on high 
throughput RNA interference (RNAi) technology, have unearthed a multitude of 
proteins and pathways that are utilised by HIV-1 (Brass et al., 2008; Konig et al., 2008; 
Yeung et al., 2009; Zhou et al., 2008). Between them, these screens listed over one 
thousand genes that are necessary for optimal viral replication. However, only 34 genes 
were replicated in two or more of the reports and some known factors were not found. 
This emphasises the need for many of these factors to be independently verified in more 
than one type of system and cell line (Pache et al., 2011). Nevertheless, these screens 
have proven extremely useful in highlighting previously unknown cellular factors on 
which HIV-1 appears to be dependent such as the nuclear pore machinery, the 
transcription related mediator complex and the NFkβ complex. 
The following sections will outline in greater detail the various steps of the HIV-1 life 
















Figure 1.2: HIV-1 life cycle. 
HIV-1 binds to the CD4 receptor on the surface of the target cell in association with either the CXCR4 or 
CCR5 chemokine co-receptors, via its gp120 envelope protein expressed on the viral surface. Membrane 
fusion occurs and the viral core is released into the target cell. It then undergoes a process termed 
uncoating before the initiation of reverse transcription. The viral RNA genome is converted to a double 
stranded DNA form and enters the nucleus to integrate into host chromosomal DNA, thus establishing the 
provirus. The provirus is transcribed and translated akin to cellular genes. The viral proteins and genomic 
RNA accumulate at the plasma membrane for the assembly of new viral particles which upon formation 
bud from the infected cell. The virion is of an immature form and must undergo a process of maturation, 





1.4.2 Attachment and entry 
Unlike some enveloped viruses, which are dependent upon an acidic environment for 
entry via endocytosis, HIV-1 enters its target cell through direct fusion of the viral 
envelope and plasma membrane in a pH independent manner. Cells express numerous 
receptors on their surface, which provide a link between the intracellular and 
intercellular compartments. One such receptor, CD4, a member of the immunoglobulin 
G (IgG) superfamily is utilised by HIV-1 for attachment and entry of its viruses. Cells 
which express this receptor, namely T helper cells, are thus prime targets for HIV-1 
infection (Clapham et al., 1991; Maddon et al., 1986). Although CD4 is generally 
necessary for infection (CD4 independent entry has also been reported), it is not 
sufficient. This was concluded from two key observations. Firstly mouse cells 
engineered to express CD4 are still resistant to HIV-1 infection (Maddon et al., 1986) 
and secondly, only a subset of CD4+ cells are infected by HIV-1 in humans. This issue 
was eventually resolved through the identification of the chemokine co-receptors, 
CXCR4 (originally termed fusin) (Feng et al., 1996b) and CCR5 (Alkhatib et al., 1996; 
Deng et al., 1996; Dragic et al., 1996). Viral isolates are designated either X4 or R5 
depending on whether they utilise CXCR4 or CCR5 as their co-receptor respectively. 
Primary viral isolates tend to be R5 tropic but in 50% of infected individuals, during the 
late stage of disease, viruses will mutate and switch from R5 to X4 tropism. This results 
in a massive depletion of CD4+ T cells and signifies decline into AIDS (Cohen and 
Fauci, 2001). There are also cases of viruses that are dual tropic (X4R5) and can use 
either co-receptor for entry. The fundamental role that these receptors play in infection 
is illustrated by a 32 base pair deletion in the CCR5 gene (CCR5Δ32), which is found in 
approximately 5 - 10% of Northern Europeans. This results in a truncated non-
functional version of the protein that is not expressed at the cell surface (Liu et al., 
1996; Samson et al., 1996). Accordingly, homozygotes for this mutation are resistant to 
HIV-1 infection and heterozygotes are afforded moderate protection and slower disease 
progression (Rowe, 1996). Although individuals with this mutation appear to be healthy, 
they may be more susceptible to other pathogens such as West Nile Virus (Glass et al., 
2006).  
The viral envelope (Env) protein mediates attachment to the cell surface receptors. This 
protein is initially synthesised in the endoplasmic reticulum (ER) as a membrane bound 
polyprotein precursor, termed gp160 and is subsequently transported to the Golgi where 
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it is cleaved by the cellular protease furin into the gp120 (Subunit, SU) and gp41 
(Transmembrane, TM) subunits (Moulard and Decroly, 2000). These subunits are 
heavily glycosylated and remain non-covalently bound as they traffick to the cell 
surface where they are incorporated into virus particles as trimers. CD4 is first bound by 
the gp120 SU protein which contains variable loops within its structure that determine 
the tropism of the virus and are also essential for membrane fusion. This binding event 
instigates a conformational change in gp120, exposing binding sites allowing 
interactions with its chemokine co-receptor. Fusion of the viral and cellular membranes 
is then mediated by the gp41 TM protein which itself undergoes a conformational 
change exposing a hydrophobic domain at its N-terminal called the fusion peptide. This 
peptide penetrates the membrane of the target cell and orchestrates the fusion process, 
with gp41 adopting a six-helix bundle formation to maintain both membranes in close 
proximity. The generation of a fusion pore allows movement of the viral core into the 
cytoplasm of the infected cell and subsequent commencement of reverse transcription.  
1.4.3 Uncoating 
Following entry into the cytoplasm of the target cell, the viral core, consisting of the 
RNA genome and associated viral proteins, including Capsid (CA) and Nucleocapsid 
(NC), undergoes a poorly defined process termed uncoating. This is where viral and 
cellular components are either added or removed to form the reverse transcription 
complex (RTC). This is believed to be composed of the viral factors Reverse 
transcriptase (RT), Integrase (IN), Matrix (MA), NC, Vpr and the viral genome (Fassati 
and Goff, 2001), plus any host factors necessary for reverse transcription to take place, 
such as the tRNAlys3 incorporated from the virus producer cell. The involvement of CA 
in this complex and its role in the subsequent translocation of the viral DNA into the 
nucleus is a matter of debate (Fassati and Goff, 2001; Yamashita et al., 2007; Zhou et 
al., 2011). Also, it is during this stage that the retroviral restriction factors Fv1 and 








1.4.4 Reverse transcription 
Formation of the RTC allows the initiation of reverse transcription, a defining event in 
the life cycle of all retroviruses. This is dependent on the pol encoded Reverse 
transcriptase (RT) enzyme. Pol is the most highly conserved region of the HIV-1 
genome and it is initially produced as a Gag-Pol fusion peptide by ribosomal frame-
shift, which is subsequently cleaved during maturation of the virion. RT harbours both 
RNA and DNA directed DNA polymerase activity as well as RNase H catalytic activity, 
which catalyses the degradation of RNA in RNA-DNA hybrids (Gilboa et al., 1979).  
All retroviruses encapsidate host tRNAs to act as primers for initiation of reverse 
transcription. The exact one will differ for different viruses, but for HIV-1 this role is 
fulfilled by tRNAlys3. This binds to the primer binding site (PBS) at the 5’end of the 
viral RNA, and DNA synthesis proceeds in a 3’ to 5’ direction. This generates a short 
fragment of minus strand DNA, termed minus strong stop, which encodes both the 
unique 5’ (U5) and the repeat (R) regions. The RNA template, now contained within an 
RNA-DNA duplex, is then degraded by the RNase H capacity of RT. The strong stop 
DNA then translocates to the 3’ end of the RNA, in what is known as first strand 
transfer, where it binds to the complimentary R region found at the 3’ end. Synthesis of 
the minus strand of DNA is then continued up until the PBS. The RNA template is 
degraded along the way except at the polypurine tract (PPT), which is partially resistant 
to the RNase H activity of RT and therefore maintains a short section of an RNA-DNA 
hybrid. Lentiviruses also harbor a second PPT (cPPT), which is situated towards the 
centre of the genome (Charneau et al., 1992; Charneau and Clavel, 1991), and either 
one of these regions can act as the primer for generation of the plus strand of DNA 
(termed plus strong stop), which proceeds in a 5’ to 3’ direction. Strong stop DNA is 
used as the template for plus strand DNA synthesis, except at the PBS, where the 
tRNAlys3 is used instead. RT degrades the tRNAlys3 primer, which exposes the PBS at 
the 3’ end and allows it to bind to the complementary site on the minus strand DNA, 
thus generating a circular intermediate form of DNA. This second strand transfer event 
allows elongation of the minus and plus strands to be completed through strand 
displacement. The final product is a linear, double stranded DNA molecule with 
identical long terminal repeat regions at each end containing the U3, R and U5 regions 





Figure 1.3: Reverse transcription. 
Schematic diagram of reverse transcription. RNA is depicted in red and DNA in blue. 1. DNA synthesis 
is primed by binding of the cellular tRNA to the viral RNA at the primer binding site (PBS). 2. Reverse 
transcriptase catalyses extension of the primer to form minus sense DNA in an RNA-DNA duplex. 3. The 
RNase H activity of reverse transcriptase digests the RNA in this duplex resulting in single stranded DNA 
(minus strand strong stop DNA). 4. This DNA translocates to the 3’ end of the viral RNA which is 
facilitated by binding of the complementary R sequences (1st strand transfer). 5. Elongation of minus 
strand DNA and degradation by RNase H digestion continues. 6. Plus strand DNA synthesis is initiated at 
the polypurine tract (PPT) or the central PPT (cPPT, unique to lentiviruses), both of which are resistant to 
RNase H digestion. 7. The U3, R and U5 regions in minus strand DNA are copied by reverse 
transcriptase to yield the complementary plus strand DNA (plus strand strong stop DNA). The tRNA 
primer is used as the template to reconstitute the PBS. The tRNA primer from minus strand and the PPT 
primers from plus strand DNA are removed by RNase H digestion. 8. Circularisation of the DNA strands 
occurs (second strand transfer) and the two long terminal repeat (LTR) sequences are generated by strand 
displacement. 9. Elongation of the plus and minus strands of DNA is continued to completion, generating 
linear double stranded DNA with two identical LTRs, which is competent for integration.   
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Although HIV-1 contains two copies of its RNA genome only one provirus is formed 
per infectious virion. However, both molecules of RNA may contribute to the 
production of the proviral DNA. The inherent poor processivity of RT means that it 
frequently switches between RNA templates during the reverse transcription process. It 
may also be forced to switch templates if one strand is damaged in any way. This means 
that a recombinant form of DNA can be produced in co-infected cells, which 
contributes to genetic diversity. Combined with the high error rate of RT, due to its lack 
of exonucleolytic proof reading capabilities, means that HIV-1 displays a very high 
level of sequence diversity even within isolates taken from the same infected individual. 
This provides the virus with greater flexibility in evading both the immune response and 
antiviral therapies.  
1.4.5 Nuclear entry 
In order to integrate into the host genome, the newly synthesised cDNA must first gain 
access to the nucleus. A unique property of lentiviruses is their ability to infect non-
dividing cells, which means that active transport across a fully intact nuclear envelope is 
required (Lewis et al., 1992; Weinberg et al., 1991). Other retroviruses, such as the 
gammaretrovirus MLV, require mitosis to penetrate the nucleus and thus they are 
restricted to infecting cells in the process of cell division (Roe et al., 1993). Even before 
the completion of reverse transcription, various cellular and viral components will 
assemble on the DNA forming the pre-integration complex (PIC). The viral proteins, 
Vpr, IN and MA all contain putative nuclear localisation signals (NLS) and thus have 
been implicated in mediating the transport of the PIC through the nuclear pore. 
However, the role these proteins play in this process is controversial (Yamashita and 
Emerman, 2005). Matrix was originally believed to be involved in nuclear import of the 
PIC (Bukrinsky et al., 1993), but more recent work with tagged versions of this protein 
show that it does not localise to the nucleus (Depienne et al., 2000). Further, HIV-1 
viruses with mutations in MA can still efficiently infect non-dividing macrophages 
(Reil et al., 1998). Although Vpr does not contain a canonical NLS, it does localise to 
the nucleus and its deletion reduces HIV-1 replication in non-dividing monocyte 
derived macrophages (Nitahara-Kasahara et al., 2007). The role of Integrase is similarly 
uncertain but mutations in this protein do appear to block nuclear entry (Gallay et al., 
1997). Another viral element, the DNA flap, which is a discontinuous segment of DNA 
formed during reverse transcription, has also been implicated in nuclear entry (Zennou 
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et al., 2000) but its exact functional role is unclear and more recent data suggests that it 
does not influence this process (Limon et al., 2002). 
The movement of the PIC is also most probably dependent on cellular factors. This 
includes the alpha and beta Importin pathways which serve to transport numerous 
cellular factors through the nuclear complex. More recently, the karyopherin 
Transportin 3 (TNPO3), in conjugation with several nuclear pore proteins, has been 
linked to nuclear entry of HIV-1 DNA from whole genome RNAi screens (Brass et al., 
2008). These findings require further validation and so the mechanism of entry into the 
host nucleus and the precise requirements of this process have yet to be fully resolved.  
1.4.6 Integration 
Along with reverse transcription, integration of viral DNA into the genetic material of 
the host is a defining feature of all retroviruses. Not only does it ensure the continued 
production of viral gene products throughout the lifetime of the cell, it also enables the 
vertical transmission of viral DNA to daughter cells.  
The integration reaction is catalysed by the viral Integrase protein (IN) (Bushman et al., 
1990), which is produced as a cleavage product of the Gag-Pol precursor polyprotein. 
This 32 kDa protein has a N-terminal zinc binding domain (important for 
multimerisation), a central domain containing the catalytic core and a C-terminal DNA 
binding domain. It is responsible for two spatially and temporally distinct reactions that 
are essential for integration to occur. Firstly, in the cytoplasm, two nucleotides from the 
3’end of both strands of DNA are removed, generating 3’OH recessed ends, in a process 
termed 3’end processing. In the nucleus, at the site of integration, these reactive 
hydroxyl ends attack phosphodiester bonds in the genomic DNA resulting in cleavage 
of the DNA at staggered sites. The 3’ends of the viral DNA are then ligated to the 5’O-
phosphates of the host DNA, completing the strand transfer reaction. Cellular repair 
machinery then acts to fill in any gaps and remove any unpaired dinucleotides. The 
integrated proviral DNA has thus lost two nucleotides at its 3’end and is flanked by a 5 
base pair duplication of the cellular target sequence as a result of the joining and repair 
process (Freed and Martin, 2001). 
The linear proviral DNA is not the only form that the viral DNA can take in the nucleus. 
In fact, the formation of DNA circles by recombination (1 LTR circle) or by ligation of 
the two LTR ends or autointegration (2 LTR circles) can result in DNA species that are 
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aberrant dead end products for the virus. However, it has been reported that a small 
amount of transcription may take place from 2 LTR circles thus providing an alternative 
source of RNA if for some reason proviral integration is impaired (Wu and Marsh, 
2001). 
The involvement of cellular proteins, like at all stages of the HIV-1 life cycle, is 
essential for the integration process. Lens epithelium growth factor (LEDGF) is one 
such protein. It is tightly bound to chromatin throughout the cell cycle and tethers IN to 
chromatin thereby facilitating integration (Llano et al., 2006). This interaction appears 
to be specific to lentiviruses. Originally identified for MLV, the barrier to 
autointegration factor (BAF) is also required for efficient integration as it prevents 
suicidal autointegration events, though its exact mechanism of action is unclear (Chen 
and Engelman, 1998; Mansharamani et al., 2003). 
For all retroviruses, integration does not occur randomly but is targeted to areas of the 
genome displaying certain characteristics. HIV-1 preferentially integrates into active 
transcription units whereas MLV prefers CpG islands and near the transcriptional start 
sites of actively transcribed genes (Wu et al., 2003). What determines these differences 
in integration patterns is not clear but has been attributed to both cellular and host 
factors. IN itself may be a contributory factor as HIV-1 chimeras containing the IN 
protein of MLV resulted in integration of the proviral DNA at sites reminiscent of MLV 
site preferences (Lewinski et al., 2006). LEDGF may also influence this process as cells 
depleted of this protein showed reduced integration at transcription start sites (Llano et 
al., 2006; Shun et al., 2007). 
1.4.7 Transcription  
The proviral DNA is recognised and processed analogous to host cellular DNA by the 
RNA polymerase II (RNA Pol II) enzyme. Transcription is initiated at the 5’ LTR, 
which contains several cis-acting elements for the binding of positive and negative 
transcription factors that seek to control the level of viral transcription. The 5’ LTR also 
facilitates the loading of RNA Pol II onto the DNA template. The processivity of RNA 
Pol II is poor, and so the majority of initial RNAs produced are short due to lack of 
elongation. Early, full-length transcripts encoding the viral gene products of Tat, Rev 
and Nef are synthesised however, albeit inefficiently. They are capped at their 5’ end, 
polyadenylated at the 3’ end and fully spliced before export into the cytoplasm via the 
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conventional NXF1 nuclear export pathway. The generation of Tat early on in this 
process allows for more efficient transcriptional elongation. It is able to bind to a stem 
loop structure within the viral RNA termed the transactivating response (TAR) region 
and recruits components of the positive activating transcription elongation factor 
complex (P-TEFb) (Mancebo et al., 1997). Tat binds with high affinity to Cyclin T, a 
component of this complex, and this interaction also increases the binding affinity of 
Tat with TAR. Cyclin T recruits and stimulates the kinase activity of cell cycle 
dependent kinase 9 (Cdk9), which leads to hyperphosphorylation of the C-terminal 
domain of RNA Pol II. This increases its processivity along the DNA and therefore 
enables more efficient transcription (Wei et al., 1998). The essential role of Cyclin T in 
this process is demonstrated by the observation that a single amino acid substitution in 
the mouse orthologue of this protein disrupts binding of the Cyclin T-Tat complex to 
TAR and contributes to one of the many blocks to HIV-1 replication in murine cells 
(Bieniasz and Cullen, 2000).  
1.4.8 Nuclear export 
Cellular mRNAs are fully spliced to remove introns before they can be transported out 
of the nucleus by the NXF1 nuclear export pathway. This checkpoint prevents the 
production of aberrant proteins that could potentially be toxic and deleterious to the cell, 
but it presents a problem for HIV-1. For the generation of infectious virions it requires 
export of the unspliced full-length 9.2 kb mRNA that will serve as the genomic RNA 
(gRNA) as well as the template for the Gag and Gag-Pol polyprotein precursors. It must 
also export the singly spliced mRNAs encoding Env, Vif, Vpr and Vpu. To overcome 
this obstacle, HIV-1 bypasses the traditional mRNA nuclear export pathway and instead 
utilises an alternative pathway normally reserved for the export of certain proteins and 
small non-coding RNAs. This is mediated by the viral protein Rev (Malim et al., 1989), 
an early product of an initial fully spliced mRNA, which is trafficked back to the 
nucleus via its nuclear localisation signal (NLS). It also encodes a leucine rich nuclear 
export sequence (NES). Rev binds to a 350 nt stem loop structure termed the Rev 
response element (RRE), situated within the env gene, and present in all unspliced or 
partially spliced transcripts. Rev is capable of multimerisation and thus several proteins 
are believed to bind to the RRE at any one time, which appears to be important for its 
activity (Malim and Cullen, 1991). Rev binds to the Chromosome regional maintenance 
1 (Crm1) protein, also known as Exportin 1, which is a member of the Importin-β 
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family of nuclear transport proteins. Crm1 interacts with a small guanine nucleotide 
binding protein termed Ran and this interaction facilitates binding between Crm1 and 
Rev. In the nucleus, Ran is bound to GTP but in the cytoplasm it is associated with 
GDP. Thus a gradient is established between these two forms of Ran that provides the 
energy and directionality of transport into and out of the nucleus. RanGTP in the 
nucleus allows the Rev-RRE cargo to be loaded onto Crm1 and this complex is then 
transported out of the nucleus. When it reaches the cytoplasm, RanGTP is converted to 
RanGDP, which favours disassociation of the complex and release of the cargo. Rev 
continually shuttles between the nucleus and cytoplasm, ensuring the constant export of 
intron containing viral RNAs. The importance of Crm1 in this process is demonstrated 
by the use of leptomycin B, an antibiotic which blocks nuclear export of Rev dependent 
RNAs by targeting Crm1 (Fornerod et al., 1997). More recently, another cellular protein, 
the DEAD box helicase DDX3, has also been reported to contribute to Crm1 mediated 
export of the Rev-RRE complex (Yedavalli et al., 2004). Its depletion leads to a 
reduction in the export of HIV-1 RNA, though its exact mechanism of action remains 
unclear. In other retroviruses, such as Mason-Pfizer monkey virus (MPMV), a stem 
loop structure termed the constitutive transport element (CTE) directly binds NXF1 and 
thus functionally replaces Rev in the orchestration of nuclear export.  
1.4.9 Assembly  
Once the necessary viral proteins and polyproteins have been produced they must 
assemble at the plasma membrane (PM) and initiate first the assembly and then the 
release of fully infectious progeny virions. The main instigator of the assembly process 
is Gag, which is sufficient in itself to form virus like particles (VLPs). Approximately 
1,500 - 2,000 Gag polyproteins are required for efficient virion assembly (Briggs et al., 
2004), that associate into oligomers and form spheres predominantly through protein-
protein interactions involving the C-terminal domain of CA (Dorfman et al., 1994; 
Krausslich et al., 1995). Within the PM, it is likely that virion assembly and budding 
takes place in specific lipid and cholesterol rich microdomains such as lipid rafts and 
tetraspanin enriched membranes (TEM) (Campbell et al., 2001; Deneka et al., 2007; 
Nguyen and Hildreth, 2000).  Myristylation of the MA domain of Gag is necessary to 
target Gag proteins to these lipid microdomains and tether them there during the 
assembly process. This is mediated by the cellular PM associated protein PI(4,5)P2, 
which binds to MA leading to exposure of its myristyl group (Ono et al., 2004; Saad et 
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al., 2006). However, for infectious particle production other components are also 
required. The MA domain is also involved in the incorporation of Env glycoproteins, a 
process which may additionally involve the cellular protein Tip47 (Bauby et al., 2010). 
Vpr is packaged through interactions with the p6 region of Gag, whereas Nef and Vif 
are believed to be packaged non-specifically. The NC region of Gag binds the Ψ 
packaging signal found only in the full length viral RNA, which ensures that only 
unspliced transcripts are incorporated as the genomic RNA. This RNA is also required 
for the synthesis of the Gag and Gag-Pol polyprotein precursors. How translation and 
packaging of this RNA are segregated and differentiated within the cell remains an issue 
of much debate. For some simple retroviruses, such as MLV, two distinct populations of 
RNA are produced that are either translated or packaged. However for other retroviruses, 
including HIV-1, a single RNA species is produced that serves as both the mRNA and 
genomic RNA interchangeably (Butsch and Boris-Lawrie, 2002). It has been postulated 
that sub-cellular compartmentalisation, such as in mRNA Processing Bodies (P-bodies), 
may facilitate sequestration of the genomic RNA away from the cellular translational 
machinery and thus allow it to be packaged into virions (Swanson and Malim, 2006) 
(discussed in more detail in section 1.9).  
A multitude of cellular factors are also incorporated into viral particles. A 
comprehensive list of those identified in virions derived from purified monocyte 
derived macrophages (MDMs) has been reported [(Chertova et al., 2006) and reviewed 
in (Ott, 2008)]. Predominantly these proteins are packaged through interactions with 
Gag and they can positively or negatively influence viral replication. The NC domain of 
Gag enables the incorporation of the cellular protein tRNAlys3, used as the primer to 
initiate reverse transcription, while Cyclophilin binds to the C-terminal of CA. In 
human cells, this protein is required for maximal HIV-1 infectivity, though its 
mechanism of action is unknown. Other positive factors include ICAM-1 (CD54), 
which increases infectivity, Actin, involved in assembly, and Staufen, which mediates 
HIV-1 genome packaging and Gag multimerisation. Conversely, under certain 
circumstances, virions can also incorporate inhibitory factors such as APOBEC3G and 
its family members which interact with the NC region of Gag and restrict viral 
replication in the target cell [reviewed in (Ott, 2008)], and Mov10 (Chertova et al., 




1.4.10 Budding and release 
Once the various viral and cellular factors required for virion formation have assembled 
at the plasma membrane, the virion must bud from the cell and be released into the 
extracellular compartment. This budding event is largely dependent upon the ESCRT 
(endosomal sorting complex required for transport) machinery comprising the protein 
complexes I, II and III [reviewed in (Martin-Serrano and Neil, 2011)]. The ESCRT 
proteins play fundamental roles in cellular membrane deformation and scission events. 
They were originally found to be involved in the formation of budding vesicles at 
multivesicular bodies in both yeast and humans, a process which is important for the 
sorting and concentration of endosomal cargo. However, the expansion of the ESCRT 
machinery to a possible 16 different complexes in humans is associated with additional 
functions that are topologically similar. The ESCRT components, Tsg101 (tumor 
susceptibility gene 101) and ALIX [apoptosis linked gene 2 (ALG-2) interacting 
protein] are involved in mediating the scission of the daughter cell from the mother cell 
during cytokinesis (Carlton and Martin-Serrano, 2007). These proteins have also been 
usurped by HIV-1 in order to release immature virions from infected cells through 
scission of a membrane stalk, which tethers them together during the budding process. 
Deletion of the proline-threonine-alanine-proline (PTAP) motif within the p6 region of 
Gag abrogated the release of HIV-1 particles with virions remaining attached to the cell 
(Gottlinger et al., 1991). This was termed a late (L) domain phenotype and other 
enveloped viruses were found to contain L domains that could be functionally 
interchangeable (Parent et al., 1995). It was subsequently demonstrated by two 
independent groups, through knock down and dominant negative mutants, that Tsg101 
was the cellular factor which interacted with the PTAP domain and recruited the 
ESCRT machinery in order to facilitate budding and release (Garrus et al., 2001; 
Martin-Serrano et al., 2001). However, HIV-1 along with other viruses also contains 
binding sites for ALIX, which mediates budding through recruitment of the CHIMP3 
ESCRT proteins and recruits the NEDD4 family of ubiquitin ligases (Strack et al., 
2003). The existence of auxillary late domains for budding may aid the virus in its 
competition for host cellular machinery. Release of mature HIV-1 particles is also 
facilitated by Vpu in certain cell types, which antagonises the action of the host 





The released virion is of an immature form and must undergo a process of maturation in 
order to generate an infectious viral particle. This is initiated by cleavage of the Gag and 
Gag-Pol polyproteins by the viral protease, which yields the structural proteins CA, NC, 
MA and p6 and the enzymes PR, RT and IN. This cleavage event is highly ordered and 
begins in a sequential manner between the p1 and NC sites. The RNA genome is 
surrounded by an NC protein coat, which is then encased in a condensed cone shaped 
core created by the CA proteins. The mature virion is composed of the following viral 
components: MA, CA, NC, p6, p2, p1, PR, IN, RT, Env, Vpr, Vpu, Vif and Nef 




























Figure 1.4: Composition of a mature HIV-1 virion. 
The mature HIV-1 virion is composed of the genomic RNA coated with Nucleocapsid (NC) and enclosed 
within a Capsid (CA) core. The other viral proteins present are Envelope (Env), Matrix (MA), Integrase 




1.5 HIV-1 accessory proteins 
HIV-1 must not only exploit numerous cellular factors in order to complete its life cycle, 
but must also modify the cellular environment to support its replication and evade host 
immune reponses. This is mainly achieved through the actions of its accessory proteins 
Nef, Vpr, Vpu and Vif. A common mechanism of action of these proteins is 
proteasomal degradation of their targets through recruitment of cullen-RING finger 
ubiquitin ligases [reviewed in (Malim and Emerman, 2008)]. Vpu and Vif specifically 
downregulate cellular proteins which act to restrict replication of the virus and so these 
will be discussed in greater detail in relation to the proteins that they target. 
1.5.1 Nef 
The 27 kDa membrane associated protein, originally named negative factor (Nef) is, 
contrary to its name, essential for virus infection in vivo. Nef deleted strains of both 
HIV-1 and SIV-1 show a much slower progression to AIDS and a reduced viral load 
(Deacon et al., 1995). Nef appears to participate in several processes. Firstly, it is 
believed to interfere with cellular signaling pathways that would activate the host 
immune response. It activates expression of FasL, which induces apoptosis of bystander 
cells that express Fas including cytotoxic T lymphocytes (CTLs) that would potentially 
destroy infected cells (Xu et al., 1999). It also downregulates MHC Class I from the 
surface of infected cells to similarly avoid detection by CTLs (Collins et al., 1998). 
Along with Vpr, it may also be involved in inhibiting apoptosis through inhibition of 
the apoptosis signal regulating kinase 1 (ASK-1). Several of the accessory proteins 
including Nef, Vpr and Vpu also mediate the downregulation of CD4 from the cell 
surface (Lama et al., 1999), which partially protects infected cells from further infection. 
While Nef mediates the endocytic degradation of cell surface CD4 (Chaudhuri et al., 
2007), Vpu binds to CD4 in the ER and recruits the βTrcp-Skp1 complex involved in 
proteasomal degradation (Margottin et al., 1998). This prevents the Env polyprotein 








The 14 kDa Vpr protein is packaged at high levels into viral particles through 
interactions with the p6 domain of Gag. It has been implicated in mediating the 
transport of the PIC into the nucleus and more convincingly, it is involved in causing 
the arrest of infected cells while in the G2 phase of the cell cycle, which occurs within 
hours of infection (Goh et al., 1998; Zimmerman et al., 2006). This is when the HIV-1 
LTR is most active and thus this action increases the rate of viral transcription and 
consequently gene expression. This appears to be dependent on the interaction between 
Vpr and the cellular receptor DCAF1 and subsequent recruitment of the Cullin4A-
DDB1-Rbx E3 ubiquitin ligase complex (Hrecka et al., 2007; Schrofelbauer et al., 
2007).  
HIV-2 and the SIVs of both sooty mangabeys (SIVsm) and rhesus macaques (SIVmac) 
also encode a Vpx gene, which is thought to have arisen from a gene duplication of Vpr 
or else through recombination with the Vpr gene from the African green monkey SIV 
(SIVagm). In these viruses, the role of Vpr has been functionally divided between these 
two proteins, with Vpx being responsible for the infection of non-dividing cells and Vpr 
inducing cell cycle arrest (Freed and Martin, 2001). Vpx is also necessary for HIV-2 
and SIVsm infection of macrophages and monocyte derived dendritic cells (Goujon et 













1.6 Cellular restriction factors 
As well as cellular proteins that have been co-opted by HIV-1 to facilitate its replication, 
several proteins have now been identified that are able to restrict replication of the virus 
at various different stages of its lifecycle. These factors form part of the innate immune 
system and as such, are often induced by Type 1 interferons. Importantly HIV-1, in 
most cases, has evolved countermeasures to circumvent these restrictive proteins 
[reviewed in (Malim and Emerman, 2008),], which has important consequences for the 
species tropism of this virus. The first such human restriction factor to be identified was 
the cytidine deaminase APOBEC3G and its family members. The following paragraphs 
summarise what is known about these cellular mediators of intrinsic resistance against 
HIV-1.  
1.6.1 Trim5α 
Trim5α was identified as the restriction factor that mediated the block to HIV-1 
infection in Old World Monkeys (OWM) (Stremlau et al., 2004). Similar inhibition to 
N-tropic strains of MLV in human cells and HIV-1 and/or SIVmac infection in non-
human primate cell lines, originally termed Ref1 and Lv1 respectively (Besnier et al., 
2002; Cowan et al., 2002) were eventually recognised as species specific variants of 
Trim5α (Hatziioannou et al., 2004). The exact mechanism by which this protein 
mediates its restrictive phenotype is unclear. It has been shown to act early on in 
infection by binding to Capsid through its PRY-SPRY domain and interfering with the 
poorly defined process of viral uncoating. Since it possesses a RING domain, with E3 
ubiquitin ligase activity, it was believed that it recruited retroviral cores to the 
proteasome where they are subsequently degraded. However, proteosomal inhibitors fail 
to rescue viral infectivity implying that a second block is also present, where reverse 
transcription products accumulate but fail to integrate [reviewed in (Towers, 2007)]. 
This latter mechanism is analogous to the effects of the murine restriction factor, Fv1, 
the first retroviral restriction protein to be identified. Human Trim5α only weakly 
inhibits HIV-1 most likely due to inefficient recognition and binding of Capsid (Towers 
et al., 2000).  
The cellular protein Cyclophilin A (CypA), a peptidyl propyl isomerase, also plays a 
part in Trim5α mediated restriction, most probably by facilitating its binding to the viral 
Capsid protein [reviewed in (Sokolskaja and Luban, 2006)]. This is highlighted by the 
discovery of the TrimCyp fusion protein (Sayah et al., 2004), which also inhibits HIV-1, 
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and remarkably arose through a retrotransposition event independently in both New 
World Monkeys and Asian Macaques. TrimCyp restriction is dependent upon binding 
of CypA to Capsid. Intriguingly, in humans, CypA is necessary for the facilitation of 
viral infectivity but the reasons for this remain unclear.  It has been proposed to protect 
the virus from an unidentified restriction factor, distinct from Trim5α (Sokolskaja et al., 
2006) or it may act as a viral co-factor.  
1.6.2 Tetherin 
A second restriction factor, which acts against HIV-1 and a range of other enveloped 
viruses is tetherin (also called BST-2/CD317). This membrane bound, highly interferon 
inducible protein inhibits the release of fully formed mature HIV-1 particles from the 
cell surface, thereby preventing the spread of infection in a cell free system (Neil et al., 
2008). These viruses can also be re-internalised and targeted to late endosomes for 
degradation although the precise molecular mechanisms of tetherin action are not yet 
fully understood. As tetherin is able to restrict the replication of a diverse array of 
enveloped viruses it is not thought to target any specific viral protein and instead may 
be packaged into virions and crosslink viral and cellular membranes (Hammonds et al., 
2010). It had been known for some time that in certain cell lines, Vpu deficient HIV-1 
viruses failed to detach from infected cells (Klimkait et al., 1990). It was subsequently 
shown that protease treatment could reverse this phenotype implying it was the result of 
a cellular protein (Neil et al., 2006), eventually identified as tetherin by microarray 
analyses comparing permissive and non-permissive cell types in the absence of Vpu 
(Neil et al., 2008). The mode of Vpu antagonism of tetherin is still incompletely defined. 
Similar to its effects on the CD4 receptor, it can downregulate tetherin from the cell 
surface and mediate its lysosomal degradation [reviewed in (Martin-Serrano and Neil, 
2011)], which may also be dependent on the ESCRT protein HRS (Janvier et al., 2011). 
However, degradation of tetherin by Vpu is not necessary for its antagonistic effects and 
instead it may predominantely alter the sub-cellular trafficking of tetherin and sequester 
it away from sites of viral assembly (Dube et al., 2010; Dube et al., 2009; Mitchell et al., 
2009; Van Damme et al., 2008). 
Other retroviruses such as HIV-2 and the SIVs do not encode a Vpu protein and thus 
have utilised their Env (Gupta et al., 2009; Le Tortorec and Neil, 2009) and Nef (Jia et 
al., 2009; Zhang et al., 2009) proteins respectively to combat tetherin. However, the 
action of tetherin is not just restricted to retroviruses but also extends to the filovirus, 
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ebolavirus (Neil et al., 2007) and the DNA virus Kaposi’s sarcoma associated 
herpesvirus (KSHV) among others. These viruses have also evolved their own 
antagonists of tetherin (Douglas et al., 2010; Kaletsky et al., 2009).  
1.6.3 SAMHD1 
It is well known that macrophages and more prominently dendritic cells are largely 
refractory to HIV-1 infection owing to a block imposed during reverse transcription. It 
has also been shown that the Vpx gene of SIVsm/HIV-2 can overcome this block to 
productive infection, although the identity of the restriction factor remained unknown 
(Goujon et al., 2007). Very recently, two groups have attributed this restriction to the 
action of the cellular protein SAMHD1 (Hrecka et al., 2011; Laguette et al., 2011). Vpx 
causes the ubiquitin mediated proteosomal degradation of this protein and knockdown 
of SAMHD1 increases the susceptibility of non-permissive cells to HIV-1. Unlike other 
restriction factors, HIV-1 has not evolved a means to counteract it. 
Intriguingly SAMHD1 has also been implicated as a negative regulator of the interferon 
response (Rice et al., 2009) as has the cellular DNase TREX1 (Yan et al., 2010). This 
enzyme is involved in clearing excess cytoplasmic HIV-1 DNA from infected cells 
thereby avoiding activation of the Type 1 interferon response (Yan et al., 2010). 
Mutations in both of these proteins can lead to Aicardi Goutieres syndrome (AGS) 
(Crow et al., 2006; Rice et al., 2009), a genetic encephalopathy that mimics congenital 
viral infections. The exact mechanism of action of these proteins, particularly in terms 
of control of the innate immune response, requires further investigation but presents 
exciting challenges ahead in the area of intrinsic immunity. 
1.6.4 APOBEC3G  
It had long been established that the HIV-1 accessory protein, viral infectivity factor 
(Vif), was absolutely necessary for viral replication in CD4+ T cells, the natural targets 
of HIV-1 in vivo, as well as certain T cell lines such as Hut78 and CEM (termed non-
permissive) but not in others such as CEM-SS and SupT1 (termed permissive) (Fisher 
et al., 1987; Gabuzda et al., 1992; Strebel et al., 1987; von Schwedler et al., 1993). It 
was also apparent that although the quantity of the virions produced was not altered in 
the absence of Vif, the quality of these virions, in terms of replication competence, was 
severely attenuated (Simon et al., 1998; Sova and Volsky, 1993). Heterokaryon analysis 
between a non-permissive and permissive cell line revealed that the non-permissive 
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phenotype was dominant demonstrating that it was attributable to the presence of a 
cellular inhibitory factor that Vif was able to circumvent (Madani and Kabat, 1998; 
Simon et al., 1998). Through a subtractive hybridisation screen comparing CEM, and its 
clonal derivative, CEM-SS cell lines, APOBEC3G (A3G) (originally named CEM15) 
was identified as the elusive inhibitory factor (Sheehy et al., 2002). It was expressed in 
all the non-permissive lines tested and ectopic expression in permissive cells rendered 
them unable to support HIV-1 delta vif (Δvif) replication. In the presence of Vif, 
however, the restriction imposed by APOBEC3G was relieved (Sheehy et al., 2002). It 
was known that Vif and APOBEC3G activity was manifest in virus producing cells and 
subsequently it was shown that Vif is able to downregulate APOBEC3G protein levels 
and prevent its packaging into virions (Conticello et al., 2003; Marin et al., 2003; Mehle 
et al., 2004; Sheehy et al., 2003; Stopak et al., 2003; Yu et al., 2003), which is essential 
for its restrictive phenotype. It was later revealed that upon directly binding to A3G, Vif 
recruits an E3 ubiquitin ligase complex consisting of ElonginB, ElonginC, Cullin5 and 
Ring-box-2 (Yu et al., 2003). This induces the polyubiquitination and subsequent 
proteosomal degradation of A3G (Figure 1.5).  
The interaction between A3G and Vif is a major determinant of the species tropism of 
HIV-1 and the related SIVs. Human APOBEC3G is sensitive to the actions of HIV-1 
Vif but the mouse APOBEC3 protein as well as A3G from African green monkeys are 
resistant and therefore can be packaged into HIV-1 virions and mediate their restrictive 
effects (Mariani et al., 2003). Conversely, human A3G is not degraded by the Vif 
protein of SIVagm and therefore humans cannot be infected by this virus. Interestingly 
this species specificity appears to be dependent upon a single amino acid residue at 
position 128 of human A3G. Mutation of this residue (D128K) conferred resistance to 
degradation by HIV-1 Vif but rendered the protein susceptible to the effects of Vif from 
SIVagm (Schrofelbauer et al., 2004).  Therefore it appears that viral Vif proteins have 
evolved to target the APOBEC3G proteins of their hosts, which thus governs zoonotic 
















Figure 1.5: Vif mediated degradation of A3G. 
In the presence of Vif, A3G is prevented from being incorporated into virions and is recruited instead to 
an E3 ubiquitin ligase complex consisting of ElonginB, ElonginC, Cullin 5 and Ring-box-2 (Rbx2), 






1.7 APOBEC3 family of cytidine deaminases 
1.7.1 Overview 
APOBEC3G is a member of a family of cytidine deaminases, clustered on chromosome 
22, that are named in relation to their founder member, Apolipoprotein B mRNA 
editing catalytic like polypeptide 1 (APOBEC1). Seven members of the APOBEC3 
subfamily have been identified in higher primates, APOBEC3A (A3A), APOBEC3B 
(A3B), APOBEC3C (A3C), APOBEC3D/E (A3D/E), APOBEC3F (A3F), APOBEC3G 
(A3G) and APOBEC3H (A3H), which arose through several gene duplication events 
(Jarmuz et al., 2002). APOBEC3E was originally believed to be a pseudogene before it 
was realised that it is the C-terminal half of the APOBEC3D protein and is thus now 
named APOBEC3D/E. Therefore, A3B, A3D/E, A3F and A3G all contain two 
deaminase domains, although only the C-terminal half is usually catalytically active, 
with the N-terminal involved in nucleic acid binding (Navarro et al., 2005). The 
remaining APOBEC3 proteins (A3A, A3C and A3H) harbour only one deaminase 
domain (Figure 1.6A). These proteins are expressed in a variety of tissues and immune 
related cell types (Jarmuz et al., 2002; Koning et al., 2009; Refsland et al., 2010). This 
locus has undergone massive expansion in primates as only one APOBEC3 gene exists 
in mice (Harris and Liddament, 2004). The reason for this expansion is most probably 
due to ancient and now extinct exogenous retroviruses, whose remnants can still be 
detected in the human genome (Kazazian, 2004). This is supported by findings that the 
APOBEC3 proteins are under very strong levels of positive selection and have been 
throughout the history of primate evolution, long before the emergence of modern 














Figure 1.6: The human family of APOBEC cytidine deaminases.  
A. There are eleven members of the APOBEC family including APOBEC1, AID, APOBEC2, 
APOBEC3A – H and APOBEC4. All proteins contain either one or two cytidine deaminase domains. B. 
The conversion of cytidine to uridine is a result of hydrolytic deamination of the C-4 position of the 
cytosine base. The process is catalysed by the APOBEC proteins and is referred to as editing. Adapted 
from (Holmes et al., 2007b). 
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1.7.2 Editing dependent means of viral inhibition  
The discovery of A3G as an innate antiviral factor was concurrent with characterisation 
of the APOBEC3 family in terms of their enzymatic activity (Jarmuz et al., 2002). This 
independent finding hinted at a possible mechanism of A3G viral inhibition, through 
cytidine deamination, which was subsequently demonstrated in a bacterial editing assay 
(Harris et al., 2002a). The cytidine deaminase domain comprising a His-X-Glu-X-Pro-
Cys-X-Cys motif provides catalytic potential for nucleophilic attack of the C4 position 
of the pyrimidine ring, causing a base change from cytidine to uridine in a process 
termed editing (Figure 1.6B). It is now well established that A3G is incorporated into 
nascent HIV-1 virions, in the absence of Vif, through interactions with the nucleocapsid 
region of Gag. This interaction is also dependent on cellular and/or viral RNA, 
postulated to be 7SL and genomic RNA, though this issue remains controversial at 
present (Bogerd and Cullen, 2008; Khan et al., 2005; Luo et al., 2004; Schafer et al., 
2004; Svarovskaia et al., 2004; Wang et al., 2007; Zennou et al., 2004). The ability of 
A3G to oligomerise is also important for its encapsidation into virions (Burnett and 
Spearman, 2007; Huthoff et al., 2009) but this has also been disputed (Khan et al., 
2009). In the viral core, A3G is able to associate with the reverse transcription complex 
(RTC) and upon entry into target cells mediates deamination of cysteine residues to 
uridines in nascent minus strand reverse transcripts. These register as guanosine to 
adenosine changes on the plus strand, which when occurring at a high rate [A3G 
induces approximately 1.5 - 1.7 changes per 100 bases, (Zhang et al., 2003)] is referred 
to as hypermutation (Harris et al., 2003a; Mangeat et al., 2003; Mariani et al., 2003; 
Zhang et al., 2003). This fits with data demonstrating that A3G preferentially acts on 
single stranded DNA substrates (Yu et al., 2004b). The extensive mutational burden 
leads to loss of sequence integrity and proviruses that no longer encode infectious 
progeny virions. The recovery of highly mutated reverse transcription products in the 
presence of A3G and in the absence of Vif, lends strong support to this mode of viral 
inhibition, as does the discovery of hypermutated sequences from HIV-1 infected 
individuals (Janini et al., 2001; Kieffer et al., 2005; Vartanian et al., 1991), which 
clearly illustrates the physiological relevance of A3G activity. In addition, it was 
originally hypothesised that the U bases may be recognised and excised by cellular 
DNA repair enzymes such as UNG2 and SMUG1, which would lead to degradation of 
the single stranded DNA as there is no complementary strand to act as a template 
(Harris et al., 2003b). This would explain the reduced accumulation of reverse 
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transcription products associated with Vif minus HIV-1 infection, in the presence of 
A3G (Bishop et al., 2006; Mangeat et al., 2003; Mariani et al., 2003). However, 
inhibition of UNG2 and/or SMUG1 did not affect A3G mediated HIV-1 Δvif restriction, 
indicating that this particular cellular repair machinery is not important for this 
phenotype (Kaiser and Emerman, 2006; Langlois and Neuberger, 2008; Mbisa et al., 
2007).  
It has been proposed that low levels of A3G (and other APOBEC3) induced mutations 
may actually be advantageous to the virus as this contributes to sequence divergence, 
which may facilitate immune evasion and drug resistance (Jern et al., 2009; Mulder et 
al., 2008; Mulder et al., 2010; Sadler et al., 2010). Therefore, in vivo, the interplay 
between A3G and HIV-1 is clearly complex and often precariously balanced.  
1.7.3 Editing independent means of viral inhibition 
Although editing dependent mechanisms of A3G retroviral restriction are clearly 
important both in vitro and in vivo, other means of inhibition are also evident. This is 
based on findings that A3G mutants that are no longer catalytically active, as 
demonstrated in bacterial editing assays, can still inhibit HIV-1 (Holmes et al., 2007b; 
Newman et al., 2005). Recovered viral cDNAs were not hypermutated, although these 
mutants were still packaged into virions. This conclusion is further supported by studies 
demonstrating that APOBEC3 inhibition of other viruses and retroelements may not be 
fully or even partially dependent on editing as once again, highly mutated sequences are 
not always readily detectable (Bogerd et al., 2006; Nguyen et al., 2007; Sasada et al., 
2005; Stenglein and Harris, 2006). Alternative means of inhibition have thus been 
sought and it has now been hypothesised that A3G may directly interfere with the 
movement of reverse transcriptase along its RNA template (Bishop et al., 2008). 
Reverse transcription was shown to initiate but elongation was impeded in an A3G dose 
dependent manner. This model of steric hindrance would also account for the lack of 
accumulation of reverse transcription products (Bishop et al., 2008). Thus the 
mechanism of A3G mediated viral restriction may be more multi-faceted than originally 






















Figure 1.7: APOBEC3G mediated inhibition of HIV-1.  
In the producer cell, in the absence of Vif, APOBEC3G (A3G) is packaged into budding virions. Upon 
entry into the target cell, it can mediate its anti-viral effect by one of two mechanisms. Firstly, it can 
deaminate cytidines to uridines in minus reverse strand transcripts, thus causing hypermutation of the 
viral DNA. Secondly, it may directly interfere with the elongation of reverse transcripts thus causing a 





1.7.4 Inhibition of HIV-1 by the APOBEC3 proteins 
Whether any of the other APOBEC3 proteins possess anti-viral activity against HIV-1 
has been an issue of intense investigation. APOBEC3F was quickly shown to inhibit 
HIV-1 replication, though not nearly as potently as A3G (Bishop et al., 2004; Wiegand 
et al., 2004). Although these proteins share almost 50% sequence identity, they differ in 
several respects. Firstly, the preferred nucleotide sequence context for cytidine 
deamination is different between these proteins. A3G preferentially deaminates in a CC 
dinucleotide context (Bishop et al., 2004; Harris et al., 2003a; Suspene et al., 2004; Yu 
et al., 2004b), while A3F, along with the other APOBEC3 proteins, targets TC 
dinucleotide sequences (edited base is underlined) (Liddament et al., 2004). Secondly, 
although A3F is able to associate in large ribonucleoprotein (RNP) complexes, which 
have a similar composition to those within which A3G is contained (see section 1.9), 
there is the noticeable absence of small RNAs, with the exception of Alu RNAs 
(Gallois-Montbrun et al., 2008). This is of interest as it has been reported that 7SL RNA 
is necessary for A3G virion incorporation, which would suggest that A3G and A3F are 
packaged by alternate means. However the role of 7SL RNA in A3G packaging is 
highly controversial and others have reported that A3F does in fact interact with this 
RNA (Wang et al., 2008). Also, A3F associated RNP complexes appear to be more 
resistant to RNase treatment implying that either the RNA components are shielded or 
that the majority of interactions occur by direct protein-protein binding (Gallois-
Montbrun et al., 2008). Finally, it has been argued that non-editing mechanisms of viral 
inhibition may be more important for A3F restriction than for A3G (Holmes et al., 
2007a). The basis for these differences remains to be resolved. Nevertheless, similar to 
A3G, A3F is also Vif sensitive (Wiegand et al., 2004), is expressed in CD4+T cells and 
hypermutated sequences displaying A3F preferred sequence contexts have been 
recovered from infected individuals (Liddament et al., 2004), indicating that these 
proteins may act in concert to co-ordinate anti-viral defence during a natural infection. 
However, its in vivo relevance to HIV-1 resistance has recently been questioned 





The anti-HIV-1 activities of the remaining APOBEC3 proteins are not so definitive. On 
the whole A3A and A3C are not thought to possess any HIV-1 restrictive capabilities 
(Bishop et al., 2004) but there is some contradictory data on this issue. A3C is 
considered by some to have very weak activity, is reported to be packaged into virions 
and degraded by Vif (Langlois et al., 2005; Rose et al., 2005), whereas A3A may 
mediate restriction of viruses in myeloid cells (Berger et al., 2011; Peng et al., 2007). 
A3B and A3D/E have also been shown to have some anti-HIV-1 activity though the 
magnitude and relevance of their effects is somewhat controversial (Dang et al., 2006; 
Doehle et al., 2005; Duggal et al., 2011; Rose et al., 2005). Four different haplotypes of 
A3H exist in the human population with only one of these, haplotype 2, producing a 
stable protein, which is anti-viral (OhAinle et al., 2008). This may explain the earlier 
discrepancies regarding the anti-viral nature of this protein (Dang et al., 2008; OhAinle 
et al., 2006). Like A3F and A3G, A3D/E is sensitive to Vif, whereas A3H is only 
partially sensitive (OhAinle et al., 2008) and A3B appears to be resistant (Doehle et al., 
2005). The Vif insensitive nature of A3B can be explained by the fact that it is primarily 
expressed in B cells (Koning et al., 2009) and is therefore unlikely to encounter HIV-1 
during the course of a natural infection. All APOBEC3 proteins are reportedly 
incorporated into assembling virions (Dang et al., 2008; Dang et al., 2006; Goila‐Gaur et  al.,  2007;  Wiegand  et  al.,  2004;  Yu  et  al.,  2004a). Recently, a comprehensive 
analysis of the anti-viral activities of all seven APOBEC3 family members was reported 
and found that only A3G, A3F, A3D/E and A3H were inhibitory to HIV-1. Further 
these proteins were all expressed in CD4+T cells, packaged into virions and sensitive to 
degradation by Vif (Hultquist et al., 2011). 
1.7.5 Inhibition of other viruses 
Nevertheless, the APOBEC3 proteins are not solely inhibitors of HIV-1 as A3G and 
A3F inhibit equine infectious anemia virus (EIAV) and MLV (Bishop et al., 2004; 
Bogerd et al., 2008; Zheng et al., 2004; Zielonka et al., 2009) and all APOBEC3s, apart 
from A3A, restrict the SIVs of rhesus macaque and African green monkeys (Dang et al., 
2006; Yu et al., 2004a). Another retroviral substrate is primate foamy virus (PFV), 
which is targeted by A3F and A3G (Russell et al., 2005). Aside from retroviruses, they 
can also inhibit the replication of the DNA virus, hepatitis B virus (HBV), which 
undergoes an obligate intracellular reverse transcription step in its life cycle, converting 
its RNA genome into a partially double stranded form inside core particles in producer 
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cells. All APOBEC3s, apart from A3A and A3H restrict HBV, which may or may not 
be the result of editing (Nguyen et al., 2007; Suspene et al., 2005; Turelli et al., 2004). 
A3A has also been shown to inhibit adeno associated virus (AAV) (Chen et al., 2006) 
and human papilloma virus (HPV), the latter of which is also targeted by A3C and A3H 
(Vartanian et al., 2008). Interestingly these proteins have all been found to be 
predominantly nuclear (Muckenfuss et al., 2006). Nuclear localisation may also 
influence the restriction of the LINE-1 retroelement, which is most potently inhibited by 
A3A and A3B (Bogerd et al., 2006; Chen et al., 2006). These proteins may be able to 
directly interfere with the process of target primed reverse transcription which for this 
retrotransposon occurs at the site of integration and hence in the nucleus. However, 
other APOBEC3 proteins (A3C, A3F and A3H) also limit the activity of this 
retrotransposon (Stenglein and Harris, 2006), which subsequently impacts upon Alu 
retrotransposition as they depend on LINE-1 encoded proteins for their replication. A3G, 
on the other hand, only weakly inhibits LINE-1 but is able to restrict Alu 
retrotransposition by potentially sequestering these elements in high molecular weight 
complexes, away from the LINE-1 machinery (Chiu et al., 2006). APOBEC3 proteins 
have also been demonstrated to restrict the retrotransposition events of retrotransposons 
from both mice and yeast (Esnault et al., 2005). The anti-viral effects of the different 
human APOBEC3 proteins for a range of known substrates are summarised in Table 1.1 





















A3A 1  HIV‐1 (myeloid cells)  AAV, HPV  LINE‐1, Alu, IAP, MusD 
A3B 2  HIV‐1, SIV,   HBV  LINE‐1, Alu, IAP, MusD 
A3C 1  SIV, PFV  HBV, HSV‐1, HPV  LINE‐1, Alu, IAP, MusD, Ty1 
A3D/E 2  HIV‐1, SIV     
A3F 2  HIV‐1, SIV, MLV PFV  HBV  LINE‐1, IAP, MusD, Ty1 
A3G 2  HIV‐1, SIV, MLV, EIAV, PFV  HBV  Alu, IAP, MusD, Ty1 
A3H 1  HIV‐1  HPV  LINE‐1, Alu 
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The fact that they form part of a broad antiviral immune response is highlighted by their 
upregulation upon interferon alpha stimulation. Although A3DE, A3F, A3G and A3H 
show modest increases at the RNA level in CD4+T cells, macrophages and dendritic 
cells, A3A shows a much more substantial increase at both the RNA and protein levels 
(Koning et al., 2009). This would indicate its prominent involvement in first line anti-
viral defence though its exact contribution requires further exploration. It has recently 
been proposed that several of the APOBEC3 proteins, particularly A3A, are able to 
mediate the clearance of foreign DNA from cells in response to interferon stimulation 
through editing dependent means (Stenglein et al., 2010). This helps protect the cell 
from aberrant DNA, viral or otherwise. The authors found that cellular genomic DNA 
was not targeted, implying a degree of specificity to the actions of the APOBEC3 
proteins. However, it has recently been reported that A3A is able to deaminate nuclear 
DNA (Suspene et al., 2011a). 
 
1.8 Other APOBEC proteins 
1.8.1 APOBEC1  
APOBEC1 is an RNA editing enzyme that preferentially edits the mRNA encoding the 
ApoB protein. It binds to its target RNA through recognition of an 11 nucleotide 
‘mooring sequence’ which is essential for editing (Shah et al., 1991). It introduces a 
stop codon into the transcript, generating two protein products, both of which are 
involved in lipid transport in the blood [reviewed in (Keegan et al., 2001)]. APOBEC1 
works in conjunction with a co-factor termed APOBEC1 complementation factor (ACF) 
(Mehta et al., 2000), which acts to suppress nonsense mediated decay (NMD) of the 
edited RNA and may recruit APOBEC1 to its target RNA (Chester et al., 2003).  
Additional targets of APOBEC1 have also now been identified with editing target sites 
primarily located in AU rich regions of the 3’UTR (Rosenberg et al., 2011). APOBEC1 
has a very limited tissue distribution and appears to be restricted to the small intestine, 
whereas ACF displays wider expression (Mehta et al., 2000). Unlike its closely related 
APOBEC3 family members it does not appear to be involved in the restriction of 
exogenous viruses. 
Murine and rat APOBEC1 are also involved in the stabilisation of mRNAs containing 
AU rich elements (ARE) within their 3’UTRs. These AU rich sequences serve to post-
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transcriptionally modify protein expression through binding of cellular proteins that can 
either induce the stabilisation or degradation of these mRNAs (see section 1.11.6). 
Targets of murine APOBEC1 include c-myc RNA and cyclooxygenase 2 (Cox-2) 
(Anant and Davidson, 2000; Anant et al., 2004). Analagous activity has not yet been 
reported for the human protein. 
1.8.2 AID 
AID (Activation Induced Deaminase) is expressed in B cells and stem cells and is 
involved in fundamental processes relating to antibody diversification, namely somatic 
hypermutation, class switch recombination and gene conversion (Arakawa et al., 2002; 
Harris et al., 2002b; Martin et al., 2002; Muramatsu et al., 2000). Mutations in AID lead 
to immunodeficiencies characterised by the presence of solely IgM antibodies (hyper 
IgM) (Muramatsu et al., 2000). Initially it was assumed that AID, like APOBEC1 
would target RNA substrates, as these proteins share several similar features. However, 
it is now known that AID, like the APOBEC3 proteins, edits single stranded DNA 
(Bransteitter et al., 2003). Similar to APOBEC1, AID achieves its function with the 
help of a co-factor, this time replication protein A (RPA), a single stranded DNA 
binding protein with roles in RNA metabolism (Chaudhuri et al., 2004).  
1.8.3 APOBEC2 and APOBEC4  
In comparison, relatively little is known about the remaining family members, 
APOBEC2 and APOBEC4. APOBEC2 is expressed exclusively in heart and skeletal 
muscle cells but mice lacking this protein show no defects in development, survival or 
fertility (Mikl et al., 2005). It may possess some cytidine deaminase activity, albeit 
weak, though the relevance of this in terms of function and target substrates has not yet 
been addressed (Liao et al., 1999). However, the fact that it is subject to negative or 
purifying selection (Sawyer et al., 2004) suggests that it does have an important 
functional role. APOBEC4 was discovered via computational prediction methods 
(Rogozin et al., 2005) and interestingly it is primarily expressed in the testes, 
postulating a potential role in defence of the germline. However, its editing capabilities 






1.9 APOBEC3 proteins and ribonucleoprotein (RNP) complexes 
The fact that all of the APOBEC3 proteins are catalytically functional raises the 
important question of how their enzymatic activities are regulated such that they do not 
erroneously mutate cellular nucleic acid. Although A3A has very recently been reported 
to edit such DNA, other APOBEC3 proteins that also localise to the nucleus were not 
found to have the same effect (Suspene et al., 2011a). As has been mentioned the 
APOBEC3 proteins may be involved in targeting and editing foreign DNA, which 
would have to be differentiated from that of host DNA as no mutations in genomic 
DNA were found (Stenglein et al., 2010). It has also been reported that in certain cell 
lines which express high levels of A3G, for instance, only very moderate amounts are 
found incorporated into Δvif virions, implicating the existence of cellular and/or viral 
regulatory mechanisms (Rose et al., 2005). A3F and A3G associate in high molecular 
mass (HMM) ribonucleoprotein (RNP) complexes under normal cellular conditions. 
Chiu et al have reported that A3G contained within these complexes is enzymatically 
inactive and its function is only restored upon dissolution of the complex through 
RNase treatment (Chiu et al., 2005). Similarly, A3G’s interaction with viral RNA in 
virions has been suggested to repress its deaminase activity. Only during reverse 
transcription, when the RNA is degraded by the RNase H activity of RT is A3G 
liberated to edit the nascent cDNA transcript (Soros et al., 2007). Relevantly, the 
activities of both APOBEC1 and AID are regulated by cellular RNA (Bransteitter et al., 
2003; Sowden et al., 1996). For example, in order for AID to target single stranded 
DNA substrates it must first be pre-treated with RNase in order to remove inhibitory 
bound RNA (Bransteitter et al., 2003). A similar finding has recently been published for 
A3G (McDougall and Smith, 2011). These examples highlight the importance of 
interactions with cellular and viral components for functional regulation and highlight 
the many levels at which this regulation can occur.  
Several groups have therefore sought to identify the specific protein and RNA 
compositions of these complexes to gain better insight into APOBEC3 function. The 
identification of these interacting factors may help uncover the determinants of the 
substrate specificities of the different APOBEC3 proteins, their involvement in cellular 
processes and potential cellular co-factors, all of which remain largely uncharacterised. 
Through a combination of affinity purifications, mass spectrometry and co-
immunoprecipitations, a large number of A3F and A3G associated proteins have now 
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been identified (Chiu, 2011; Chiu et al., 2006; Gallois-Montbrun et al., 2008; Gallois-
Montbrun et al., 2007; Kozak et al., 2006; Wichroski et al., 2006). Predominantly these 
are RNA binding proteins, involved in the metabolism and turnover of RNA, implying 
that the APOBEC3 proteins may contribute to the regulation of RNA. Although the 
majority of these interactions were bridged by RNA, the Argonaute proteins appeared to 
interact with A3F and A3G in a partially RNase insensitive manner (Gallois-Montbrun 
et al., 2008; Gallois-Montbrun et al., 2007), suggestive of a close and potentially direct 
interaction, although this was not reproduced by another group (Wichroski et al., 2006). 
The APOBEC3 proteins also co-localised with the Argonautes and a subset of other 
identified associated cellular factors to cytoplasmic foci termed mRNA Processing 
Bodies (P-bodies, discussed in more detail in section 1.10.1) in both primary cells and 
cell lines (Gallois-Montbrun et al., 2007; Wichroski et al., 2006). The Argonaute 
proteins are fundamental components of the RNA induced silencing complex (RISC), 
which is involved in the post-transcriptional control of gene expression through small 
non-coding RNAs, both microRNAs (miRNAs) and small interfering RNAs (siRNAs) 
(see section 1.11.1). The functional relevance of this interaction has yet to be 
determined but it has been reported that the APOBEC3 proteins can inhibit miRNA and 
siRNA mediated regulation of protein expression (Huang et al., 2007a), thus attributing 
an antagonistic role to the APOBEC3 proteins in this cellular pathway. However, these 
findings have yet to be independently verified. 
Therefore the full functional roles of the APOBEC3 proteins, both cellular and anti-viral, 
have yet to be determined, as well as the basis for the underlying differences in anti-
viral activities and target substrate specificities. The identification of associated proteins 
involved in a diverse array of functions relating to RNA regulation may provide some 









1.10  Cytoplasmic foci 
1.10.1 mRNA Processing bodies (P-bodies) 
The dynamic equilibrium between translation and decay is an important mechanism in 
the control of gene expression. mRNAs exiting the nucleus may be translated 
immediately, degraded or be diverted into a state of repression, followed by either 
translation or decay. These differential fates of an mRNA transcript will be governed by 
changing cellular requirements in response to both internal and external stimuli.  
An mRNA marked for degradation requires removal of the pre-initiation complex 
consisting of the small 40S ribosomal subunit, eIF4F factors (eIF4A, eIF4E, eIF4G) and 
the poly A binding protein (PABPC1), among others, and formation instead of a 
translationally repressed messenger ribonucleoprotein (mRNP) complex. The first step 
in this process is removal of the 3’-polyadenosine [poly(A)] tail in a process called 
deadenylation. In mammalian cells this is initiated by the PARN2-PARN3 poly(A) 
nucleases and continued by the CCR4/Pop2/Not complex of deadenylases. This is then 
followed by degradation which can occur by one of two pathways in eukaryotic cells. 
The first is mediated by a series of 3’ - 5’ exonucleases, termed the exosome, which 
executes decay of the RNA from the 3’ end. Alternatively, the mRNA may first be 
decapped by the Dcp1a/Dcp2 decapping enzymes and several co-activators such as 
DDX6, Lsm1, Ge1, Pat1 and EDC3, and is then subject to 5’ - 3’ exonucleolytic 
degradation by Xrn1 [reviewed in (Parker and Song, 2004)]. These two pathways 
appear to be spatially segregated as components of the latter, as well as several 
deadenylases (Zheng et al., 2008), have been found to concentrate in non-membraned 
cytoplasmic foci termed mRNA Processing Bodies (P-bodies) (Cougot et al., 2004; 
Sheth and Parker, 2003). These RNP aggregates have been implicated in the storage 
and/or decay of untranslated mRNA and thus components of several post-transcriptional 
regulatory pathways have also been identified in P-bodies. These include miRNAs, 
siRNAs, the Argonaute proteins, GW182 and Mov10 (miRNA/siRNA mediated 
silencing) (Eystathioy et al., 2003; Liu et al., 2005b; Meister et al., 2005); Upf1, Upf2, 
Upf3 and SMG-7 (nonsense mediated decay) (Sheth and Parker, 2006); TTP, FXR1 and 
Brf1 (ARE mediated decay) (Franks and Lykke-Andersen, 2007). These pathways will 
be discussed in more detail in the following sections. Intriguingly, several APOBEC3 
proteins have also been found associated with P-bodies, including A3F and A3G 
(Gallois-Montbrun et al., 2008; Gallois-Montbrun et al., 2007; Niewiadomska et al., 
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2007; Wichroski et al., 2006). The relevance of their localisation to these structures 
however, remains to be determined. P-bodies are further characterised by the relative 
absence of ribosomes and translation initiation factors, except for eIF4E. However, it is 
most likely to be in an inactive state as its binding partner and functional antagonist, 
eIF4E-T, co-localises with it to these foci (Andrei et al., 2005). 
P-bodies are highly conserved and in yeast they consist of a similar, though not 
identical, protein composition. There are no GW182 or Ge1 homologues in yeast, nor is 
there a functional miRNA pathway. Further, although Lsm1 depletion leads to loss of P-
bodies in human cells, in yeast it results in an increase in their size and number, 
indicating that even if the same proteins are present they may not function in the same 
way (Teixeira and Parker, 2007). What is absolutely fundamental, however, is the 
presence of RNA. The formation of P-bodies is dependent upon the pool of untranslated 
mRNA (Teixeira et al., 2005) and drugs which inhibit translation initiation (eg 
puromycin) result in larger P-body formation. Conversely, those that inhibit translation 
elongation, such as cyclohexamide, decrease the size and number of P-bodies (Brengues 
et al., 2005; Teixeira et al., 2005). Further, partially purified P-body fractions are 
disassembled upon treatment with RNase (Teixeira et al., 2005) indicating that RNA is 
necessary for structural integrity.  
Nevertheless, the manner in which P-bodies assemble is not fully understood. It is most 
likely based on associations between RNA and proteins and several P-body proteins 
have been shown to interact either directly or indirectly via co-immunoprecipitation and 
yeast 2 hybrid analysis (Hock et al., 2007; Landthaler et al., 2008; Meister et al., 2005; 
Zheng et al., 2011). Intriguingly, several P-body proteins contain a 
glutamine/asparagine (Q/N) rich like prion domain which may allow the self 
aggregation of proteins such as GW182 and Ge1 both of which are essential for P-body 
formation (Jakymiw et al., 2005; Reijns et al., 2008; Yu et al., 2005). These proteins 
may then act as scaffolds with which other proteins could interact, which is analogous 
to the assembly of the closely related stress granule structures (discussed in section 
1.10.2). Also some components appear to be more important than others as knockdown 
of DDX6 or Lsm1 but not EDC3, will cause the dissolution of visible P-bodies. This 
may be related to their effects on translation, as P-body formation may be dependent on 
a critical mass of untranslated mRNA. Thus, DDX6, which is a known translational 
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repressor may impact upon this threshold more than other proteins [reviewed in (Parker 
and Sheth, 2007)].  
It has also been suggested that different populations of P-bodies may exist within the 
cell and may serve to segregate the repressive and degradative functions of these 
structures. This is based on the observation that although GW182 and Dcp1a co-localise 
and interact with a variety of P-body proteins, the foci that they mark only partially 
overlap, which implies they represent two separate pools of mRNP complexes 
(Gibbings et al., 2009). Further, different types of P-bodies may be present at different 
stages of the cell cycle, which has been noted in yeast as well as in human cells 
(Teixeira et al., 2005; Vasudevan et al., 2008; Yang et al., 2004). In yeast, P-bodies are 
highly sensitive to cellular stress, with the size and number of these foci increasing in 
response to external stimuli with a concomitant decrease in translation rates. In human 
cells, several P-body components, such as the Argonautes and DDX6, re-localise to 
stress granules during periods of cellular stress. This highlights the very dynamic and 
mobile nature of P-bodies with proteins continually shuttling between these foci and the 
diffuse cytoplasm. In fact, it has been reported that for Ago2, only 1.3% of the total 
amount of cellular protein is in P-bodies at any one time (Leung et al., 2006). Therefore 
even though the local concentration is high in P-bodies, it may represent only a small 
fraction of the total cellular pool.  
1.10.2 Stress granules (SGs) 
Related to P-bodies, though distinct foci found in human cells are stress granules (SGs), 
which are rapidly and reversibly formed in response to cellular stresses such as heat 
shock. Stress granules are conserved in S. pombe but are not found in S. cerevisae. In 
response to stress, mRNAs encoding housekeeping proteins are translationally repressed 
while those encoding proteins involved in the stress response such as molecular 
chaperones and damage repair enzymes are preferentially translated (Kimball et al., 
2003).  
Formation of SGs is triggered by phosphorylation of eIF2α by one of several stress 
induced kinases, such as protein kinase R (PKR). This results in ribosome run off 
whereby stalled initiation complexes assemble on the mRNA, leading to the 
disassembly of polysomes and hence inhibition of translation initiation (Kedersha et al., 
1999). These complexes are then targeted to SGs, supported by the fact that several 
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translation initiation factors such as eIF2, eIF3, eIF4E and eIF4G, PABPC1 and the 
small 40s ribosomal subunit have been found to localise to them (Buchan and Parker, 
2009). SG assembly is dependent upon self-aggregation of RNA binding proteins such 
as TIA-1 and G3BP, which are also involved in RNA metabolism. They aggregate 
through their glutamine rich prion like domains and thus form a scaffold on which other 
proteins can assemble (Gilks et al., 2004). Other components of SGs include FXR1, 
HuR and TTP, proteins associated with ARE mediated RNA regulation (see section 
1.11.6). Upon relief of the stress, SGs disassemble and normal translation is resumed 
with mRNAs released back into the cytoplasm or targeted to P-bodies. Certain P-body 
proteins have been identified in or re-localise to SGS during their formation including 
the Argonaute proteins, DDX6 and Xrn1 (Buchan and Parker, 2009), though the 
implications of this are not known and in fact the majority of these proteins may be re-
directed from the cytoplasm rather than from P-bodies. Other proteins such as GW182 
and Dcp1a are exclusively associated with P-bodies (Anderson and Kedersha, 2006). In 
many ways, P-bodies and SGs are intimately linked. Both are dependent on untranslated 
mRNA for their maintenance and SGs are similarly affected by inhibition of translation 
initiation and elongation as observed for P-bodies (see section 1.10.1). Also these foci 
are often in close physical proximity (Kedersha et al., 2005). Arsenite treatment, for 
instance, results in the assembly of P-bodies and SGs that are physically connected, but 
how material is exchanged between them is not well understood. Translationally 
repressed mRNAs may be targeted to SGs for translation initiation complex formation 
before being directed to polysomes. On the other hand, mRNAs in SGs may be sent to 
P-bodies for degradation. Most probably, components shuttle bi-directionally between 









1.11 Post-transcriptional regulatory pathways 
Once an mRNA has been transcribed it can either be translated into protein or may be 
subject to several post-transcriptional regulatory mechanisms that serve to regulate gene 
expression at the RNA level. These processes allow the cell to rapidly respond to 
changing environmental conditions and external stimuli, such as viral infection, by fine 
tuning expression of individual genes (Bartel and Chen, 2004). The preceding sections 
will serve to outline the cellular RNA regulatory pathways of miRNA mediated 
translational repression, ARE-mediated decay and nonsense mediated decay, and 
highlight their close interplay in the control of RNA.  
1.11.1 miRNA mediated translational repression 
microRNAs (miRNAs), small interfering RNAs (siRNAs) and PIWI-interacting RNAs 
(piRNAs) are three types of small non-coding, endogenously encoded RNAs that serve 
to regulate both cellular and foreign RNA transcripts. Although they are closely related 
and interact with similar complexes of proteins to mediate their effects, their biogenesis 
and mechanisms of actions, as well as their target RNAs appear to be somewhat distinct. 
miRNAs are approximately 18 - 22 nucleotides long and are conserved from plants to 
mammals. Approximately 1000 miRNAs have been described thus far in humans and 
more than 60% of all cellular mRNAs are predicted to be targets of miRNAs (Sayed and 
Abdellatif, 2011). They have been implicated in influencing a number of cellular 
processes including cell proliferation, differentiation, apoptosis, development and the 
stress response (Bushati and Cohen, 2007). The importance of miRNA control is 
highlighted by their dysregulation, which is often associated with diseases such as 
cancer (Farazi et al., 2011). 
miRNAs are found mostly within introns and are transcribed, like cellular mRNAs, by 
RNA polymerase II. This yields a primary miRNA transcript (pri-miRNA) containing a 
stem loop structure. This transcript is first processed in the nucleus by the RNase III 
enzyme Drosha (Lee et al., 2003; Lee et al., 2002) and its binding partner, 
DGCR8/Pasha, which cleave the hairpin structure to generate a pre-miRNA precursor. 
The 2 nt 3’ overhang created by this cleavage event is recognised by Exportin 5, which 
directs its transport out of the nucleus and into the cytoplasm (Lund et al., 2004; Yi et 
al., 2003). A second processing event then occurs, this time mediated by the RNase III 
enzyme Dicer (Hutvagner et al., 2001) and its interacting partners TAR RNA binding 
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protein (TRBP) and PKR associated protein activator  (PACT). This produces a double 
stranded duplex which is unwound to release the two strands, one of which is 
subsequently degraded (Schwarz et al., 2003). However, recent reports in Drosophila 
suggest that both strands may in fact be functionally active (Czech et al., 2009; 
Ghildiyal et al., 2010; Okamura et al., 2009)). The remaining strand, termed the guide 
strand, is incorporated into an RNA induced silencing complex (RISC) (Gregory et al., 
2005; Hammond et al., 2001), recruited by TRBP. Minimally RISC comprises one 
member of the Argonaute protein family and the miRNA. The miRNA will then guide 
RISC to the target mRNA based on sequence complementarity of its seed region 
(between the 2nd and 8th base) with the 3’UTR of the mRNA (Hutvagner and Zamore, 
2002). Perfect complementarity results in endonucleolytic cleavage mediated by 
Argonaute 2 (Martinez and Tuschl, 2004), the only catalytically active Argonaute 
protein in mammals (Liu et al., 2004; Meister et al., 2004). However endogenous 
mammalian miRNAs tend to be imperfectly base-paired with their targets and are thus 
translationally repressed and usually degraded by any one of the four Argonaute 
proteins expressed in humans (Figure 1.8). The lack of necessity for perfect homology 
between the miRNA and its target means that one miRNA can potentially influence the 











Figure 1.8: miRNA biogenesis and mechanism of action. 
miRNAs are transcribed by RNA Pol II into pri-miRNA precursors and are subsequently processed by the 
RNase III enzyme Drosha and exported into the cytoplasm as a pre-miRNA. This is then processed by the 
RNase III enzyme Dicer, which cleaves the hairpin structure to yield a miRNA duplex. The two strands 
are unwound and the guide strand is incorporated into RISC and directs its binding to the 3’UTR of the 
target mRNA. The degree of complementarity between the miRNA and the mRNA determines whether 
the mRNA is cleaved by Argonaute 2 or translationally repressed and subsequently degraded.  
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The mechanism of translational repression, instigated by the Argonaute proteins, is very 
poorly understood and highly controversial [reviewed in (Eulalio et al., 2008a)]. It has 
been proposed that translation initiation is inhibited, as cap independent translation is 
not affected by miRNAs. The mode of inhibition has been attributed to direct 
competition between Ago2 and the eIF4E translation initiation factor for binding to the 
m7G Cap (Kiriakidou et al., 2007). However, these findings have since been challenged 
(Eulalio et al., 2008b). It is also possible that a step after translation initiation is affected, 
such as elongation, summarised by the ribosome drop off model where ribosome 
binding to mRNA transcripts is of low affinity and hence short lived. The controversies 
surrounding this issue may imply that a multitude of mechanisms may exist that are 
dependent on the specific miRNAs and mRNAs involved as well as the cellular 
conditions. However, other cellular factors have also been shown to be necessary for 
miRNA mediated repression, most prominently GW182 (Jakymiw et al., 2005; Liu et 
al., 2005a; Meister et al., 2005). This protein directly interacts with the Argonautes yet 
it can independently mediate effects that promote translational repression (Behm-
Ansmant et al., 2006; Li et al., 2008). This is reportedly a result of its interaction with 
PABPC1 and subsequent recruitment of the CCR4-NOT deadenylase complex (Zekri et 
al., 2009) 
Repressed transcripts may be temporarily stored at P-bodies. Importantly, this can be a 
reversible process where, if cellular conditions permit, these mRNAs can be released 
back into the cytoplasm for translation. For example, the Cat1 mRNA, targeted by the 
mir122 miRNA, is translationally repressed and stored in P-bodies. Upon cellular stress, 
however, the mRNA is released from P-bodies and transported to polysomes with the 
aid of the ARE-rich-element (ARE) binding protein HuR (Bhattacharyya et al., 2006). 
Aside from cleavage and repression, mRNAs may also be degraded by the 5’ - 3’ 
exoribonuclease Xrn1, in P-bodies. Recently, miRNAs have also been implicated in 
promoting mRNA translation indicating that their affects are not solely limited to 







1.11.2 Other small non-coding RNAs 
As mentioned, other small non-coding RNAs also exist. siRNAs (approximately 21-23 
nt in length) are transcribed from long double stranded RNA and subsequently 
processed by Dicer (Kim et al., 2009). siRNAs are nearly always identical to their RNA 
targets and are thus dependent on Argonaute 2 and endonucleolytic cleavage for 
silencing, in a process commonly referred to as RNA Interference (RNAi). It was 
widely believed that animals, unlike plants and fungi, did not encode siRNAs. Recently, 
however, endo-siRNAs have been identified in the germline of mice (Tam et al., 2008; 
Watanabe et al., 2008) and the germline and somatic cells of flies (Czech et al., 2008; 
Ghildiyal et al., 2008; Kawamura et al., 2008; Okamura et al., 2008) that are products of 
Dicer processing. It is believed that these endo-siRNAs depend upon Ago2 for silencing 
and primarily function to target transposable elements, thereby protecting cells from 
their deleterious effects. This is analogous to the actions of piRNAs present in the 
germline of both flies and mammals (Aravin et al., 2006; Girard et al., 2006; Grivna et 
al., 2006; Lau et al., 2006). These RNAs are typically longer than miRNAs and siRNAs, 
at 26 – 31 nucleotides in length. They are encoded in areas of the genome that also 
contain fragments of transposable elements thus generating antisense transcripts 
directed at these mobile genetic elements (Aravin et al., 2007; Klattenhoff and 
Theurkauf, 2008). In contrast to endo-siRNAs, however, piRNAs are generated by a 
Dicer independent mechanism (Vagin et al., 2006) and associate with a separate sub-
family of Argonaute proteins, termed PIWI proteins, to mediate silencing. Nevertheless 
this highlights the close interplay and overlapping functions of small non-coding RNAs. 
1.11.3 Argonaute proteins 
The Argonaute proteins are fundamental components of the RISC complex which 
mediates miRNA mediated translational repression and RNAi. Because of this they are 
highly conserved from plants to mammals, though they differ in number. Fission yeast 
have only one Argonaute protein, for example, whereas C. elegans has twenty-four. In 
humans, eight members of the Argonaute protein family have been identified (Sasaki et 
al., 2003) and are equally divided into two sub-families; the Argonaute proteins which 
are ubiquitously expressed and the PIWI proteins whose expression is restricted to the 
germline but are still involved in RNA silencing (see section 1.11.2).  
The four Argonaute proteins expressed in human somatic cells, Argonautes 1 - 4, share 
approximately 80% amino acid sequence identity (Sasaki et al., 2003). The structure of 
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these proteins can be divided into four main domains; the N-terminal, PAZ, PIWI and 
MID domains. Crystal structures of the full length Argonaute protein from P.furiosis 
(Song et al., 2004) and the PAZ domains of the Drosophila Argonaute proteins (Lingel 
et al., 2003; Song et al., 2003; Yan et al., 2003) have shed light on the contributions of 
these domains to Argonaute function. The MID domain forms a highly basic pocket and 
binds the 5’ phosphate of RNAs, thus helping maintain association with the Argonaute 
protein. The PAZ domain is found in all Argonaute and Dicer proteins and contains an 
OB fold, which is critical for nucleic acid binding. This domain forms a binding module 
for 2 nt 3’ overhang RNAs generated by RNase III type enzymes. The PIWI domain is 
unique to the Argonautes and consists of an RNase H fold with conservation of two 
aspartate residues forming a critical active site, common to all RNase H proteins. 
However, unlike these other proteins, in the Argonautes, this is followed by a histidine 
rather than another aspartate, garnering a unique Asp-Asp-His motif [reviewed in (Tolia 
and Joshua-Tor, 2007)]. Although all of the Argonaute proteins are able to facilitate 
miRNA mediated repression, as demonstrated by direct tethering experiments (Pillai et 
al., 2004), only Argonaute 2 has retained its enzymatic capacity and is therefore capable 
of endonucleolytic cleavage (Liu et al., 2004). However the Asp-Asp-His motif is 
necessary but not sufficient to confer enzymatic activity as it is also present in the 
catalytically inactive Argonaute 3 protein. This points towards a contribution of either 
cellular co-factors or post-translational modifications for endonuclease activity. In 
Drosophila the two Argonaute proteins retain very distinct functions with Argonaute 1 
involved in repression and Argonaute 2 mediating cleavage (Forstemann et al., 2007). 
The Argonaute proteins may also be involved in miRNA biogenesis as it has been 
reported that they cleave the pre-miRNA hairpin structure and thus aid removal of the 
passenger strand of the RNA duplex (Cheloufi et al., 2010; Cifuentes et al., 2010). 
Further Argonaute 2 has been implicated in miRNA mediated translational upregulation 
of mRNAs in stress induced serum starved conditions (Vasudevan and Steitz, 2007a). 
The Argonaute proteins are predominantly cytoplasmic and components of P-bodies but 
can re-locate to stress granules during periods of cellular stress (Liu et al., 2005b; Pillai 
et al., 2005; Sen and Blau, 2005). This allows control of cellular translation in response 
to changing environmental conditions as various translational initiation factors are also 
found in these structures. These findings highlight the varied roles played by the 
Argonaute protein in RNA regulation. 
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1.11.4 miRNAs and viruses 
RNAi has long been established as a means of antiviral defence in both plants and 
invertebrates. Conversely viruses that infect these organisms encode inhibitors of the 
RNAi pathway as a means of overcoming this innate immunity. For example, the P19 
protein, encoded by the tomato bushy stunt virus is able to bind to siRNAs and prevent 
their loading onto RISC (Voinnet et al., 1999). Whether a similar system exists in 
mammals remains to be determined. The components of this pathway, e.g. Argonaute 2, 
are present and functional in mammals but only very recently have endogenous siRNAs 
been shown to exist and the subject of virally encoded siRNAs remains controversial. 
Further, unlike plants and nematodes, mammals do not appear to encode an RNA 
dependent RNA polymerase (RDRP), which in these organisms greatly increases the 
number of siRNAs for an mRNA target, thereby amplifying the RNAi response (Aoki et 
al., 2007; Diaz-Pendon et al., 2007). More importantly, mammals have developed a 
more sophisticated form of immunity that is based on protein recognition and induction 
of the interferon response, which may make more ancient nucleic acid based immunity 
somewhat redundant.  
However there is increasing interest in the interplay between cellular and/or viral 
miRNAs in both the control and promotion of virus replication. Potentially, this can 
work in one of four ways: virally encoded miRNAs targeting viral mRNAs, virally 
encoded miRNAs targeting cellular mRNAs, cell encoded miRNAs targeting cellular 
mRNAs and cell encoded miRNAs targeting viral mRNAs [reviewed in (Umbach and 
Cullen, 2009)]. The fact that miRNAs are small and non-antigenic means that host 
and/or viral gene expression can be modulated without eliciting cellular immune 
responses. 
Virally encoded miRNAs have now been identified, mostly from DNA viruses with a 
nuclear phase of their life cycle, thus granting them access to the miRNA processing 
machinery (Cullen, 2011; Grundhoff and Sullivan, 2011). Whether RNA viruses, 
including retroviruses, also harbor miRNAs is the subject of much debate as 
endonucleolytic processing of RNA genomes to generate encoded miRNAs may prove 
detrimental to the virus. Thus the identification of putative miRNAs, for this subset of 
viruses, remains controversial. The first virally derived miRNAs were identified from 
the gamma herpes virus, Epstein Barr virus (EBV), by Pfeffer and colleagues (Pfeffer et 
al., 2004). To date more than 200 miRNAs from members of the herpesvirus family 
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have since been discovered which suggests that they may make important contributions 
to the life cycle of these viruses. It has been proposed that herpesvirus encoded miRNAs 
may facilitate latent infection of the virus by downregulating viral protein synthesis. 
This self-regulation allows the virus to avoid cellular immune responses as well as anti-
viral therapies. Latent infection of herpes simplex virus 1 and 2 (HSV1 and HSV2) is 
accompanied by miRNA expression but not viral protein expression. On the other hand, 
infection with a miRNA deleted EBV mutant strain did not result in increased 
replication of the virus, indicating that these miRNAs may not be involved in 
establishing latency for this particular virus (Seto et al., 2010).  
In several instances, virally encoded miRNAs are able to perturb cellular function. In 
most cases, this relates to inhibition of either an apoptotic response or a cellular immune 
response. One example of the latter is the downregulation of MICB by the human 
cytomegalovirus (HCMV) encoded miRNA, mir UL112-1 (Stern-Ginossar et al., 2007). 
MICB is expressed on the surface of cells in response to cellular stress, such as viral 
infection, and is recognised by the NKG2D receptor found on natural killer (NK) cells. 
This subsequently results in NK mediated destruction of the infected cell, which HCMV 
avoids by miRNA mediated targeting of MICB expression. Through a mechanism of 
convergent evolution, EBV and Kaposi’s sarcoma associated herpes virus (KSHV) also 
encode miRNAs that target MICB (Nachmani et al., 2009), highlighting this as an 
important means of immune avoidance by herpesviruses. 
More rarely, viruses can also utilise cellular miRNAs for their own propagation. mir122 
which is abundantly expressed in the liver, facilitates replication of hepatitis C virus 
(HCV) and unusually binds to sites contained within the 5’UTR of the virus rather than 
the conventional 3’UTR observed for all animal miRNAs (Jopling et al., 2005). The 
underlying mechanism behind this is not completely understood but it explains the 
inability of HCV to replicate in cells that do not express mir122. Relatedly, knockdown 
of Dicer and/or the Argonaute proteins decreases HCV replication (Randall et al., 2007).  
On the other hand, it has also been demonstrated that cellular miRNAs are able to target 
RNA sequences within viruses, such as primate foamy virus (PFV) (Lecellier et al., 
2005) and influenza A (Song et al., 2010), and inhibit their replication. However, the 
impact of these miRNAs during the course of a natural infection remains to be 
determined. Therefore the complex dynamics of host and viral miRNAs in the life cycle 
of a range of different viruses is becoming increasingly evident.  
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1.11.5 miRNAs and HIV-1 
Since the miRNA pathway appears to be important for both the control and promotion 
of several DNA and RNA viruses, including a retrovirus (PFV), increasing attention has 
turned to the role it may play in the replication of HIV-1. However, despite continued 
investigation into this area, it remains a highly controversial issue.  
HIV-1 encoded miRNAs have been identified, including those generated from the 
structured TAR element of the viral RNA, located within all HIV-1 transcripts (Klase et 
al., 2007; Ouellet et al., 2008). This RNA is potentially recognised and cleaved by Dicer 
and protects cells from stress induced cell death, by targeting cellular mRNAs (Klase et 
al., 2009). However, the expression of these miRNAs appears to be very low and work 
by Lin and Cullen (2007) failed to find significant levels of miRNAs or siRNAs in HIV 
(and human T-cell lymphotropic virus, HTLV-1) infected T cells (Lin and Cullen, 
2007). This questions the contribution of these putative miRNAs to HIV-1 replication.  
Alternatively, HIV-1 may perturb host encoded miRNAs and the miRNA pathway for 
its own benefit. HIV-1 infection is reported to cause global changes in cellular miRNA 
expression as determined by miRNA profiling of uninfected versus infected individuals 
(Houzet et al., 2008). Several cellular miRNAs were found to be downregulated and 
similar results have been obtained from in vitro infection studies in cell lines (Hayes et 
al., 2011; Yeung et al., 2005). This also implies that humans may be able to utilise the 
miRNA pathway for viral restriction despite the presence of more sophisticated forms 
of innate immunity. Plant viruses encode suppressors of RNA silencing (SRS) that act 
to antagonise the RNAi pathway, which is the primary mechanism of anti-viral defence 
in these organisms. Similarly, SRS activity has been attributed to the viral accessory 
proteins Tat and Vpr, a subject that remains heavily debated.  Both proteins have been 
proposed to interact with Dicer and affect its function in miRNA biogenesis (Bennasser 
and Jeang, 2006; Bennasser et al., 2005; Coley et al., 2010; Hayes et al., 2011). The 
viral TAR RNA may also compete with Dicer for binding to its essential co-factor 
TRBP. However, other groups have found that expression of Tat in infected cells does 
not inhibit miRNA production or expression (Lin and Cullen, 2007; Sanghvi and Steel, 
2011). The reason for these discrepancies remains unclear at present but the role of Tat 
and its effects on the miRNA pathway requires further experimental validation.  
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Other studies have also alluded to the fact that the miRNA pathway may be inhibitory 
to viral replication. Knockdown of Drosha and/or Dicer has been shown to increase 
both HIV-1 virus production and infectivity (Nathans et al., 2009; Triboulet et al., 2007). 
However, it must be noted that knockdown of these enzymes will also affect cellular 
miRNA expression which may subsequently impact upon cell growth and metabolism. 
Thus these results have to be interpreted with some caution and disentangling direct and 
indirect effects of the miRNA pathway on HIV-1 replication may not be a 
straightforward task.  
Nevertheless, specific host encoded miRNAs have also been identified which are 
thought to regulate the life cycle of this virus. The mir17/92 polycistronic cluster is 
downregulated by HIV-1 and has been proposed to target PCAF, a cellular co-factor of 
Tat, which results in reduced viral protein expression (Triboulet et al., 2007). Also, the 
mir29a miRNA acts to repress HIV-1 mRNA expression by facilitating the association 
of Gag mRNA with Ago2 and P-bodies. Conversely, this may be beneficial to the virus 
in terms of establishing a latent infection and avoidance of host immune responses. 
Other studies show that mir29a instead targets the Nef protein to interfere with viral 
replication (Ahluwalia et al., 2008) and is actually downregulated upon HIV-1 infection 
(Houzet et al., 2008). On a similar note, expression of five cellular miRNAs, also 
targeting Nef, in resting CD4+ T cells, have been reported to contribute to viral latency 
by minimising viral protein expression and maintaining a pool of HIV-1 infected cells 
that are not accessible by HAART (Huang et al., 2007b).  Inhibition of these miRNAs 
resulted in increased HIV-1 protein translation. However, this has been difficult to 
verify due to the low absolute expression of these miRNAs and debates over whether 
they still constitute resting cells after experimental manipulation.  
These examples highlight the complexities and controversies surrounding the 
involvement of the miRNA pathway in HIV-1 replication. Therefore, whether viral or 
host encoded miRNAs can influence the life cycle of HIV-1 is unresolved at present and 







1.11.6 ARE mediated decay (AMD) 
A second form of post-transcriptional gene regulation is that mediated by adenosine (A) 
and uridine (U) rich elements (ARE). These are repetitive and often overlapping 
AUUUA pentamers contained within U rich regions of the 3’UTR, although no formal 
consensus sequence exists. These elements have been classified into three groups (class 
I, II and III) based on loose sequence homology rather than any biological function 
[reviewed in (Chen and Shyu, 1995)]. ARE sequences are often found within mRNAs 
coding for proteins that regulate cell growth or determine the cells ability to respond to 
external stimuli, such as transcription factors, cytokines and cell cycle regulatory 
proteins (Bakheet et al., 2006). ARE sites are recognised and bound by ARE binding 
proteins (ARE-BPs), which will typically promote the degradation or stabilisation of the 
mRNA.  
Several ARE-BPs, along with their mRNA targets have now been identified [reviewed 
in (Barreau et al., 2005)], and one such example, mouse APOBEC1, has already been 
described (see section 1.8.1). Others include AUF1 (Zhang et al., 1993), which can 
affect c-myc, c-fos and granulocyte-macrophage colony-stimulating factor (GM-CSF) 
mRNAs both positively and negatively, with the effects most likely to be cell type 
specific. The Elav related protein, HuR, increases the stability of mRNAs that it 
associates with (Fan and Steitz, 1998), which includes c-fos, tumor necrosis factor alpha 
(TNFα), Cox-2 and interleukin 3 (IL3). Tristetraprolin (TTP) on the other hand is 
mostly destabilising for its targeted mRNAs, such as TNFα (Carballo et al., 1998), Cox-
2 and interleukin 2 (IL2). These data demonstrate that ARE containing mRNAs can be 
bound by more than one ARE-BP and these proteins can thus have overlapping and 
often antagonistic functions. This highlights the versatility of this system and the ability 
of the cell to influence protein expression in response to changing conditions. 
The precise mechanism by which ARE-BPs modulate these effects is not completely 
understood. It is believed that they recruit other cellular components that can either 
degrade or translationally repress the bound mRNA. Indeed it has been shown that ARE 
mediated decay (AMD) is initiated by deadenylation followed by 3’ to 5’ exosomal 
mediated degradation (Mukherjee et al., 2002). However it is now well established that 
degradation can also occur in the opposite direction, where this time loss of the poly A 
tail is followed by decapping and then exonucleolytic decay by the 5’ to 3’ exonuclease 
Xrn1, associated with P-bodies (Stoecklin et al., 2006). Importantly these ARE 
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associated proteins are often found in the closely related, stress induced foci termed 
stress granules (Kedersha and Anderson, 2002). It is believed that a function of ARE-
BPs may be to shuttle mRNAs between P-bodies and stress granules, thereby arresting 
translation without causing degradation in response to the changing requirements of the 
cell.  
Not only do miRNA and ARE effectors localise to the same cytoplasmic structures they 
may also work in unison to regulate translation. As has already been discussed, the 
ARE-BP HuR is able to mitigate the effects of the miR122 miRNA and release the 
translationally repressed Cat1 mRNA from P-bodies into polysomes for translation 
during periods of cellular stress (Bhattacharyya et al., 2006). Jing et al (2005) have also 
reported that Dicer and the Argonaute proteins are involved in the decay of TNFα 
mRNA. Specifically the mir16 miRNA was identified as binding to ARE sequences and 
recruiting the ARE-BP TTP, which indirectly leads to the destabilisation of the mRNA 
(Jing et al., 2005). However the sequence targeted by the miRNA is thought to reside 
outside the ARE region (Vasudevan et al., 2007b). It has also been shown that the 
translational upregulation induced by fragile X mental retardation protein 1 (FXR1) and 
Ago2 on TNFα transcripts during serum starvation is directed by the mir369-3 miRNA 
(Vasudevan et al., 2007b). This miRNA orchestrates the binding of these proteins to the 
ARE sequence and thus allows them to activate translation but only during cell cycle 
arrest. Other miRNAs, such as let-7, were shown to have similar effects. These 
examples highlight the complex interplay between different RNA regulatory 
mechanisms in the control of RNA translation.  
1.11.7 Nonsense mediated decay (NMD) 
A third RNA regulatory pathway is termed nonsense mediated decay (NMD). This is 
where mRNAs harbouring premature termination codons (PTC) are rapidly degraded. 
Premature in frame termination codons can be generated by a number of means 
including insertions, deletions and mutations, which links NMD to a number of genetic 
disease phenotypes.  Like the pathways described above, NMD is conserved from plants 
to mammals although the exact mechanism of degradation and the key components 
involved are the not the same in all cases [reviewed in (Shyu et al., 2008)]. A core 
component of the NMD machinery is the RNA helicase Upf1 which can catalyse the 
unwinding of double stranded RNA (Bhattacharya et al., 2000). The precise mechanism 
of NMD mediated degradation has not been well defined but in mammals it appears to 
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be triggered by accelerated decapping, deadenylation and then decay via the 5’ - 3’ 
pathway, with Upf1 interacting with several components of these processes (Lejeune et 
al., 2003). NMD factors have also been linked to P-bodies, implying that degradation 
may be facilitated by targeting mRNAs to these structures (Sheth and Parker, 2006). 
However, NMD can still occur in the absence of visible foci (Stalder and Muhlemann, 
2009). 
The manner is which these PTCs are recognised and degradation is mediated is not well 
understood but several features appear to be important, though not necessary, such as 
the presence of an exon junction protein complex (EJC) (Le Hir et al., 2000), 
competition between the Poly A Binding Protein (PABPC1) and Upf1 for binding to 
translation release factors (Hilleren and Parker, 1999) and the distance between the PTC 
and the 3’UTR. Recently it has been reported that Upf1 is able to sense the length of 
3’UTRS and preferentially binds to those mRNAs that are sensitive to NMD and thus 
prepares them for decay (Hogg and Goff, 2010) (Figure 1.9). 
1.11.8 Pumilo and FBF (PUF) proteins 
Additionally, PUF proteins, expressed in a wide variety of organisms ranging from 
yeast to humans, also act to modulate mRNA translation and stability with roles in 
differentiation, development, the cell cycle and mitochondrial biogenesis [reviewed in 
(Wharton and Aggarwal, 2006; Wickens et al., 2002)]. These proteins are traditionally 
considered post-transcriptional repressors, as they are able to recruit the CCR4-Pop2-
Not deadenylase complex to mRNAs by directly binding to Pop2 and the 3’UTR of the 
target mRNA (Goldstrohm et al., 2006). This may also lead to recruitment of DDX6 
and Dcp1a, who also interact with the deadenylase complex, leading to decapping and 
subsequent mRNA degradation (Goldstrohm et al., 2006). However, other mechanisms 
of translational repression also exist, such as inhibition of eIF4E binding to the mRNA 
cap thus preventing translation initiation (Cao et al., 2010; Cho et al., 2005). Recently, 
PUF proteins have been attributed with addtitional roles including translation activation 












Figure 1.9: mRNA regulatory pathways.  
mRNAs exiting translation due to post transcriptional regulatory mechanisms including miRNA mediated 
repression, ARE mediated decay or nonsense mediated decay, undergo removal of the polyA tail 
(deadenylation) and then either decay via the exosome (3’-5’) or subsequent decapping and then decay by 
Xrn1 (5’-3’) in P-bodies. mRNAs may be temporarily stored in P-bodies and released back to polysomes 
to be translated or may be trafficked to stress granules. mRNAs in stress granules may then be re-directed 
to polysomes after formation of a pre-initiation complex. During periods of stress mRNAs temporarily 
repressed in stress granules may be directed to P-bodies for decapping and decay. 
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1.12 Functional role of P-bodies  
As has been discussed, components of various different RNA regulatory pathways have 
been found to localise to P-bodies, and decapping, degradation and repression actively 
occur in these foci demonstrating that they are not just storage facilities for these 
proteins (Sheth and Parker, 2003). However, whether P-bodies are necessary for post-
transcriptional processes to occur has been the subject of much debate. Knockdown of 
the essential P-body proteins, GW182 (Eulalio et al., 2008b) and DDX6 (Chu and Rana, 
2006), leads to impairment of miRNA mediated translational repression but the effects 
of individual proteins must be separated from the effects of P-bodies in general. In light 
of this it has been demonstrated that P-body integrity is not necessary for either siRNA 
mediated silencing or DDX6 dependent miRNA repression as concluded from depletion 
of DDX6 and Lsm1 respectively (Chu and Rana, 2006). Similarly in Drosophila, loss of 
P-bodies did not impact upon miRNA, siRNA nor NMD mediated RNA regulation 
suggesting that these processes can occur independently of these foci (Eulalio et al., 
2007b). In fact, it appears that P-bodies are dependent upon the translationally repressed 
mRNAs that these pathways generate (Eulalio et al., 2007b; Stalder and Muhlemann, 
2009). This can be explained, in part at least, by the fact that mRNA degradation/decay 
can occur outside of P-bodies and in the yeast S.cerevisiae it may even occur co-
translationally, while the mRNA is still engaged with ribosomes (Hu et al., 2010; Hu et 
al., 2009). Others have proposed the existence of smaller P-bodies which are 
undetectable by light microscopy but which can serve the same functions as their more 
visible counterparts.  
Since P-bodies are not functionally necessary for RNA regulatory pathways to occur, 
and since most P-body proteins are actually diffuse in the cytoplasm, the conservation 
of these microscopically visible RNA-protein aggregates is intriguing. One advantage 
may be that spatially segregating the decay machinery away from the translating pool of 
mRNA helps avoid unwanted degradation of cellular transcripts. It may also make the 
decay process more efficient, if the necessary machinery is concentrated in one place. 
As has already been discussed, P-bodies also allow mRNAs to be temporarily repressed 





1.13  P-bodies and viral life cycles  
1.13.1 P-bodies as positive regulators of viral replication 
Recently, attention has also focused on the role that P-bodies may play in viral life 
cycles (Beckham and Parker, 2008). Viruses often utilise host machinery in order to 
promote translation of their own mRNAs and certain cellular components will work to 
interfere with this, but the interplay between host factors and viral translation is not well 
understood. Since P-bodies are devoid of translation initiation factors and ribosomes, 
they represent attractive cellular compartments within which viruses may segregate 
translation and assembly or replication of their genetic material. This is especially 
pertinent for retroviruses where the RNA serves as both the template for translation of 
viral gene products and the genomic RNA which needs to be packaged into virions 
(Swanson and Malim, 2006). Therefore P-bodies may positively impact upon the 
replication of viruses. 
In support of this hypothesis, several examples have now been uncovered whereby P-
bodies/P-body components appear to promote replication of both exogenous viruses and 
endogenous retroelements. Firstly, replication and/or translation of the plant brome 
mosaic virus (BMV), which can fully complete its replication cycle in yeast, has been 
shown to require normally repressive P-body components including Dhh1p/DDX6 and 
Lsm1 (Mas et al., 2006; Noueiry et al., 2003). Further, viral proteins were also found to 
localise to P-bodies, which could associate with the plasma membrane, providing a link 
between P-bodies and viral assembly (Beckham et al., 2007). Similarly, hepatitis C 
virus (HCV) replication is also facilitated by P-body components, with the Lsm1 - 7 
hepatmeric complex specifically binding to regulatory elements controlling translation 
and replication in the untranslated regions of the viral RNA (Galao et al., 2010; Scheller 
et al., 2009). This may stabilise the mRNA by protecting it from decapping and 
subsequent decay. Also, the DEAD box helicase protein DDX3 has been shown to 
interact with the HCV core protein, with loss of DDX3 resulting in reduced HCV 
replication (Ariumi et al., 2007; Owsianka and Patel, 1999). The yeast homologue of 
DDX3, Ded1p has been identified as a component of P-bodies (Beckham et al., 2008). 
Although the protein appears to be highly conserved across organisms, whether the 
human protein behaves reciprocally remains to be formally verified. Finally, the 
replication of the yeast Ty1 and Ty3 retroelements is also dependent upon these 
cytoplasmic foci and components contained therein. Ty3 mRNA, proteins and virus like 
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particles (VLPs) have been demonstrated to localise to P-bodies and knockdown of P-
body associated proteins leads to a decrease in retrotransposition events (Beliakova-
Bethell et al., 2006; Checkley et al., 2010). The authors indicate that assembly of VLPs 
appears to be dependent upon P-body integrity. The situation for replication of the Ty1 
retroelement appears to be slightly more complex as although P-body proteins appear to 
enhance formation of retrotransposition competent VLPs, viral mRNA and Gag proteins 
accumulated in foci that were distinct from P-bodies (Checkley et al., 2010). However, 
another group found significantly greater overlap between P-bodies and Ty1 
components (Dutko et al., 2010). Both groups did report that knockdown of P-body 
components decreased formation of VLP clusters and levels of viral proteins as well as 
the association of these viral factors with these particular foci. This suggests that P-body 
proteins may be involved in the trafficking of viral mRNA and Gag to these foci, which 
appear to be sites of virus assembly.  
1.13.2 P-bodies as negative regulators of viral replication 
Conversely, P-bodies could play an inhibitory role in virus replication as viral mRNA 
once targeted to P-bodies may be maintained in a state of translational repression and 
more fatally, be subject to degradation. Several lines of evidence are now emerging to 
lend credence to this theory. Firstly, poliovirus infection causes the disruption of P-
bodies and the degradation of key components such as Dcp1a and Xrn1 (Dougherty et 
al., 2011). Similar observations were also made for stress granules. This data implies 
that to some extent these cytoplasmic foci can somehow antagonise viral replication. 
Secondly, contrary to what has been observed for the Ty retrotransposons in yeast, 
depletion of P-bodies in human cells results in an increase in retrotransposition events 
for the murine intracisternal A particle (IAP) retroelement (Lu et al., 2011). IAP mRNA 
was found to localise to P-bodies thus preventing its association with Gag, which 
accumulated at the ER. These effects were not due to perturbation of the miRNA 
pathway upon knockdown of P-body components. Finally, with regards to HIV-1, two 
groups have recently reported that depletion of P-body and miRNA associated 
components, including Ago2, DDX6 and Lsm1, leads to increases in both virus 
production and infectivity (Chable-Bessia et al., 2009; Nathans et al., 2009). This 
suggests that P-bodies can limit HIV-1, most likely via the miRNA pathway. Both 
studies demonstrated the localisation of HIV-1 viral components, either gRNA and/or 
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Gag at P-body foci. This suggests that HIV-1 may traffic to P-bodies, which in turn may 
serve to limit its replication.  
The fact that several APOBEC3 proteins are known to localise to P-bodies (Gallois-
Montbrun et al., 2008; Gallois-Montbrun et al., 2007; Niewiadomska et al., 2007; 
Wichroski et al., 2006), postulates a possible mechanism of viral inhibition. It has 
recently been claimed that visible ‘A3G complexes’ that partially overlap with P-bodies, 
inhibit HIV-1 particle production, mediated by a reduction in the half-life of Gag 
(Martin et al., 2011). APOBEC3 localisation to these structures may also enable their 
incorporation into nascent virions if indeed Gag does transit through these foci. This is 
further supported by the fact that A3G localisation to P-bodies in yeast is important for 
its inhibition of the Ty1 retroelement, most likely through facilitating its interaction 
with viral components which mediates its incorporation into VLPs (Dutko et al., 2010; 
Dutko et al., 2005). The putative DEAD box helicase, Mov10, which is strongly 
inhibitory to HIV-1 infectivity when overexpressed (Burdick et al., 2010; Furtak et al., 
2010; Wang et al., 2010), is packaged into HIV-1 virions (Chertova et al., 2006) and is 
also a component of P-bodies (Meister et al., 2005). Therefore, the influence that P-
bodies may have in regulating viral life cycles, either positively or negatively, appears 
to be highly complex and multi-faceted. Whether cellular proteins that are able to 
modulate virus replication, such as the APOBEC3 proteins, require P-bodies for their 














It has been demonstrated that the anti-viral proteins A3F and A3G assemble in large 
RNP complexes and associate with a multitude of proteins involved in RNA 
metabolism and turnover. They also localise with a subset of these proteins to P-bodies, 
sites of RNA storage and degradation, which have recently been implicated in 
influencing diverse viral life cycles, both positively and negatively. Of particular 
interest are the Argonaute proteins which interact with A3F and A3G in a partially 
RNase independent manner suggestive of a close and potentially direct association. 
Further, although no known cellular function has been defined for the APOBEC3 
proteins, their interaction with the Argonuate proteins and localisation to P-bodies 
suggests an involvement in the regulation of RNA through post-transcriptional 
processes. How specific proteins or sub-cellular localisation may influence the anti-viral 
and potential unidentified cellular activities of the APOBEC3 proteins remains to be 
determined, either as co-factors or functional regulators.  
Therefore, this thesis aims to address several outstanding issues. Firstly, the interaction 
between the APOBEC3 and Argonaute families will be examined in more detail to 
determine whether interaction with the Argonaute proteins is correlated to the anti-viral 
phenotypes of the APOBEC3 proteins. Further, the functional implications of this 
interaction will also be addressed, in terms of both Argonaute involvement in 
APOBEC3 anti-viral activity and a potential cellular role for the APOBEC3 proteins in 
the regulation of RNA. Finally, the significance of APOBEC3 localisation to P-bodies 
in relation to their anti-viral phenotypes will also be investigated and consequently the 



































2. MATERIALS AND METHODS 
 
2.1 Plasmids  
All expression plasmids used in this study were confirmed to be correct by restriction 
enzyme mapping and/or sequencing where necessary. A list of the primers used for 
cloning is provided in the Appendix. 
2.1.1 Plasmids for transfection 
pCMV4 expression plasmids containing cDNA sequences of APOBEC3A, APOBEC3B, 
APOBEC3C, APOBEC3F, APOBEC3G and APOBEC3G point mutants (described in 
section 5.1) with a 3 x C-terminal HA epitope tag have been previously described 
(Bishop et al., 2004; Huthoff et al., 2009; Huthoff and Malim, 2007). APOBEC3D/E, 
APOBEC3H (haplotype 2) and green fluorescent protein (GFP) cDNAs were cloned 
into the same vector using the HindIII and Xba1 restriction endonucleases. The 
Argonaute 2 cDNA was similarly cloned into the same vector. This Argonaute 2 clone 
contains a HindIII restriction site requiring a 3-way ligation of the insert in order to 
obtain the full cDNA sequence. Wild type DDX6 cDNA was also cloned into this 
vector, again using the HindIII and Xba1 restriction endonucleases. The DDX6 double 
point mutant R89A+K91A (DDX6-A), and the single mutants G346A (DDX6-B) and 
R423Q/HRIGQ (DDX6-C) were generated by site directed mutagenesis using 
overlapping PCR. cDNAs containing the desired mutations were then subcloned into 
the pCMV4 expression vector as described above.  
Untagged APOBEC3A, APOBEC3F and APOBEC3G cDNAs in the pCDNA3.1 vector, 
as well as human and rat APOBEC1 in the same vector are as previously described 
(Bishop et al., 2004) 
An untagged Luciferase expression plasmid was generated for use in infectivity assays 
by cloning Luciferase cDNA, using the Asp718 and HindIII restriction endonucleases, 
with two stop codons encoded in the 3’ primer. This was then inserted into the pCMV4 




The NL43 Δvif proviral plasmid was created by insertion of two stop codons at the end 
of the Pol/Vif reading frame by overlapping PCR in pCMS309 (Vif transfer vector) 
using the Age1 and EcoR1 restriction endonucleases. The mutated insert was then sub-
cloned into the full length NL43 proviral sequence using the Sph1 and EcoR1 
restriction endonucleases. The wild-type NL43 proviral plasmid was a kind gift from Dr 
Malcolm Martin. The IIIB Δvif proviral clone and the pVSV-G expression plasmid are 
as previously described (Bishop et al., 2004; Fouchier et al., 1997).  
cDNAs of DDX6 and Luciferase were cloned into the p3xFLAG CMV expression 
vector as controls for mlin41 assays using the HindIII and BamH1 restriction 
endonucleases.  
Expression plasmids for yeast 2 hybrid assays were generated by insertion of Argonaute 
1 and Argonaute 2 cDNAs into the myc epitope tagged KT7 and HA epitope tagged 
HB18 vectors (kindly provided by Dr Juan Martin-Serrano) using the EcoR1 and Xho1 
(for Argonaute 1) and the EcoR1 and Sal1 (for Argonaute 2) restriction endonucleases. 
The KT7 and HB18 expression plasmids containing the APOBEC3G cDNA had been 
previously generated by Dr Hendrik Huthoff. The Tsg101 cDNA expressed in the KT7 
vector and the Vps28 cDNA expressed in the HB18 vector were kindly provided by Dr 
Juan Martin-Serrano.  
For HIV-1 gRNA and Gag localisation studies, NL43 constructs containing 24xMS2 
binding loops and Gag-Cherry fusions were generated by Dr Nathan Sherer. Briefly, the 
SacII and BsmB1 restriction sites were introduced at the end of the Gag reading frame 
in the wild-type pNL43 expression plasmid by overlapping PCR. The 24xMS2 binding 
loops were then directly sub-cloned into the proviral plasmid using the SacII and 
BsmB1 sites to give pNL43-24xMS2. For generation of the proviral plasmid 
additionally containing mCherry, Gag was fused to mCherry by overlapping PCR and 
sub-cloned into pNL43-24xMS2 using the SacI and SacII restriction sites to give 
pNL43-mCherry-24xMS2. The MS2-YFP fusion plasmid was a kind gift from Dr 
Robert Singer.  
For FRET/FLIM analyses, Argonaute 2 was cloned in frame with the mCherry cDNA in 
the pCMV2B vector (Stratagene) with the EcoR1 and Sal1 restriction endonucleases to 
generate an Argonaute 2 expression plasmid with an N-terminal mCherry fusion. 
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pCMV2B expressing mCherry, YFP and an A3G-YFP fusion had been previously 
generated by Dr Sarah Gallois-Montbrun. 
For pulse labelling experiments, the codon-optimised Gag construct is as previously 
described (Swanson et al., 2010). 
The Argonaute 1, Argonaute 2, Argonaute 3, Argonaute 2-PAZ9 and Argonaute 2-
PAZ10 mutants in the myc epitope tagged pCDNA3.1 vector were kind gifts from Dr 
Gregory Hannon. The Argonaute 2-F2V2 mutant was a kind gift from Dr Zissimos 
Mourelatos.  
The luciferase reporter constructs for the let-7/miRNA assays (wild type/FF4LCS and 
mutant/FFrm4LCS) and for the ARE assays (ARE, AREmt, CTRL and UTR) as well as 
the FXR1 expression plasmid containing both an N-terminal λN and C-terminal FLAG 
epitope tags and HuR expressed in pCDNA3.1 were kind gifts from Dr Joan Steitz. The 
luciferase reporter construct used for the siRNA assay (Lucmir30p) as well as the 
mir30p miRNA and the VA1 expression plasmid were kind gifts from Dr Brian Cullen. 
The DND1 expression plasmid and the pCS2+ empty vector were kind gifts from Dr 
Reuven Agami. The mlin41 expression plasmid containing a 3xFLAG N-terminal 
epitope tag was a kind gift from Dr F. Gregory Wulczyn. The Tat expression plasmid in 
the pCDNA3.1 vector had been previously generated by Dr Chad Swanson.  
The Renilla expression plasmid under the control of the TK promoter was purchased 
from Promega. 
2.1.2 Plasmids for transduction 
For production of stable cell lines wild type and mutant DDX6 cDNAs were also cloned 
into the pCMS28 retroviral vector already containing the yellow fluorescent protein  
(YFP) cDNA (kindly provided by Dr Juan Martin-Serrano) to enable production of N-
terminal YFP fusion proteins. The pCMS28 retroviral vector is a bi-cistronic construct 
derived from MigR1, which contains a polylinker and puromycin resistance gene in 
place of GFP. The resistance gene is linked via an internal ribosomal entry site (IRES) 
to the multi-cloning site, thereby coupling antibiotic selection to mRNA production of 
the gene of interest. This vector was engineered to contain an EcoR1, Not1, Xho1 
multiple-cloning site after the YFP cDNA with a GST linker sequence placed between 
the EcoR1 and Not1 endonuclease restriction sites. The cDNAs of wild type and mutant 
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DDX6 sequences were inserted into this vector using the Not1 and Xho1 restriction 
endonucleases.  APOBEC3G was cloned into the pNG72 retroviral vector (as described 
for pCMS28) using the EcoR1 and Xho1 restriction endonucleases. The YFP cDNA 
expressed in pNG72 was kindly provided by Dr Juan Martin-Serrano. The p8.91 
packaging plasmid was a kind gift from Dr Didier Trono. The pCgp packaging plasmid 
was a kind gift from Dr Paula Cannon. 
 
2.1.3 Reagents for RNAi 
The shRNA encoded lentiviral GIPZ vectors targeting Ago2, DDX6 and Lsm1 as well 
as the non-silencing control were obtained from Open Biosystems. siRNA 
oligonucleotides targeting the ALIX and DDX6 proteins were purchased from 
Dharmacon and Ambion Life Technologies respectively. The control scrambled siRNA 
oligonucleotide was also purchased from Ambion Life Technologies. Sequences of the 
shRNAs and siRNAs used in this study are presented in Table 2.1.  
 
Table 2.1: Sequences of siRNAs and shRNAs. Only sequences of the sense strand are 
presented. For DDX6 the shRNA used for knockdown studies in HeLa cells is 
underlined.  
Target Type Sequence 
Ago2 shRNA GGCAAGAAGAGATTAGCAA 
DDX6 shRNA GGGTTATTCTTGCTTCTAT    (1) 
CACAAAGCCTTGAGTATAA  (2) 
CTGAGTTTATAAGGTTCCA   (3) 
CGGAGTCTGCTGAGTTTAT   (4) 
CAGATAATGGAGGATATTA  (5) 
Lsm1 shRNA GGCATAGACTCCTTCACAC 
ALIX siRNA GCAGUGAGGUUGUAAAUGU 
DDX6 siRNA GAUGAUCGCUUCAACCUGATT 








2.2.1 Bacterial Strains and Maintenance 
Transformations were conducted using Top10 competent cells (Invitrogen) with the 
exception of proviral DNA, in which case Stable 2 cells (Stbl2, Invitrogen) were used 
instead. Bacterial cells were grown in Luria-Bertani Broth [LB, 1% tryptone (w/v), 
0.5% yeast extract (w/v), and 1% NaCl (w/v) dissolved in ddH2O) or on LB-Agar (37 
g/1L ddH2O) set in 10 cm sterile dishes for solid phase growth cultures. Where 
appropriate media was supplemented with the following antibiotics: 100 µg/ml 
Ampicillin (Calbiochem), 50 µg/ml kanamycin monosulfate (Fisher) or 100 µg/ml 
zeocin.  
2.2.2 Production of competent bacterial cells 
Top10 competent cells were inoculated in 5 ml of LB overnight at 30°C with shaking at 
~200 rotations per minute (rpm). The following day 0.5 ml of this culture was then used 
to inoculate 50 ml of LB which was again grown at 30°C with shaking until an OD550 of 
between 0.5 - 0.6 had been reached, typically after 5 - 6 hours. The cells were then 
chilled on ice for 10 minutes before being pelleted by centrifugation for 10 minutes at 
3,500 rpm at 4°C. The pellet was re-suspended in 20 ml of pre-chilled, filter sterilised 
buffer TfB1 (30 mM KAc, 100 mM RbCl, 10 mM CaCl2, 50 mM MnCl2 and 15% 
glycerol, made up to 100 ml with ddH2O) and chilled on ice for 5 minutes. The cells 
were then centrifuged as before and re-suspended in 2 ml of pre-chilled, filter sterilised 
buffer TfB2 (10 mM PIPES, 75 mM CaCl2, 10 mM RbCl and 15% glycerol, made up to 
100 ml with ddH2O) before being incubated for 10 minutes on ice. Cells were then 
aliquoted into sterile eppendorf tubes on dry ice and stored at -80°C.  
2.2.3 Transformation of competent bacterial cells  
30 µl of competent bacterial cells were incubated with 3 µl of ligated DNA or 2 µl of 
plasmid stocks for 30 minutes on ice. Cells were heat shocked at 42°C for 45 seconds 
and then allowed to recover on ice for 2 minutes. 1 ml of sterile LB was then added to 
the cells and incubated at 37°C for 1 hour or at 30°C for 2 hours (in the case of proviral 
DNA and lentiviral and retroviral vectors), in a shaking incubator. For ligated DNA, 
reaction mixtures were pelleted by brief centrifugation and the pellet re-suspended in 
100 µl LB before plating onto LB-Agar plates containing the appropriate antibiotic and 
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incubated at 37°C or 30°C. For transformation of plasmid stocks, the reaction mixture 
was diluted 1:10, without centrifugation, before plating.  
 
2.3 DNA extraction 
2.3.1 Plasmid DNA purification from bacteria by miniprep 
From a transformed bacteria plate, a single colony was used to inoculate 5 ml of sterile 
LB broth containing appropriate antibiotics. This was then incubated at 37°C or 30°C 
overnight in a shaking incubator. The following day, 1 ml of the culture was transferred 
to an eppendorf tube and cells pelleted at 14,000 rpm for 30 seconds. The supernatant 
was removed and another 1 ml of culture transferred to the same tube and the process 
repeated. The pellet was re-suspended in 250 µl Buffer P1 (50 mM Tris-HCL pH 8.0, 
10 mM EDTA) and vortexed. Cells were then lysed in 250 µl Buffer P2 [200 mM 
NaOH and 1% SDS (w/v)], mixed by inverting the tubes and incubated at room 
temperature for 5 minutes. This was followed by the addition of 250 µl of Buffer P3 and 
incubation for 10 minutes on ice, to neutralise the mixture. Samples were then 
centrifuged at 14,000 rpm for 10 mins to pellet bacterial debris and chromosomal DNA. 
The supernatant was transferred to new eppendorf tubes and incubated with 800 µl of 
96% ethanol at room temperature for 2 minutes to precipitate the DNA. Mixtures were 
then centrifuged at 14,000 rpm for 1 minute, the supernatant removed and the pellet air 
dried at room temperature for 5 minutes. The pellet was then washed in 70% ethanol 
and centrifuged at 14,000 rpm for 5 minutes. The ethanol was removed and the pellet 
dried using a vacuum centrifuge (Speedvac, eppendorf concentrator 5301) for 5 minutes. 
DNA was then re-suspended in 50 µl ddH2O containing 0.5% RNaseA.  
2.3.2 Plasmid DNA purification from bacteria by midi/maxi prep 
From a transformed bacteria plate, a single colony was used to inoculate 50 ml/200 ml 
of sterile LB broth containing appropriate antibiotics. Cultures were grown overnight at 
37°C or 30°C in a shaking incubator. Cells were pelleted by centrifugation at 6,000 x g 
for 15 minutes. Plasmid DNA was then purified by alkaline lysis using the Machery-
Nagel Nucleobond Xtra midi/maxi prep kit as per the manufacturer’s instructions. 
Briefly, cell pellets were re-suspended in 8 ml/12 ml of Buffer RES and then mixed 
with 8 ml/12 ml of Buffer LYS by gentle inverting, followed by incubation at room 
temperature for 5 minutes. This was followed by addition of 8 ml/12 ml of Buffer NEU 
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which was again mixed by gentle inverting. The lysate was then immediately added to 
Nucleobond Xtra Columns that had been pre-equilibrated with 12 ml/25 ml of Buffer 
EQU. The column and filter were then washed by adding 5 ml/15 ml of Buffer EQU to 
the rim of the filter and allowed to empty by gravity flow. The filter was then removed 
and the column was washed again with 8 ml/25 ml of Buffer WASH and allowed to 
empty by gravity flow. To elute the DNA from the column, 5 ml/15 ml of Buffer ELU 
was added and collected in 50 ml costar falcon tubes. The eluted DNA was then 
precipitated with 3.5 ml/10.5 ml of room temperature isopropanol, vortexed and 
incubated at room temperature for 2 minutes. The DNA was pelleted by centrifugation 
at 15,000 x g for 30 minutes at 4°C, the supernatant was then removed and the pellet 
washed by re-suspension in 1 ml of 70% ethanol. The DNA was transferred to sterile 
eppendorf tubes and centrifuged at 14,000 rpm for 10 minutes. The ethanol was 
removed by aspiration and the pellet was washed again as before. After removal of the 
ethanol, the pellet was air dried at room temperature for 15 minutes before being re-
suspended in 100 µl/250 µl of ddH2O. To aid homogenous re-suspension of the DNA, 
samples were heated at 50°C for 10 - 20 minutes. To ensure all the ethanol had been 
removed from the DNA, the solution was dried in a vacuum centrifuge for 12 minutes.  
2.3.3 DNA Concentration Determination 
DNA concentrations were determined using a Nanodrop ND-1000 Spectrophotometer 
(Labtech International), with optical density measurements at 260 nm [with the 
assumption that 1 OD260 unit corresponds to 50 µg/ml of double stranded (ds) DNA]. 











2.4 Polymerase chain reaction (PCR)  
2.4.1 Standard PCR conditions 
PCR reactions were carried out in a total volume of 50 µl. Reaction mixtures contained 
2 µl of plasmid DNA (10 ng/µl), 2.5 µl of sense and anti-sense oligonucleotide primers 
(10 pmol/µl), 10 µl of F-518 5X Phusion HF or 10µl 5X Phusion GC buffer (both of 
which contain 1.5 mM MgCl2), 1 µl dNTP mix (10 mM each of dATP, dCTP, dGTP 
and dTTP) and 0.5 µl of F-530L Phusion DNA polymerase (2 U/µl). Buffers and 
enzymes were supplied by Finnzymes, New England Biolabs (NEB). Oligonucleotide 
primers were synthesised by MWG Eurofins (formerly MWG Biotech) and stock 
solutions of 100 pmol/µl were made using ddH2O. PCR reactions were performed using 
an Eppendorf Mastercycler epgradient S thermocycler. Standard PCR conditions are 
presented in Table 2.2. 5 µl of the PCR reaction was run on an agarose gel. 
 
Table 2.2: Standard PCR thermal cycling conditions  
 Temperature Time Step 
1 98°C 30 seconds Initial denaturation 
2 98°C 10 seconds Denaturation 
3 55°C 30 seconds Annealing 
4 72°C 30 seconds Elongation 
5 (go to step 2, repeat 27 times)   
6 72°C 10 minutes Final extension 
7 4°C Hold  
 
2.4.2 Site directed mutagenesis by overlapping PCR 
For site directed mutagenesis, the first round of PCR was performed as described in 
section 2.4.1, generating fragments of the insert containing the desired mutation(s). For 
the second round of PCR, equal amounts of the purified DNA fragments were used as 
templates for the DNA reaction. 5 cycles of PCR were first performed without primers, 






2.4.3 Agarose gel electrophoresis 
1% (or 1.5% for smaller DNA fragments) agarose gels were made by adding 0.5 g of 
powdered agarose to 50 ml of TBE (supplied by Fisher, 0.09 M Tris, 0.09 M borate, 2 
mM EDTA, pH 8.4) and heating to dissolve. Once the solution had cooled, 0.5 µg/ml of 
ethidium bromide was added and the mixture was poured into an electrophoresis tank 
and allowed to set. DNA samples were mixed with 6X loading dye (30% glycerol, 25 
mg bromophenol blue, ddH2O) and run on the gel in 1x TBE buffer. Band sizes were 
assessed by also running the DNA ladders λ DNA-HindIII digest and ΦX174 DNA-
HaeIII (NEB) giving band sizes of 23130, 9146, 6557, 4361, 2322 and 2027 and 1353, 
1078, 872, 603, 310, 281, 271, 234, 194, 118 and 72 base pairs respectively. Gels were 
run at 80V for approximately 1 hour, depending on the expected size of the bands. DNA 
was visualised on an ultra violet trans-illuminator using a CCD camera and gel 
quantification software (all supplied by BioRad).  
 
2.5 DNA manipulation 
2.5.1 PCR Purification 
After verification of the size and quantity of the PCR product by gel electrophoresis, the 
PCR reaction mixture was purified using the QIAquick PCR purification kit supplied by 
QIAgen. 50 µl of ddH2O was added to ~50 µl of the PCR reaction mix, followed by the 
addition of 500 µl of buffer PB. This was then thoroughly mixed and transferred to a 
QIAquick spin column. The column was centrifuged at 14,000 rpm for 1 minute and the 
flow through was discarded. 750 µl of buffer PE was then added and centrifuged as 
before. After removal of the flow through, the column was spun again for an additional 
2 minutes to remove any residual ethanol. The column was then transferred to a sterile 
eppendorf tube and DNA eluted with the addition of 30 µl ddH2O. The column was left 
to stand for 2 minutes at room temperature before centrifugation at 14,000 rpm for 1 







2.5.2 DNA digestion by restriction endonucleases 
For cloning digests, reactions were performed in 50 µl total volume. 30 µl of PCR 
purified DNA (or 3 µl of purified expression plasmid DNA plus 27 µl of ddH2O) was 
digested with 1 µl of each restriction enzyme (supplied by NEB in all cases), 5 µl of the 
appropriate 10X buffer and 0.5 µl of 100 µg/ml bovine serum albumin (BSA), where 
recommended (NEB). For analytical digests, reactions were performed in 15 µl total 
volume. 3 µl of DNA was digested with 0.5 µl of each restriction enzyme, 1.5 µl of the 
appropriate 10X buffer and 0.15 µl of BSA, where recommended. All reactions were 
carried out at 37°C for 2 - 3 hours, unless recommended otherwise by manufacturers 
instructions.  
2.5.3 De-phosphorylation of digested DNA 
In order to prevent re-ligation of the compatible ends of the digested vector DNA, it was 
de-phosphorylated using calf intestinal alkaline phosphotase (CIP, supplied by NEB). 1 
µl of CIP was added to 50 µl of the digested DNA and incubated at 37°C for 1 hour.  
2.5.4 Gel extraction and purification 
In order to purify the DNA from the digest reaction mixture, digested DNA was run on 
agarose gels as described in section 2.4.3 and visualised using ultra violet radiation. 
DNA fragments of the correct size were isolated from the gel using a clean razor blade. 
Gel fragments were transferred into eppendorf tubes and purified using the QIAgen 
QIAquick gel extraction kit. 3 volumes of Buffer QG were added to 1 volume of gel 
slice and incubated at 50°C for 10 minutes or until the gel had completely dissolved. 
700 µl was first transferred to a QIAquick column and centrifuged at 14,000 rpm for 1 
minute. The flow-through was discarded and the rest of the solution was applied to the 
column as before. 500 µl of Buffer QG was then added to the column and centrifuged at 
14,000 rpm for 1 minute. The flow through was discarded and the column was washed 
with 750 µl Buffer PE before being centrifuged at 14,000 rpm first for 1 minute (with 
removal of the flow through) and then for an additional 2 minutes to ensure the 
complete removal of ethanol. The columns were then placed into sterile eppendorf tubes 
and 50 µl of ddH2O was added to the columns to elute the DNA. Columns were left to 
stand at room temperature for 2 minutes before centrifugation at 14,000 rpm for 1 




2.5.5 DNA Ligation 
Prior to ligation, 4 µl of the purified digested DNA was run on an agarose gel (as 
described in section 2.4.3) in order to check the yield of DNA following purification.  
Ligation reactions were carried out in a total volume of 20 µl. Typically 9 µl of the 
digested insert and 1 µl of the digested vector was ligated with 2 µl of T4 DNA ligase 
buffer and 1 µl of T4 DNA ligase (both supplied by NEB). The reaction mixture was 
incubated at room temperature from 4 hours to overnight and used to transform 
competent bacterial cells.  
 
2.6 Cell lines and cell culture 
2.6.1 Cell lines, media and maintenance 
293T cells derived from human embryonic kidney fibroblasts, HeLa cells derived from 
a human epithelial cervical adenocarcinoma and TZM cells, a modified HeLa cell line 
engineered to express CD4+, CXCR4+ CCR5+ as well as the luciferase and lacZ genes 
under the control of the HIV-1 LTR promoter, were grown in Dulbecco’s modified 
Eagle medium (DMEM, Invitrogen), supplemented with 10% heat inactivated foetal 
calf serum (GIBCO, 30 minutes at 56°C) and 1% penicillin/streptomycin (Invitrogen). 
The Hut78 T-cell line was maintained in Roosevelt Park Memorial Institute medium 
(RPMI, Invitrogen), supplemented with 10% heat inactivated foetal calf serum and 1% 
penicillin/streptomycin, as described above. All cell lines were kept at 37°C and 5% 
CO2 in a humidified chamber and passaged every 2 days. Adherent cells were first 
washed in 1x phosphate buffered saline (PBS, Sigma) and then detached from tissue 
culture plates by the addition of 1 ml of the Trypsin substitute TrpLE Express + Phenol 
Red (Invitrogen). Cells were incubated at 37°C for approximately 5 minutes before 
being re suspended in fresh pre-warmed DMEM. Non-adherent cells were split into new 
culture dishes with fresh RPMI.  
All tissue culture plastic consumables were obtained from Corning Incorporated. 
2.6.2 Freezing and thawing 
Long-term frozen stocks of all cell lines were kept in liquid nitrogen. Cells from a semi-
confluent plate, were pelleted by centrifugation at 1,200 rpm for 5 minutes. Cell pellets 
were then re-suspended in medium containing 30% foetal calf serum and incubated on 
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ice for 15 minutes. Freezing medium was then added consisting of 30% foetal calf 
serum plus 20% DMSO (in either DMEM or RPMI). Cells were immediately slow 
cooled at -80°C before being transferred to liquid nitrogen the following day.  
Frozen vials of cells were thawed at 37°C for approximately 1 minute before being 
rapidly transferred to 10ml of pre-warmed media. Cells were centrifuged at 1,200 rpm 
for 5 minutes before re-suspension of the pellet in 5 ml media and transfer to a 6 cm 
tissue culture dish.  
 
2.7 Transfection 
2.7.1 Transient transfection with cDNA 
All transfections were performed on sub-confluent monolayers of cells plated 24 hours 
beforehand, unless otherwise stated. 
HEK-293T cells were transfected with polyethylenimine (PEI, Polysciences). For cells 
seeded in a 24 well cell culture plate, 1 µg of DNA was mixed with 1 µl of PEI and 96 
µl of serum free DMEM by gentle vortexing and incubated at room temperature for 10 
minutes. The transfection mixture was then added dropwise to cells and culture media 
was replaced 6 - 8 hours post-transfection.  
HeLa cells were transfected with Fugene 6 (Roche) or specifically for luciferase 
reporter assays with Lipofectamine 2000 (Invitrogen). For the former, 3 µl of Fugene 6 
transfection reagent was mixed with 100 µl of Optimem (GIBCO, Invitrogen) by gentle 
vortexing. The transfection mixture was then added dropwise to 1 µg of DNA in 
separate eppendorf tubes and incubated at room temperature for 10 minutes. The 
transfection mixture was then added dropwise to the cells. For Lipofectamine 
transfections in a 24 well cell culture plate, 1 µl of Lipofectamine 2000 transfection 
reagent was mixed with 49 µl of Optimem. Separately, 1 µg of DNA was mixed with 49 
µl of Optimem, before the two mixtures were combined and incubated at room 
temperature for 20 minutes. The transfection mixture was the added dropwise to cells 
and the cell culture media was replaced 6 hours post transfection. 




2.7.2 Transient transfection with siRNAs 
Stock solutions of 50 µM or 75 µM siRNA oligonucleotides (obtained from either 
Dharmacon or Ambion Technologies) were made in RNase free ddH2O (supplied by the 
manufacturer). 
HEK-293T and HeLa cells were seeded 24 hours and 2 hours, respectively, prior to 
transfection in 24 well cell culture plates. Cells were transfected with Dharmafect1 
transfection reagent (Dharmacon) as described for Lipofectamine 2000 transfections 
(section 2.7.1) and typically with 50 pmol of siRNA. 24 hours later, HEK-293T cells 
were re-seeded into new cell culture plates and transfected as before, the following day. 
For HeLa cells, 24 hours after the initial transfection, cell media was replaced and the 
following day, cells were re-seeded and transfected again 2 hours later. 24 hours later, 
cell media was replaced and 48 hours post the second transfection cells were harvested. 
Alternatively, 12 hours post the second transfection cells were infected with virus or 
transfected with DNA as required.  
2.7.3 Generation of stable cell lines 
Sub-confluent monolayers od 293T cells, seeded in 10 cm dishes, were transfected with 
8 µg of the lentiviral or retroviral expression plasmid, 8 µg of the p8.91 or pCgp Gag-
Pol expression plasmid (for production of lentiviral and retroviral vectors respectively) 
and 4 µg of a Vesicular Stomatitis Virus-G envelope protein (VSV-G) expression 
plasmid, using PEI (as described in section 2.7.1). 48 hours later, viral supernatants 
were harvested and filtered through a 0.45 µm PVDF Millex®-HA filter (Millipore) and 
used to transduce either HEK-293T or HeLa cells, seeded in 24 well plates 24 hours 
beforehand, in the presence of polybrene (5 µg/ml). 48 hours post transduction, cells 
were placed under selection, either puromycin dihydrochloride (1 µg/ml) for lentiviral 
vectors or G418 disulphide (neomycin, 1mg/ml) for retroviral vectors. Cells were 
maintained under selection and analysed for protein expression when all untransduced 







2.8 Protein manipulation 
2.8.1 Sodium dodecyl sulphate polyacrylamide gel electrophoresis  (SDS-PAGE) 
SDS-PAGE was used to separate proteins according to size. Denaturing separating gels 
[7-12% (30% acrylamide bis/solution 37.5:1, Biorad), 375 mM Tris-HCL (pH 8.8), 
0.1% SDS, 0.1% ammonium persulphate, 0.0004% N, N, N’, N’-
tetramethylethyenediamine (TEMED)] of either 7% (proteins > 80kDa), 10% (20kDa < 
proteins > 80kDa) or 12% (proteins < 20kDa), were cast using the Mini-PROTEAN® 3 
electrophoresis system (Biorad). Gels were levelled with the addition of 70% ethanol, 
which was removed before addition of the stacking gel [4% acrylamide mix, 125 mM 
Tris-HCL (pH 6.8), 0.1% SDS, 0.1% ammonium persulphate and 0.001% TEMED), 
using 0.75mm spacers. Samples were diluted in 3x gel loading dye [30% glycerol, 9% 
SDS, 180 mM Tris-HCL (pH6.8), 0.00125% bromophenol blue), made to 1x with 10 
mM DL-Dithiothreitol (DDT) and ddH2O. Lysates were homogenised either by 
sonication (Branson Sonifier 250) for 2 x 10 seconds or by passing through a 25G x 5/8” 
needle (Terumo Neolus) with a 1 ml sterile syringe (BD PlastipakTM) approximately 10 
times. Before loading, samples were boiled for 5 - 10 minutes. Gels were run at 100V 
for approximately 2 hours in running buffer [0.1% SDS, 27.6 mM Tris base, 0.2 M 
glycine, pH >8.8]. Protein sizes were determined by comparison to the Benchmark Pre-
stained protein ladder (NEB).  
2.8.2 Immunoblot analysis 
Proteins were transferred onto 0.45 µm nitrocellulose (Anachem) or PVDF (BDH-
VWR) membranes. PVDF membranes must be pre-activated by soaking in methanol 
prior to transfer. Transfers were carried out at 16V overnight in transfer buffer (0.1% 
SDS, 27.6 mM Tris Base, 0.2 M glycine, 20% methanol, pH > 8.8).  
Following transfer, membranes were first blocked in 1% milk solution (milk powder, 
0.1% tween, dissolved in PBS) for 1 hour at room temperature. Membranes were then 
incubated with the primary antibody, diluted in milk solution, for approximately 2 hours 
at room temperature, followed by 4 washes for 5 minutes in wash buffer (0.1% tween in 
PBS). Membranes were then incubated for 1 hour with either horseradish peroxidase 
(HRP) conjugated secondary antibodies (for detection by enhanced chemiluminescence, 
ECL) or with 680λ or 800λ Infrared IRDye® conjugated secondary antibodies (for 
detection by Li-cor Odyssey infrared imaging systems). In the latter case, upon addition 
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of the antibody, membranes were protected from light. Subsequently blots were washed 
4 times for 10 minutes in wash buffer, as before.  
For ECL development, HRP-conjugated antibodies were detected by incubation of the 
membrane for 5 minutes with either SuperSignal® West Pico Chemiluminescent 
substrate (Pierce) or ECL Plus Western Blotting Detection System (Amersham), for 
more difficult to detect proteins, as per manufacturer’s instructions. Proteins were 
visualized using an ImageQuant LAS 4000 mini system consisting of a Luminescent 
Image Analyser and F0.85 43mm LAS high sensitivity lens (Fujifilm), all provided by 
GE Healthcare. For Li-cor analysis, membranes were rinsed in 1x PBS and imaged 
using the Li-cor Odyssey infrared imaging systems (Li-cor Biosciences).  
Details of the antibodies used for immunoblot, as well as immunofluorescence and 

















 Table 2.3: Primary antibodies. 
IF = immunofluorescence, IP = immunoprecipitation, WB = western blot 
 
Table 2.4: Secondary Antibodies. 
Antibody Conjugation Source Dilution 
Goat α-chicken HRP Sigma 1/1000 
Goat α-mouse HRP Chemicon 1/2000 
Goat α-rabbit HRP Cell Signalling 1/2000 
Goat α-rat HRP Cell Signalling 1/2000 
800nmλ Goat α-mouse IRDye Li-cor Biosciences 1/5000 
800nmλ Goat α-rabbit IRDye Li-cor Biosciences 1/5000 
680nmλ Goat α-mouse IRDye Li-cor Biosciences 1/5000 
680nmλ Goat α-rabbit IRDye Li-cor Biosciences 1/5000 
488nmλ Goat α-mouse Alexa Fluor 488 Molecular Probes 1/500 
488nmλ Goat α-rabbit Alexa Fluor 488 Molecular Probes 1/500 
594nmλ Goat α-mouse Alexa Fluor 594 Molecular Probes  1/500 
594nmλ Goat α-rabbit Alexa Fluor 594 Molecular Probes  1/500 
Antibody Species Source Dilution 
α A3G Rabbit (Newman et al, 2005) 1/1000 (WB) 
1/500 (IF) 
α Ago2 (11A9) Rat Sigma 1/1000 (WB) 
α ALIX Rabbit kind gift from Dr Wesley Sundquist 1/10,000 (WB) 
α β-actin Mouse Abcam 1/1000 (WB) 
α DDX6 Rabbit Cambridge Biosciences 1/2000 (WB) 
1/500 (IF) 
α FLAG (MS2) Mouse Stratagene 1/1000 (WB) 
α Ge1/s6 kinase Mouse Santa Cruz 1/500 (IF) 
α GFP Mouse Roche 1/2000 (WB) 
1/500 (IF) 
α HA (12CA5) Mouse (Chen et al., 1993) 1/1000 (WB/IP) 
1/500 (IF) 
α HA Rabbit Rocklands 1/3000 (WB) 
1/500 (IF) 
α HSP90 Rabbit Santa Cruz 1/3000 (WB) 
α Lsm1 Chicken Sigma 1/500 (WB) 
α myc (9E10) Mouse (Evan et al., 1985) 1/1000 (WB/IP) 
α p24Gag (24.2) Mouse (Fouchier et al., 1997) 1/1000 (WB) 
α p24Gag (UP598) Rabbit (Simon et al., 1997) 1/500 (IP) 
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2.9 Single cycle infectivity assay 
2.9.1 Production of virus stocks 
Virus stocks were produced from HEK-293T or HeLa cells seeded in 6 well culture 
plates and transfected accordingly as described in section 2.7. Typically 48 hours post-
transfection, viral supernatants were harvested and filtered through a 0.45 µm PVDF 
Millex®-HA filter (Millipore). 100 µl of supernatant was removed for quantification by 
p24Gag ELISA (see section 2.9.2) and stored at either 4°C for no longer than 6 hours (for 
virion incorporation assays, see section 2.9.4) or at -80°C for long-term storage. 
Infected HEK-293T cells were removed from the plate in 1 ml 1x PBS and centrifuged 
at 500 x g for 5 minutes. Pellets were then re-suspended in 3x loading dye and subjected 
to immunblot analysis (see section 2.8.2). HeLa cells were directly harvested in 3x 
loading dye.  
2.9.2 p24Gag quantification by ELISA 
This assay was performed using a p24Gag enzyme-linked immunosorbent assay (ELISA) 
kit (Perkin ElmerTM) with all described reagents supplied with the kit. 100 µl of virus 
stock was diluted in 400 µl of 0.1% Triton X-100® in PBS (protected from light). From 
this initial 1:5 dilution, further dilutions were made as necessary, typically of between 
1:50 - 1:250. 200 µl of the diluted virus stock was then loaded onto a pre-washed [6 
times with plate wash (0.05% Tween-20 in PBS with 0.1% 2-chloroacetamide as a 
preservative)] antibody covered microplate (96-well microplate coated with monoclonal 
antibody to HIV-1 p24Gag with 0.01% Proclin-300 as a preservative). The plate was also 
loaded with 6 standard solutions of the following concentrations: 1000, 2000, 500, 150, 
60 and 25 pg/ml. The standards were prepared using the p24Gag positive control 
(containing 200 ng/ml HIV-1 p24Gag in PBS plus PBS and Triton X-100® with 0.1% 
sodium azide as a preservative) diluted in lysis buffer (0.5% Triton X-100® in PBS plus 
an inert blue dye and 0.002% sodium azide as a preservative). The first well (A1) was 
left empty and the second was loaded with 200 µl of lysis buffer only, as negative 
controls, before addition of 200 µl of the standards and then the samples, in that order. 
The plate was then incubated at 37°C for 30 minutes to allow binding of the p24Gag 
protein to the monoclonal antibody coating the plate. The plate was then washed 6 times 
as before and 100 µl of detector antibody (biotinylated rabbit polyclonal anti-p24Gag 
antibody in PBS containing animal sera, casein and human serum non-reactive for 
hepatitis B surface antigen and antibodies to HIV-1, HIV-2 and HCV with 0.2% 
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Proclin-300 and <0.1% sodium azide as a preservative) was added to each well (except 
A1), and incubated at 37°C for 1 hour, before the plate was washed 6 times. 
Streptavidin-HRP [streptavidin-HRP (horseradish peroxidase) concentrate in citrate 
buffer with BSA, detergent and 0.5% 2-chloroacetamide] was diluted 1:100 in 
streptavidin-HRP diluent (PBS with BSA, 0.05% Tween-20 and 0.5% 2-
chloroacetamide as preservative), and 100 µl of this was added to each well (except A1) 
and incubated at 37°C for 30 minutes. This allows the streptavidin-HRP to form a 
complex with the biotinylated secondary antibody. An orthophenylenediamine-HCL 
(OPD) tablet was then dissolved in 11 ml of substrate diluent (citrate buffer containing 
0.03% hydrogen peroxide and 0.002% sodium stannate as a stabilizer) by vortexing and 
100 µl of this OPD substrate solution was added to all wells (including A1) after the 
plate had been washed 6 times. The OPD substrate reacts with the streptavidin-
HRP/biotinylated secondary antibody complex that is bound to the p24Gag protein, 
producing a yellow colour that is directly proportional to the amount of HIV-1 p24Gag 
protein present in each well. The plate was then incubated for 15 - 20 minutes at room 
temperature in the dark before addition of 100 µl of STOP solution to all wells, to 
quench the reaction. The plate was then read using a Benchmark PlusTM microplate 
spectrophotometer (Bio-Rad) at dual (subtractive) wavelengths of 405 and 630 mm. 
Values were analysed using the Microplate Manager 5.2.1 software (Bio-Rad) to give a 
quantified concentration of p24Gag protein in pg/ml.  
2.9.3 β-galactosidase reporter assay 
TZM-βL cells harbouring the lacZ gene under the control of the HIV-1 LTR promoter 
were seeded in 24 well plates at 1 x 105 cells per well, 24 hours before infection. Cells 
were challenged with virus equivalent to 5 ng of p24Gag for 24 - 30 hours, before media 
was removed, cells washed in 1x PBS and subsequently lysed in 100 µl of Galacto-
StarTM Lysis Solution (100 mM potassium phosphate pH7.8, 0.2% Triton X-100®, 
Applied Biosystems) for 5 minutes at room temperature before the plate was frozen at -
80°C, typically overnight. Tropix Galacton-StarTM substrate for β-galactosidase, diluted 
1:50 in Reaction Buffer Diluent [100 mM sodium phosphate (pH 7.5), 1mM MgCl2, 5% 
Sapphire-IITM enhancer], both from Applied Biosystems, was prepared and 100 µl was 
added to 20 µl of thawed cell lysate in white polystyrene 96 well plates (Costar). The 
substrate and Sapphire-IITM enhancer produce light emissions upon contact with β-
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galactosidase that was measured using a luminescence counter (Perkin Elmer) and 
Wallac 1420 Workstation software.  
2.9.4 Virion incorporation analysis 
20 ng of virus stocks, quantified by p24Gag ELISA (see section 2.9.2), were loaded onto 
a 20% sucrose cushion (20% sucrose in PBS) and purified by centrifugation at 14,000 
rpm for 2 hours at 4°C. The supernatant was then removed by aspiration and the pellet 
re-suspended in 3x loading dye and subjected to immunoblot analysis (see section 2.8.2).  
 
2.10 Replication curve 
Virus stocks were produced in 293T cells seeded in 10 cm cell culture plates and 
transfected at 70% confluency as described in section 2.9.1. 48 hours later, viral 
supernatants were harvested, filtered through a 0.45 µM PVDF Millex®-HA filter 
(Millipore) and 100 µl removed for quantification by p24Gag ELISA (see section 2.9.2). 
The remainder was aliquoted and stored at -80°C.  
5 ng, 25 ng or 125 ng of p24Gag quantified virus (wild-type or Δvif) was used to infect 
approximately 3 x 106 Hut78 cells in 1 ml of RPMI media total, at 37°C for 2 hours. 
Cells were then pelleted by centrifugation at 300 x g for 5 minutes. The pellet was re-
suspended in 5 ml of 1x PBS and centrifuged as before. This was repeated a further 2 
times, to ensure that all input virus had been removed. Cells were then re-suspended in 
10 ml RPMI media and centrifuged as before. 100 µl of supernatant was removed as 
time point zero and diluted in 400 µl of 0.1% Triton X-100® for p24Gag analysis by 
ELISA (see section 2.9.2). The cells were then re-suspended in RPMI media, 
transferred to 25 cm2 flasks and incubated at 37°C with 5% CO2. Every 2 days post 
infection, 5 ml of cells was centrifuged as before, with 100 µl of supernatant removed 
for p24Gag quantification as described for time point zero. Cell pellets were washed in 
1x PBS and lysed in 3x loading dye for immunoblot analysis. 5 ml of fresh RPMI media 
was added back to the flasks to maintain cell cultures, which were continued for 
approximately 8-10 days post infection. Viral supernatants were quantified by p24Gag 






Virus stocks were produced in 293T cells seeded in 10 cm cell culture plates and 
transfected at 70% confluency as described in section 2.7. For wild type and Δvif but 
not Δenv viral stocks, viruses were produced in the presence of VSV-G to generate 
pseudotyped virions for infection of HeLa cells, which do not express the necessary 
receptors to allow HIV-1 infection. Transfections were carried out at a ratio of 3:1 
(proviral plasmid DNA to VSV-G plasmid DNA). 48 hours later, viral supernatants 
were harvested, filtered through a 0.45 µM PVDF Millex®-HA filter (Millipore) and 
100 µl removed for quantification by p24Gag ELISA (see section 2.9.2). The remainder 
was aliquoted and stored at -80°C.  
Virus equivalent to 50 ng or 100 ng of p24Gag was used to infect HeLa cells seeded at 2 
x 105 cells per well in 6 well cell culture plates in 800 µl of DMEM total, at 37°C for 4 
hours. Cells were then washed 4 times in 1x PBS to remove all input virus and 2 ml of 
fresh DMEM was added back. 48 hours later, viral supernatants were harvested, 
quantified by p24Gag ELISA and a β-galactosidase reporter assay performed and virion 
incorporation assessed (see section 2.9). 
 
2.12  Protein interaction assays 
2.12.1 Co-immunoprecipitation 
293T cells seeded at 5 x 105 cells per well in 6 well cell culture plates were transfected 
as described in section 2.7. 24 - 48 hours later, media was removed and cells were 
harvested in 1 ml of chilled 1x PBS and centrifuged at 500 x g for 5 minutes at 4°C. The 
supernatant was removed and cells were lysed in 600 µl of immunoprecipitation (IP) 
buffer [150 mM NaCl, 50 mM Tris (pH 7.5), 1% Nonidet P-40 (NP-40) and complete 
protease inhibitor cocktail (Roche)] for 30 minutes at 4°C on a rotational tumbler. 
Lysates were then cleared by centrifugation at 18,000 x g for 15 minutes. 10 µl of 
supernatant was removed and resuspended in 3x loading dye for immunoblot analysis to 
check for cellular protein expression. 580 µl was transferred to new eppendorf tubes 
containing 30 µl of Protein G agarose (Invitrogen) per sample that had been pre-washed 
(3 times in IP buffer) and pre-incubated with the appropriate antibody for 
immunoprecipitation on a rotational tumbler for 90 minutes at 4°C. The agarose beads 
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and cell lysate mix was then incubated on a rotational tumbler at 4°C for 2 - 4 hours. 
Agarose beads were then washed 3 times in IP buffer and bound complexes eluted in 3x 
loading dye for immunoblot analysis (see section 2.8.2). 
2.12.2 Co-immunoprecipitation with formaldehyde cross-linking 
293T cells seeded at 5 x 105 cell per well in 6 well cell culture plates were transfected as 
described in section 2.7. 48 hours later, cells were harvested in 1 ml of chilled 1x PBS 
and centrifuged at 500 x g for 5 minutes to pellet the cells. The pellet was re-suspended 
in 0.05% formaldehyde (36.5%), diluted in PBS and incubated at 37° for 10 minutes. 
Cells were then pelleted by centrifugation at 18,000 x g for 1 minute and washed in 1x 
PBS, before re-suspension in 0.25 M Glycine (pH 7.0) and incubation at room 
temperature for 5 minutes. Cells were washed again as before and then lysed in 1x BB 
Lysis Buffer [150 mM NaCl, 10 mM Hepes (pH 7.0), 6 mM MgCl2, 2 mM DDT, 10% 
Glycerol, 0.5% NP-40 and complete protease inhibitor cocktail] for 10 minutes on ice. 
Lysates were then sonicated (Branson Sonifer 250) 3 times for 10 seconds and then 
clarified by centrifugation at 1000 x g for 10 minutes. 10 µl of supernatant was removed 
and re-suspended in 3x loading dye for immunoblot analysis to check cellular protein 
expression levels. The remaining supernatant was transferred to new eppendorf tubes 
containing Protein G agarose and antibody prepared as described in section 2.12.1. The 
agarose beads and cell lysate mix was then incubated on a rotational tumbler at 4°C for 
2 hours before being washed 5 times in filter sterilised RIPA Buffer [NaCl, 100 mM 
Tris-HCl (pH 7.5), 1% Triton X-100®, 0.1% SDS, 1% sodium deoxycholate, 1 mM 
EDTA]. After the final wash, agarose beads were re-suspended in reverse cross-linking 
buffer (10 mM EDTA, 5 mM DDT, 0.5% SDS) and heated at 65°C for 45 minutes. 
Samples were then re-suspended in 3x loading dye for immunoblot analysis (section 
2.8.2).  
2.12.3 Yeast 2 hybrid 
Y190 cells (a kind gift from Dr. Juan Martin-Serrano), encoding the β-galactosidase 
enzyme under the control of the GAL4 transcriptional activator and with mutations in 
the LEU2 and TRP1 genes, were used. Cells were grown in liquid cultures of YPD 
broth (50 g/L) and YPD agar (67 g/L, Q-BIO gene) plates for yeast stocks, both 
supplemented with Adenine sulphate (100 mg/L, Q-BIO gene). Experimentally 
transformed yeast were grown on synthetic drop-out (SD) agar (46.7 g/L) supplemented 
with synthetic drop-out medium without Leucine and Tryptophan (1.54 g/L).   
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Y190 cells from stock culture plates were used to inoculate SD media at a dilution of 
1:8. Overnight cultures were grown at 30°C in a shaking incubator until they reached an 
OD600 of 0.5 - 0.7. Cells were pelleted by centrifugation at 1,800 rpm for 5 minutes. The 
pellet was then washed in 200 ml ddH2O and centrifuged as before. Cells were then re-
suspended in 500 µl of filter sterilised Lithium Acetate (LiAc) solution [0.1 M LiAc 
(pH 7.5), 10 mM Tris-HCL (pH7.5), 1 mM EDTA) per 100 OD’s. Cells were then 
either incubated at room temperature for 90 minutes before transformation or aliquoted 
in sterile eppendorf tubes with 25% glycerol for long-term storage at -80°C.  
For transformation of competent yeast cells, salmon sperm carrier ssDNA (10 mg/ml) at 
10% the volume of re-suspended yeast cells was boiled for 8 minutes, chilled on ice for 
5 minutes and then added to the competent yeast cells and mixed by gentle tapping. 30 
µl of this mixture was then added to eppendorf tubes already containing 1 µg each of 
plasmid DNA in the pGBKT7 (DNA binding domain) and HB18 (transcriptional 
activation domain) vectors. This was followed by addition of 230 µl of 40% 
Polyethylene glycol (PEG) solution [50% PEG 3350, 0.1 M Liac (pH 7.5), 10 mM Tris 
(pH 7.5), 1 mM EDTA]. The mixture was gently vortexed and incubated at 30°C for 45 
minutes before heat shocking at 42°C for 15 minutes. Cells were then plated onto -
Leucine, -Tryptophan SD agar plates and incubated at 30°C for 3 - 4 days.  
Colonies of transformed yeast cells were scraped off culture plates using a clean pipette 
tip and re-suspended in 0.5 ml lysis buffer [1 ml filter sterilised 5X Z buffer [1 M 
Na2HPO4.7H2O, 1 M KcL, 1M MgSO4.7H2O (pH7.0), 14 µl 2-Mercaptoethanol, 4 µl 
10% SDS, 4 ml ddH2O]. This was followed with the addition of 25 µl of chloroform 
and the sample was vortexed to mix. The reporter gene substrate, chlorophenol red β-D-
galactopyranoside (CPRG) (Roche) was used to measure β-galactosidase production as 
a read-out of lacZ activation. 50 µl of CPRG was added to the samples, vortexed and 
incubated at room temperature for 30 minutes. Samples were then centrifuged at 14,000 
rpm for 30 seconds and 100 µl of supernatant was assayed for optical density 
measurements at OD540 using a Benchmark microplate spectrophotometer (BIORAD).  
 
2.12.4 FRET/FLIM 
HeLa cells were seeded onto coverslips in 12 well plates and transfected as described in 
section 2.7. 24 hours later, cells were washed in 1x PBS and fixed in 4% formaldehyde. 
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Cells were washed again and then permeabilised with 0.25% Triton X-100® to enable 
staining of HA-tagged Ago2 included as a negative control. Cells were then quenched 
with the addition of 1 mg/ml sodium borohydride for 5 minutes which was subsequently 
removed and cells washed as before. Primary anti-mouse Cy-5 conjugated antibody 
(Jacksons Immunoresearch Laboratories) was diluted 1/1000 in 1% BSA and incubated 
with the cells for 2 hours at room temperature in the dark. Cells were then washed 3 
times for 5 minutes in 1x PBS before addition of the anti-mouse secondary antibody 
(kindly provided by Dr Simon Ameer-Beg), for 1 hour. Cells were washed as before 
and coverslips were mounted onto slides using Mowiol mounting medium  (ICN) 
containing 2.5% (w/v) 1,4-diazabicyclo (2.2.2) octane as an antifade reagent. Slides 
were dried overnight. All FLIM measurements were undertaken with a 40x (1.3 NA) 
Nikon Plan-Fluor oil objective lens on a modified multiphoton microscopy system and 
were conducted and analysed by Dr Simon Ameer-Beg. 
 
2.13 Immunofluorescence analysis 
HeLa, HEK-293T and Hut78 cells were seeded onto coverslips in 12 well cell culture 
plates. In order for Hut78 cells to adhere, coverslips were pre-treated with poly-L-lysine 
according to manufacturer’s instructions. Cells were then either transfected (see section 
2.7) or fixed 24 hours later, if they had been previously transduced with lentiviral and/or 
retroviral vectors. For fixation, cells were carefully washed 3 times in 1x PBS and then 
fixed with 4% paraformaldehyde (Electron Microscopy Sciences), diluted in PBS, for 
10 minutes at room temperature. Once fixed, cells were protected from light as much as 
possible. Cells were then washed again, as before and permeabilised (where necessary) 
with 0.2% Triton X-100® for 12 minutes at room temperature. Cells were then blocked 
and simultaneously quenched in NGB buffer (50 mM NH4Cl, 2% goat serum, 2% BSA 
and 0.05% sodium azide in PBS) for 30 minutes. Primary antibody diluted in NGB 
buffer was then added for 2 hours at room temperature. Coverslips were then washed 3 
times for 5 minutes in 1x PBS before addition of the appropriate Alexa Fluor 
conjugated secondary antibody (see Table 2.4), again diluted in NGB buffer, for 1 hour. 
The secondary antibody was removed and cells were additionally stained for 1 minute 
with 4’,6-diamidino-2-phenyllindole (DAPI) dilactate (Molecular Probes) diluted 
1:25,000 in PBS, for visualisation of the nucleus. Coverslips were then washed again as 
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before and mounted onto glass slides (Fisher) using 12 µl of Mowiol mounting media 
(Calbiochem). Slides were dried overnight in the dark.   
Images were collected using a TCS SP2 AOBS confocal laser scanning microscope 
(DM IRE2: Leica), with a 63.0x oil objective lens and processed with the LSC software 
(version 2.02, Leica), Openlab (Improvision, Openlab, version 5.02) and Adobe 
Photoshop (version 8.0).   
 
2.14 Luciferase reporter assays 
Assays were performed using the Dual Luciferase® Reporter Kit, supplied by Promega. 
HeLa cells seeded at 1 x 105 cells per well in 24 well plates were transfected as 
described in section 2.7. 24 - 48 hours later, supernatants were removed and cells 
washed in 1x PBS before addition of 100 µl of Passive Lysis Buffer (supplied as a 5X 
stock, diluted in ddH2O) for 15 minutes at room temperature with gentle agitation. 20 µl 
of cell lysate was transferred to a white polystyrene 96 well plate (Costar). Luciferase 
Assay Reagent II (LAR II) was prepared by dissolving Luciferase Assay Substrate in 
Luciferase Assay Buffer II and 100 µl of this reagent was added to each well in order to 
measure firefly luciferase activity. Samples were mixed by pipetting, and light 
emissions were immediately read using a luminescence counter (Perkin Elmer) and 
Wallac 1420 Workstation software. 100 µl of Stop & Glo® reagent was then added to 
simultaneously quench firefy luciferase activity and activate Renilla luciferase. This 
solution was prepared by mixing Stop & Glo® substrate with Stop & Glo® Buffer at a 
1:50 ratio. Samples were then mixed by pipetting and measurements taken as before. 
Typically results are presented as firefly luciferase values divided by Renilla luciferase 
values (after subtraction of background values which were measurements taken from 
untransfected cell lystates), when Renilla values were equivalent across all samples, 







2.15  Pulse labelling 
2.15.1 Radiolabelling 
HeLa cells seeded in 6 well cell culture plates were transfected with siRNAs and DNA 
as described in section 2.7. 48 hours post transfection, viral supernatant was removed 
and filtered through a 0.45 µM PVDF Millex®-HA filter (Millipore) with 100 µl 
removed for quantification by p24Gag ELISA (see section 2.9.2). Cells were then washed 
twice in warm 1x PBS. 1 ml of pre-warmed and equilibrated depletion media (-Cys, -
Met DMEM, 10% dialysed serum, 1% glutamine) was added and cells incubated at 
37°C for 20 minutes. 35S[cysteine/methionine] (Perkin-Elmer) was then added directly 
to each well, equivalent to 0.25 mCi, and cells incubated at 37°C for 5 minutes, this 
time contained within a Perspex charcoal trap. Media was then removed and cells 
washed in 1x PBS. 1 ml of RIPA buffer (see section 2.12.2) was then added to each 
well and using cell scrapers, lysates were transferred to screw-capped tubes and stored 
at -80°C. All radioactive waste was disposed of appropriately and as directed by King’s 
College London Health and Safety guidelines.  
2.15.2 Immunoprecipitation 
Lysates were thawed, vortexed and briefly centrifuged before homogenisation using a 
25G x 5/8” needle (Terumo Neolus) and 1 ml sterile syringe (BD PlastipakTM). Lysates 
were then clarified by centrifugation at 14,000 rpm for 30 minutes. 20 µl of lysate, post 
clarification, was removed for immunoblot analysis. 750 µl of lysate was added to new 
screw capped tubes and incubated with the Gag specific UP598 antibody (see Table 2.3) 
overnight at 4°C on a rotational tumbler. Samples were then centrifuged and 30 µl of 
pre-washed Protein G Agarose beads (see section 2.12) was added to each tube and 
incubated at 4°C for 1 hour on a rotational tumbler. Samples were then centrifuged for 1 
minute at 4,500 rpm and supernatant removed by aspiration before the agarose beads 
were washed 3 times in 500 µl RIPA buffer (see section 2.12). Agarose beads were then 
re-suspended in 30 µl of 3x loading dye and subjected to freezing and thawing to aid 
lysis. 
2.15.3 Imaging 
Before loading onto denaturing polyacrylamide gels, samples were boiled for 10 
minutes. 10 µl was loaded onto 10% polyacrylamide gels, made using New Brunswick 
apparatus, which were run at 50V overnight. The following day, gels were transferred 
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onto PVDF membranes as per immunoblot analysis (see section 2.8.2) for 4 hours at 
325 mA. Membranes were then dried by successive placement between clean sheets of 
Whatman paper for 10 minutes at a time. Once dried, membranes were placed in a 
phosphoimager screen (Molecular Dynamics) in a Kodak BioMAX cassette overnight 
and visualised by autoradiography using a Typhoon TRIO Variable Mode Imager (GE 
Healthcare). Membranes were also transferred onto Kodak BioMAX T-MAT MS film 
with a Transcreen Intensifying Screen (Kodak) for 5 days at -80°C and subsequently 
developed with a Kodak X-OMAT 2000 Processor.  











































Interactions between the APOBEC3 and Argonaute protein 
families 
 
3. 1 Introduction 
Several APOBEC3 proteins are known to associate in large ribonucleoprotein (RNP) 
complexes comprised of a variety of cellular proteins involved in RNA regulation (Chiu 
et al., 2006; Gallois-Montbrun et al., 2008; Gallois-Montbrun et al., 2007; Kozak et al., 
2006; Wichroski et al., 2006). Whether any of these proteins act as co-factors for 
APOBEC3 activity and how these interactions may impact upon both the anti-viral and 
cellular functions of the APOBEC3 proteins remains poorly understood. In this regard, 
the interaction with the miRNA associated Argonaute proteins is particularly intriguing 
as this association is partially resistant to RNase treatment (Gallois-Montbrun et al., 
2008; Gallois-Montbrun et al., 2007), suggestive of a close and possibly direct 
interaction. Therefore it was important to first establish the extent of the interactions 
between these protein families and subsequently to unearth any correlations which may 
exist with the anti-viral phenotypes of the APOBEC3 proteins 
 
3.2 Antiviral activities of the APOBEC3 proteins 
The discovery that human APOBEC3G is a potent inhibitor of Vif-deficient HIV-1 
(Sheehy et al., 2002) led to intense interest in the anti-viral properties of the other 
APOBEC3 proteins. However, only one very recent study has compared them all at the 
same time and in the same experimental context (Hultquist et al., 2011), which has 
therefore led to uncertainties over which APOBEC3 proteins are indeed anti-viral and to 
what extent (Bishop et al., 2004; Bogerd et al., 2006; Dang et al., 2008; Dang et al., 
2006; OhAinle et al., 2008; OhAinle et al., 2006; Wiegand et al., 2004; Yu et al., 2004a). 
Therefore, it was necessary to first verify the antiviral activities of all the APOBEC3 
proteins in a comparable experimental setting. To this end, a single cycle infectivity 
assay was employed. 293T cells were co-transfected with APOBEC3 protein encoding 
plasmids and a HIV-1 delta vif (Δvif) proviral construct. 24 - 48 hours later, viral 
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supernatants were harvested and the amount of p24Gag quantified using an enzyme 
linked immunosorbent assay (ELISA). Virus equivalent to 5 ng of p24Gag was then used 
to infect the TZM-bl reporter cell line (Wei et al., 2002). These modified HeLa cells 
stably express the CD4 and CCR5 receptors and more importantly, express both the 
lacZ and luciferase genes under the control of the HIV-1 LTR promoter. Upon infection, 
expression of the viral protein Tat drives expression of the reporter genes and thus 
productive infection can be measured by determining the activity of the reporter gene of 
choice (Figure 3.1). TZM-bl cells were harvested approximately 30 hours post infection 
and β-galactosidase activity was measured using a chemiluminscent-based reaction. 
Figure 3.2 shows the anti-viral activities of the different APOBEC3 proteins, with 
increasing amounts of input DNA (ranging from 0.03 µg to 1 µg), against HIV-1 Δvif. 
As can be seen, and in agreement with previous reports, A3G is strongly anti-viral, even 
when titrated down to less than 0.05 µg of DNA, compared to the other APOBEC3 
proteins. A3F and A3H also show strong anti-viral activity at the highest concentration 
of DNA but their affects appear to be lost when expressed at lower levels. A3B and 
A3D/E show a similar level of HIV-1 inhibition but once again these effects are quickly 
titrated out especially for A3D/E. As has been published, A3A and A3C did not appear 
to possess any anti-viral activity against Δvif HIV-1 (Bishop et al., 2004). These 
findings are in good general agreement with the work of Hultquist et al in the context of 
transient transfection in 293T cells.  Similar results were obtained with a NL43 Δvif 




















Figure 3.1: Single cycle infectivity assay. 
Schematic diagram of the single cycle infectivity assay used in this study, utilising the TZM-bl reporter 
cell line. 293T or HeLa cells are either co-transfected with plasmids encoding the protein of interest and a 
provirus or else infected with virus. Typically 48 hours later, viral supernatants are harvested and 
quantified by p24Gag ELISA. Virus equivalent to 5 ng of p24Gag is then used to infect the TZM-bl reporter 
cells which express the CD4, CXCR4 and CCR5 receptors. These cells also harbour the lacZ gene under 
the control of the HIV-1 LTR promoter. Infectivity is determined as a measure of β-galactosidase levels 
approximately 30 hours post infection. Virus equivalent to 20 ng of p24Gag is also concentrated through a 
















Figure 3.2: Anti-HIV-1 activities of the APOBEC3 proteins.  
293T cells were co-transfected with increasing amounts of HA-tagged APOBEC3 expression vectors 
(0.03 µg, 0.1 µg, 0.3 µg and 1 µg) and 1 µg of the IIIB Δvif proviral plasmid. DNA concentrations were 
kept constant at 2 µg by the addition of an untagged Luciferase expression vector. 48 hours later, viral 
supernatants were harvested, quantified by p24Gag ELISA and 5 ng was used to challenge TZM-bl 
reporter cells. 30 hours later TZM-bl cells were harvested, lysed and assayed for β-galactosidase activity. 
Data is presented as the average of three independent experiments and all values are normalised to the 





3.3 Virion incorporation of the APOBEC3 proteins 
The inhibition of HIV-1 by the APOBEC3 proteins requires that they are packaged into 
assembling viruses in producer cells so that they are able to exert their anti-viral effects 
during reverse transcription in the target cell.  As with the anti-viral nature of the 
APOBEC3 proteins, their incorporation into assembling virions is also an issue of 
contention as they have all been reported to be packaged (Dang et al., 2008; Dang et al., 
2006; Goila-Gaur et al., 2007; Wiegand et al., 2004; Yu et al., 2004a), but as shown in 
Figure 3.2, not all are anti-viral. Therefore it was of interest to determine which 
APOBEC3 proteins were incorporated into budding virions and whether this 
corresponds with their anti-viral activity. Viral supernatants were prepared in 293T cells 
as described in section 3.2 and 20 ng of p24Gag, normalised by ELISA, was concentrated 
through a 20% sucrose cushion. Viral pellets were then lysed and prepared for 
immunoblotting and corresponding cell lysates were collected in parallel. Figure 3.3 
reveals that A3G, the most potent APOBEC3 family member in terms of HIV-1 
inhibition, is also packaged most efficiently, closely followed by A3F. A3H and A3D/E 
are also present in virions but to a much lower extent. However the cellular expression 
level of A3D/E is greatly reduced when compared to the other APOBEC3 proteins 
which may also explain its reduced anti-viral activity. When stably expressed in human 
T cells, it has been shown to be more anti-viral than what is observed in transient 
overexpression systems (Hultquist et al., 2011). Therefore the full anti-viral nature of 
this protein may not be apparent in the infectivity assay described above due to its 
inherently poor expression, which makes it difficult to draw any conclusions for this 
protein. Overall, these data demonstrate that the most anti-viral APOBEC3 proteins, 
A3G, A3F and A3H, are also the ones that are most effectively incorporated into HIV-1 

















Figure 3.3: Incorporation of APOBEC3 proteins into HIV-1 particles. 
Virions produced from 293T cells co-transfected with HA-tagged APOBEC3 plasmids and an NL43 Δvif 
proviral plasmid at a ratio of 1:3, were concentrated through a 20% sucrose cushion and lysed. 
Corresponding lysates from the virus producing cells were prepared in parallel. Immunoblots were 
analysed with an anti-HA and then either an anti-HSP90 or anti-p24Gag antibody as loading controls for 





3.  4 Sub-cellular localisation of the APOBEC3 proteins 
3.4.1 Co-localisation of APOBEC3 proteins with Argonaute 2  
It is clear from the data presented thus far that not all of the APOBEC3 proteins are 
anti-viral nor are they equally anti-viral, but what accounts for these differences remains 
to be elucidated. As previously discussed, a potential contributory factor may be their 
cellular interactions and in this respect the Argonaute proteins are of particular interest. 
It has been shown that A3F and A3G are able to co-localise with these proteins at 
mRNA Processing bodies (P-bodies) (Gallois-Montbrun et al., 2008; Gallois-Montbrun 
et al., 2007; Wichroski et al., 2006), which are sites of mRNA storage and/or 
degradation. To determine whether other APOBEC3 proteins behaved similarly and 
whether this related to their anti-viral phenotypes, immunofluorescence studies were 
performed to establish their subcellular localisation and possible co-localisation with 
Argonaute 2 (Ago2). HeLa cells were co-transfected with equivalent amounts of HA-
tagged APOBEC3 plasmids and a myc-tagged Ago2 construct. 24 hours later cells were 
fixed, permeabilised and stained with primary antibodies directed against the epitope 
tags and appropriate secondary antibodies, before images were taken using a Leica 
confocal microscope. From Figure 3.4 it can be seen that A3A, A3B and A3C possess 
both a nuclear and cytoplasmic distribution within the cell (panels 1 - 3). In some cells 
A3H displayed a weak nuclear localisation (panel 7), but in others it appeared to be 
entirely cytoplasmic (see Figure 3.5, panel 7). The remaining APOBEC3 proteins are 
exclusively cytoplasmic (panels 4-6). These results are summarised in Table 3.1. In 
agreement with previous reports (Gallois-Montbrun et al., 2008; Gallois-Montbrun et al., 
2007; Wichroski et al., 2006), A3F and A3G localise to Ago2 marked foci and this is 
also true for A3DE and A3H. However, the remaining APOBEC3 proteins only weakly 








Figure 3.4: Several APOBEC3 proteins co-localise with Argonaute 2. 
HeLa cells were co-transfected with equivalent amounts of HA-tagged APOBEC3 plasmids and a myc-
tagged Ago2 plasmid and 24 hours later fixed in 4% formaldehyde and then permeabilised. Cells were 
first stained with rabbit anti-HA and mouse anti-myc primary antibodies and then with Alexa Fluor 
conjugated rabbit 488 and mouse 594 secondary antibodies, as well as DAPI for visualisation of the 
nucleus. Coverslips were mounted onto slides and dried overnight before imaging on a Leica confocal 
microscope. Images are Z-series compilations of 4 - 6 images in a stack with merged views displayed on 
the right. Images are representative of four independent experiments. Scale bar = 10 µm. 
  
  120 
  Table 3.1: Subcellular localisation of the APOBEC3 proteins 
 
        
3.4.2 Co-localisation of APOBEC3 proteins with DDX6 
Since different populations of P-bodies have been postulated to exist within the cell 
(Gibbings et al., 2009; Vasudevan and Steitz, 2007a), it was necessary to ascertain 
whether the APOBEC3 proteins were associating solely with Ago2 marked bodies or P-
bodies in general, as has already been reported for a subset of them (Niewiadomska et 
al., 2007). Consequently, APOBEC3 co-localisation with the known P-body marker, 
DDX6, was also investigated (Figure 3.5) and a similar pattern of co-localisation was 
observed, as described for Ago2. To obtain a more quantitative analysis, 100 cells were 
counted for each APOBEC3 protein and their presence at both Ago2 and DDX6 marked 
foci was scored. These data are presented in Figure 3.6, where in more than 90% of 
cases, co-localisation was observed between Ago2 and A3DE, A3F, A3G and A3H. 
Near equivalent results were also obtained when DDX6 was used as the marker. A3B 
and A3C only localised to Ago2 bodies in approximately 50% of the cells counted and 
this was substantially reduced when looking at DDX6 bodies. This difference may be 
explained by the fact that overexpression of DDX6 induces more P-bodies [(Chu and 
Rana, 2006) and compare the number of P-bodies per cell with ectopic expression of 
Ago2, Figure 3.4 with that of DDX6, Figure 3.5] and thus weak co-localisation 
phenotypes may be exaggerated. A3A co-localisation with either Ago2 or DDX6 was 
virtually non-existent. Therefore the most anti-viral APOBEC3 proteins appear to 
localise most strongly to Ago2 and DDX6 marked foci.  
Protein Sub-Cellular Localisation Co-localisation with Ago2 and 
DDX6? 
A3A Nuclear/Cytoplasmic No 
A3B Nuclear/Cytoplasmic Weak 
A3C Nuclear/Cytoplasmic Weak 
A3D/E Cytoplasmic Yes 
A3F Cytoplasmic Yes 
A3G Cytoplasmic Yes 




Figure 3.5: Several APOBEC3 proteins co-localise with DDX6.  
HeLa cells were co-transfected with equivalent amounts of HA-tagged APOBEC3 plasmids and a myc-
tagged DDX6 plasmid and 24 hours later fixed in 4% formaldehyde and then permeabilised. Cells were 
first stained with rabbit anti-HA and mouse anti-myc primary antibodies and then with Alexa Fluor 
conjugated rabbit 488 and mouse 594 secondary antibodies, as well as DAPI for visualisation of the 
nucleus. Coverslips were mounted onto slides and dried overnight before imaging on a Leica confocal 
microscope. Merged views are displayed on the right. Images are representative of three independent 


















Figure 3.6: Quantification of APOBEC3 localisation to Argonaute 2 and DDX6 foci.  
HeLa cells were prepared as described in Figures 3.3 and 3.4 and 100 cells were counted per APOBEC3 
protein for co-localisation at Ago2 and DDX6 marked cytoplasmic foci. Only those cells in which the 
majority of the APOBEC3 protein co-localised at these foci were scored as positive. Any cells displaying 
stress granules were excluded from the analysis. Data is presented as the average of three independent 




3.5 Co-immunoprecipitatation of APOBEC3 and Argonaute 
proteins           
3.5.1 Optimisation of co-immunoprecipitation coupled to formaldehyde cross 
linking 
As several APOBEC3 proteins demonstrated co-localisation with Ago2, it was then 
important to determine whether there were any detectable interactions between these 
proteins as previously described for A3F and A3G (Gallois-Montbrun et al., 2008; 
Gallois-Montbrun et al., 2007; Wichroski et al., 2006). In order to evaluate this, a 
modified co-immunoprecipitation (Co-Ip) protocol was adopted which incorporates 
formaldehyde (HCHO) cross-linking (Niranjanakumari et al., 2002; Vasudevan and 
Steitz, 2007a). 293T cells were transfected with HA-tagged APOBEC3 and myc-tagged 
Ago2 expression vectors, as used in the immunofluorescence studies described in 
section 3.4. 48 hours post transfection, cells were harvested and incubated with 0.05% 
HCHO, which was then quenched with the addition of Glycine. The cells were lysed, 
subjected to sonication and then immunoprecipitated as standard using an anti-myc 
antibody. Prior to immunoblotting, cross-links were reversed by heating samples at 
65°C for 45 minutes. Conventional Co-Ip protocols that do not involve the cross-linking 
of protein – protein or protein – nucleic acid interactions may be vulnerable to artificial 
interactions that are generated from the re-association of molecules after cell lysis (Mili 
and Steitz, 2004). Therefore, these protocols may not always reflect true in vivo 
interactions. Other advantages of this cross-linking assay include more stringent 
washing to remove any non-specific binding and the break-up of large insoluble 
complexes, such as P-bodies, by sonication, thereby making more protein available in 
the soluble fraction. When cross-linking is not used, and a conventional Co-Ip protocol 
is followed (Figure 3.7A), approximately 50% of the protein is found in the insoluble 
(pelletable) fraction, especially evident for A3G (compare lanes 1 - 4 with 5 - 8), and 
therefore lost from subsequent analysis.  However, when samples are cross-linked, the 
majority of the protein is now retained in the supernatant (Figure 3.7B, compare amount 
of protein present in the supernatant, S, versus pellet, P, lanes). This is also the case, but 
to a lesser extent, for those samples treated with 0% formaldehyde indicating that the 
slower clarification spin used in this protocol also helps maintain proteins in the soluble 
fraction. The concentration of formaldehyde used also needs to be optimised for the 
different proteins studied, as Ago2 may be more readily degraded in the presence of 
higher amounts of formaldehyde (Figure 3.7B, compare Ago2 protein levels at 0.05% 
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with 0.2%, for example). Therefore, for this work, a concentration of 0.05% 




























Figure 3.7: Optimisation of formaldehyde cross-linking protocol for co-immunoprecipitations.  
A. 293T cells were transfected with equivalent amounts of a HA-tagged A3G plasmid and either myc-
tagged Ago2 or Luciferase (Luc) as a negative control. 48 hours later, cells were harvested and lysates 
clarified by centrifugation at 14,000 rpm for 30 minutes. The pellet and a sample of the supernatant was 
collected and re-suspended in gel loading buffer and samples were loaded onto the gel in duplicate. 
Immunoblots were analysed by probing with anti-myc and anti-HA antibodies. B. Cells were transfected 
as in A. 48 hours post transfection cells were lysed and incubated in either PBS (0%), 0.05%, 0.1%, 0.2% 
or 0.3% formaldehyde for 10 minutes at 37°C. The formaldehyde was then quenched by the addition of 
0.25 M Glycine for 5 minutes at room temperature. Cells were then re-suspended in 1x BB lysis buffer 
for 10 minutes on ice prior to sonication for 3 x 10 seconds. Lysates were then clarified for 30 minutes at 
1000 x g. The pellet and a sample of the supernatant was collected and re-suspended in gel loading buffer. 





3.5.2 Co-immunoprecipitation of APOBEC3 proteins with Ago2 
The APOBEC3 proteins were then co-expressed with Ago2 in 293T cells and a co-
immunoprecipitation assay coupled with formaldehyde cross-linking was performed as 
described for Figure 3.7B.  From Figure 3.8, and in agreement with previously 
published reports (Gallois-Montbrun et al., 2008; Gallois-Montbrun et al., 2007; 
Wichroski et al., 2006), it is clear that A3G and to a lesser extent A3F, co-
immunoprecipitate with Ago2. The weaker interaction between A3F and Ago2, seen 
here, may be due to the harsher washing conditions employed in this protocol (and 
discussed further in section 3.5.3). It is also apparent that some of the other APOBEC3 
proteins are also able to interact with Ago2, namely A3H, A3C and very weakly A3A. 
There were no interactions observed for the negative control GFP, nor A3B or A3DE, 
although once gain the cellular expression of the latter is not comparable with its family 
members. Therefore several APOBEC3 proteins are able to interact with Ago2 to some 
extent, though none as strongly as A3G. Unlike localisation to Ago2 foci/P-bodies, the 
ability to interact with Ago2 does not appear to closely correlate with the anti-viral 
phenotypes of the APOBEC3 proteins, although the most anti-viral proteins (A3F, A3G 
and A3H) do interact most strongly with Ago2. However, an important point to note 
with this experiment is that due to the lack of particular negative controls, such as using 
no antibody or an irrelevant antibody for the immunoprecipitation, means that it cannot 
be conclusively ruled out that the APOBEC3 proteins are not simply binding to the 


















Figure 3.8: Several APOBEC3 proteins interact with Argonaute 2 by co-immunoprecipitation.  
293T cells transfected with equivalent amounts of HA-tagged APOBEC3 plasmids (or GFP as a negative 
control) and a myc-tagged Ago2 plasmid were cross-linked with 0.05% formaldehyde 48 hours later. The 
formaldehyde was quenched by the addition of 0.25 M Glycine before cells were lysed in 1x BB lysis 
buffer. Samples were then sonicated for 3 x 10 seconds before immunoprecipitation for 2 hours with an 
anti-myc antibody and protein G coupled Agarose. Before immunoblotting cross-links were reversed by 
the addition of reverse cross-linking buffer and heating at 65°C for 45 minutes. Immunoblots were 




3.5.3 APOBEC3 interaction with other Argonaute proteins 
The four human Argonaute proteins share approximately 80% amino acid identity 
(Sasaki et al., 2003) yet functionally distinct differences exist. They are all involved in 
miRNA mediated repression (Pillai et al., 2004) but only Ago2 has retained its catalytic 
activity and is therefore able to cleave target mRNAs, characteristic of siRNA mediated 
silencing (Liu et al., 2004; Meister et al., 2004). Because of this there is much more 
experimental focus on Ago2 than the other Argonaute proteins, yet they may not behave 
in the same way. It has recently been reported that Ago2 unlike the other Argonaute 
proteins may not act co-operatively with its family members to mediate its repressive 
effects (Broderick et al., 2011). Therefore Ago1 and Ago3 were also assessed for their 
ability to interact with the APOBEC3 proteins, specifically A3F, A3G and A3H as they 
showed the strongest association with Ago2. Unfortunately Ago4 could not be included 
in this analysis as this protein was very poorly expressed (data not shown).  
Co-immunopreciptation was carried out as described in section 3.5.1 (with 
formaldehyde cross-linking) and results are presented in Figure 3.9. The APOBEC3 
proteins tested were all able to interact with Agos 1 and 3, and to the same extent as 
described for Ago2. Even though Ago3 is not as well expressed or immunoprecipitated 
as the other Argonaute proteins (lanes 9 - 12), detectable interactions were still observed. 
An interesting point to note is that the Argonaute proteins do not appear to be as well 
immunoprecipitated in the presence of A3F when compared to the other APOBEC3 
proteins (bottom panel, lanes 1, 5 and 9). The reasons for this are unclear but either 
overexpression of A3F is detrimental to the cells in general or more specifically it 
affects Argonaute expression levels. There may be some evidence for the latter in the 
cell lysate blots (bottom left hand panel) but this is not conclusive. This would also 
explain the weaker interaction observed between Ago2 and A3F as if less Argonaute 
protein is imunoprecipitated, then less A3F will also be pulled down. Overall, these 
results confirm that the APOBEC3 interactions presented in Figure 3.8 are not specific 
to Ago2 but extend to other members of the Argonaute protein family as well. However, 
as before, the interpretation of a conclusive interaction between the APOBEC3 and 














Figure 3.9: APOBEC3 proteins interact with other Argonaute family members. 
293T cells co-transfected with equivalent amounts of either HA-tagged A3F, A3G or A3H and myc 
tagged Ago1, Ago2 or Ago3 expression vectors (and GFP as a negative control) were harvested 48 hours 
later and an anti-myc immunoprecipitation was performed as described for Figure 3.7. Immunoblots were 
analysed using anti-myc (Ip) or anti-HA (Co-Ip) antibodies. * denotes the position of the light chain of 




3.6 Interaction by yeast 2 hybrid 
In order to further validate the interaction between A3G, in particular, and the 
Argonaute proteins, a yeast 2 hybrid (Y2H) assay was performed (Fields and Song, 
1989). This genetic assay is based on the principle that eukaryotic transcription factors 
are modular and therefore the activating and binding domains can be separated. The two 
proteins of interest are fused to separate halves of the transcription factor and if the 
proteins interact, the two domains will be in close enough proximity to activate 
transcription of a reporter gene.  
Competent yeast cells were transformed with A3G and Ago1 or Ago2 fusion plasmids 
(expressed in both the KT7 DNA binding domain and the HB18 activation domain 
vectors) and plated on –Leu (leucine), -Trp (tryptophan) LB media. 3 days later, 
colonies were harvested and protein binding determined by reaction with the reporter 
gene (lacZ) substrate, chlorophenol red β-D-galacopranoside. A red colour indicates a 
positive result and this can be quantified by optical density measurements at 540 nm. 
Tsg101 and Vps28 were included in this experiment as they are known to strongly 
interact in a yeast 2 hybrid system. A value at or above 1 is taken to indicate the 
occurrence of an interaction and this positive control pairing was in fact off the scale 
indicating that the assay itself is functional (Figure 3.10A and B). As A3G is known to 
dimerise (Huthoff et al., 2009), an A3G - A3G pairing was also included as a second 
positive control. This interaction was very close to the cut-off value for a positive 
association. However, no detectable interaction was observed between A3G and the two 
Argonaute proteins, irrespective of which vector pairings were used (Figure 3.10A and 
B). Values were at or below background values in both cases, as represented by the 
empty vector control. However, a large part of this may be attributable to the fact that 
the Argonaute proteins do not appear to be well expressed in either vector but 
particularly the KT7 vector as indicated in Figure 3.10C, which could help explain the 
lack of a positive interaction. On the other hand Tsg101 was also not particularly well 
expressed yet a positive interaction could still be observed when it was co-expressed 
with Vps28. Thus the yeast 2 hybrid assay used here fails to support the conclusion that 







Figure 3.10: Yeast 2 hybrid analysis of the interaction between A3G and Argonaute proteins. 
A. Competent yeast cells were transformed with equivalent amounts of KT7 DNA binding domain (myc-
tagged) and HB18 activation domain (HA-tagged) fused expression vectors as indicated. Tsg101 KT7 and 
Vps28 HB18 were included as a positive control and empty vectors included as negative controls. 
Transformed yeast were then plated onto -Leu, -Trp LB plates and incubated at 30°C for approximately 
72 hours. Pellets were then scraped from the plates and incubated with the reporter gene substrate 
chlorophenol red β-D-galacopranoside to measure β-galactosidase activity. A red colour indicates a 
positive result and this can be quantified by optical density measurements at 540 nm. B. As in A, except 
proteins of interest were expressed in the opposing vectors. C. Expression levels of proteins of interest in 
yeast were determined by immunoblotting using anti-HA and anti-myc antibodies. Data is representative 




3.6 A3G interaction with Ago2 mutants 
The interaction between A3F/A3G and the Argonautes is of particular interest since it is 
at least partially resistant to RNase treatment, unlike many of the other interactions 
described between the APOBEC3s and cellular RNA binding proteins (Gallois-
Montbrun et al., 2008; Gallois-Montbrun et al., 2007). However, whether this is indeed 
a direct interaction or bridged by RNA, and potentially miRNAs, is unknown. To 
investigate these possibilities, a panel of Ago2 RNA binding mutants was employed. 
The structure of the Argonaute proteins can be divided into 4 domains: the N-terminal, 
PAZ, MID and PIWI domains (see Chapter 1, section 1.11.3). The PAZ9 and PAZ10 
mutants contain either 9 or 10 point mutations respectively, within the PAZ region of 
Ago2. This abrogates the ability of these proteins to bind single stranded nucleic acids 
such as miRNAs. It was also reported that these mutants were unable to cleave target 
mRNAs or accumulate in P-bodies (Liu et al., 2005b). The F2V2 mutant (Kiriakidou et 
al., 2007) harbours two phenylalanine to valine substitutions within the Mid domain of 
the protein, which abolishes its silencing activity. Originally it was claimed that these 
mutations prevented the protein from competing with eIF4E for binding to the cap 
structure of mRNAs and thus inhibiting translation initiation (Kiriakidou et al., 2007). 
However, subsequent studies in Drosophila have shown that this protein no longer 
binds GW182 or miRNAs (Eulalio et al., 2008b), which would also explain its inability 
to silence mRNAs. Therefore these mutants could help determine whether the 
interaction between Ago2 and A3G is dependent on miRNAs. A schematic diagram of 
the mutant proteins is presented in Figure 3.11A.  
These mutant Ago2 proteins were assessed for their ability to interact with A3G. In this 
case, 293Ts were transfected with HA-tagged A3G and myc-tagged Ago2 expression 
vectors. 24 hours later, cells were lysed and the Ago2 proteins immunoprecipitated, 
without formaldehyde cross-linking, using an anti-myc antibody before cells were 
subjected to immunoblotting with anti-myc and anti-HA antibodies. From the two upper 
panels in Figure 3.11B it can be seen that the mutant Ago2 proteins are expressed and 
immunoprecipitated just as well as the wild type protein. Although A3G is able to 
interact with all of the mutant proteins (4th panel down), the efficiency of this 
interaction is five fold lower than with wild type Ago2 (compare lanes 2 - 4 with lane 1). 
This implies that the inability of Ago2 to bind miRNAs impacts upon its ability to 
interact with A3G. This may be because miRNAs are required to bridge the interaction 
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between these two proteins. An alternative explanation, however, is that these mutations 
have induced conformational changes in Ago2 which partially hinder its interaction 
with A3G. Therefore, further characterisation of these mutant Ago2 proteins may be 
















Figure 3.11: Ago2 miRNA binding mutants show reduced association with A3G. 
A. Schematic diagram of the Ago2 protein outlining the various domains with the positions of the PAZ9, 
PAZ10 and F2V2 mutants indicated. B. 293T cells were transfected with equivalent amounts of 
expression vectors encoding HA-tagged A3G and either myc-tagged wild-type Ago2 or the PAZ9, 
PAZ10 and F2V2 mutants as well as Luciferase (Luc) as a negative control. 24 hours later cells were 
harvested and immunoprecipitated with an anti-myc antibody and G protein coupled Agarose. Samples 
were then washed and lysed before immunoblot analysis using anti-myc (Ip) and anti-HA (CoIp) 
antibodies. Protein bands were quantified using Licor Odyssey software. * denotes the position of a 
background band. Data is representative of 3 independent experiments. 
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3.8 Interaction by FRET/FLIM 
The interaction between A3F/A3G and Ago2 may also be a direct protein-protein 
interaction as Ago2 directly interacts with several other P-body proteins such as GW182 
and DDX6 (Behm-Ansmant et al., 2006). This is often difficult to prove, however, 
without purified protein and attempts to purify A3G have so far proved unsuccessful 
due to its insoluble nature. Another way in which to measure direct interactions between 
two proteins is by fluorescence resonance energy transfer (FRET). This is based on the 
principle that two fluorophores that are in close enough proximity and with partially 
overlapping emission and absorption spectra, will enable the transfer of energy from 
one molecule (the donor) to another (the acceptor). The fluorescence of the donor is 
quenched as energy is transferred to the acceptor molecule, which can then be measured 
(sensitised emission). Alternatively, the acceptor molecule can be photobleached and 
the increase of fluorescence in the donor can be measured (photobleaching). Fusing 
proteins of interest to fluorescent molecules allows determination of protein interactions 
as the rate of energy transfer occurs at distances of 10 nm or less. However, there are 
some inherent drawbacks to FRET, as often the concentration of the donor and acceptor 
molecules is both difficult to control and calculate and the fact that it requires spectral 
overlap between the two fluorophores can often lead to increased background signals 
via bleed-through. Therefore, a more quantitative and robust approach is to combine 
FRET with fluorescence lifetime imaging microscopy (FLIM) (Lleres et al., 2007). This 
measures the decay in signal from the donor fluorophore (its lifetime) only, which will 
decrease if and when energy is transferred to the acceptor molecule. The closer the 
molecules are, the faster the energy will be transferred and the shorter the lifetime will 
be of the donor fluorophore. This combined approach allows both the spatial and 
temporal resolution of protein interactions [reviewed in (Chen et al., 2003)]. In fact, 
FRET based techniques have proved very useful in verifying interactions between P-
body components and determining where in the cell these interactions are occurring 
(Andrei et al., 2005; David Gerecht et al., 2010; Ingelfinger et al., 2002).  
Therefore, in collaboration with Professor Tony Ng and Dr Simon Ameer-Beg, of the 
Cell Imaging Facility in the Randall Division of Cell and Molecular Biophysics, Kings 
College London, a FRET/FLIM approach was attempted in order to confirm the 
interaction between the APOBEC3 and Argonaute proteins as well as establish its 
cellular location. However, this technique is particularly sensitive to 
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background/autofluorescence signals and therefore the expression of the proteins of 
interest must be considerably higher than background in order to obtain an accurate 
measurement of the lifetime of the fluorophores. HeLa cells were transiently transfected 
with A3G-YFP and Ago2-Cherry fused expression vectors before fixation and 
fluorescence imaging for FRET/FLIM analysis and calculation of FRET efficiency. 
FRET efficiency is strongly dependent on the distance between the donor and acceptor 
fluorophores and is inversely proportional to the lifetime of the donor, with a higher 
efficiency indicating a lower lifetime and thus reflecting a positive interaction. When 
A3G and Ago2, were significantly overexpressed, a positive interaction was observed 
by FRET/FLIM, as determined by the increase in FRET efficiency when these proteins 
were co-expressed as compared to the control (A3G expressed in the absence of Ago2) 
(Figure 3.12). However gross overexpression of proteins can cause mis-localisation and 
protein aggregation and in the specific case of A3G and Ago2, may have possibly 
induced their localisation to stress granules (Figure 3.13, panels a and c). This is 
therefore not biologically representative nor physiologically relevant. Thus attempts to 
utilise FRET/FLIM in this study proved unsuccessful due to these technical difficulties 
but may still be possible, with more stringent optimisation, as has been demonstrated 












             
 
Figure 3.12: FRET/FLIM analysis of the interaction between A3G and Ago2 
HeLa cells were transiently transfected with expression plasmids encoding A3G-YFP and Ago2-Cherry 
fusion proteins, or HA tagged Ago2 as a control. 24 hours later, cells were fixed in 4% formaldehyde, 
permeabilised and then treated with 1 mg/ml sodium borohydride to quench background fluorescence. 
Cells were then stained with an anti-HA conjugated Cy5 primary antibody and the appropriate secondary 
antibody, mounted and dried overnight prior to fluorescence measurements. Mean FRET efficiency was 
calculated using the following equation in each pixel and averaged per cell. FRET efficiency = 1 – τda/ 
τcontrol where τda is the lifetime displayed by cells co-expressing A3G-YFP and Ago2-Cherry and 
τcontrol is the mean A3G-YFP lifetime measured in the absence of acceptor. Figure produced in 





This work set out to investigate in more detail the interaction between the APOBEC3 
and Argonaute protein families and subsequently identify any correlations that may 
exist between APOBEC3 anti-viral activity and Argonaute association. It has been 
shown that several APOBEC3 proteins, besides A3F and A3G, are able to co-localise 
and interact with Ago2 and other Argonaute protein family members. More importantly, 
the most anti-viral APOBEC3 proteins appear to associate most strongly with Ago2 
foci/P-bodies, the relevance of which requires further investigation.  
Although the anti-viral nature of A3G has been well established and extensively studied 
(Bishop et al., 2004; Liddament et al., 2004; Wiegand et al., 2004; Zennou and Bieniasz, 
2006), the anti-viral phenotypes of the remaining APOBEC3 proteins has been 
controversial, especially in relation to one another. The activity of A3H, for example, is 
highly sensitive to epitope tag positions as C-terminally tagged constructs are not as 
anti-viral as their N-terminal counterparts (data not shown). Epitope tags at the C-
terminal end may also affect the ability of Vif to bind to and thus degrade this protein 
(Hultquist et al., 2011). Variables such as this, along with differences in cell lines, 
expression levels and so forth will also explain much of the discrepancies. In order to 
directly compare them, it therefore becomes important to study these proteins in the 
same experimental context, as shown in Figure 3.2. This demonstrates that A3G is 
much more potent than any of the other APOBEC3 proteins as its effects are still 
evident at very low concentrations of input DNA, which is not the case for A3F and 
A3H, for instance. A3A and A3C displayed virtually no antiviral activity against HIV-1, 
which is in agreement with previous reports (Hultquist et al., 2011; Wiegand et al., 
2004). The poor expression of A3D/E, even when overexpressed, has made it difficult 
to establish the true anti-viral nature of this protein. Recent work by Hultquist et al, 
found similarly weak expression of A3D/E in 293T cells, which resulted in only a 
moderate level of anti-HIV-1 inhibition as has been observed here. However, the fact 
that it is sensitive to degradation by Vif, is packaged into virions even when very poorly 
expressed (Figure 3.3) and is under very high levels of positive selection (Sawyer et al., 
2004) imply that it may be more relevant to in vivo viral defence than what is suggested 
from the results presented in Figure 3.2. Conversely, A3B displayed some anti-viral 
activity when overexpressed (Figure 3.2) but it is not thought to encounter HIV-1 
during the course of a natural infection.  
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In order to exert their anti-viral effects the APOBEC3 proteins must be packaged into 
virions and therefore it may be expected that the most anti-viral APOBEC3 proteins are 
also the ones that are most efficiently encapsidated. Editing independent means of viral 
inhibition, such as steric hinderance (discussed in Chapter 1, section 1.7.3), also rely 
upon packaging of A3G in order to mediate its effects in the target cell. However, A3A 
and A3C possess virtually no anti-HIV-1 activity yet both are reported to be packaged 
into viral particles (Goila-Gaur et al., 2007; Yu et al., 2004a). Thus it became important 
to establish how virion incorporation relates to the anti-viral activities of the different 
APOBEC3 proteins. The results presented in this study show that there is in fact a 
positive correlation between anti-viral activity and packaging (Figure 3.3). A3G is 
packaged to the greatest extent, followed by A3F and A3H. A3A and A3C, on the other 
hand, only appear to be packaged when grossly over expressed [data not shown and 
(Hultquist et al., 2011)] and not when expressed at the more physiologically relevant 
levels displayed here. A3D/E also shows some degree of virion incorporation despite its 
low cellular expression level (as discussed above).  
The underlying basis for these differences in anti-viral activities and consequently 
packaging is not clear but a key consideration may be the presence (or absence) of 
cellular co-factors. This point is particularly noteworthy as co-factors have been shown 
to be necessary for the physiological functions of the closely related family members, 
AID (Chaudhuri et al., 2004) and APOBEC1 (Lellek et al., 2000; Mehta et al., 2000). 
Thus the identification and study of APOBEC3 associated cellular proteins, such as 
Ago2, becomes increasingly important as well as other factors which may influence 
their substrate specificities, such as subcellular localisation. With regards to this, the 
nuclear APOBEC3 proteins, for example, are more effective at inhibiting LINE-1 
retrotransposition, which reverse transcribes its RNA in the nucleus rather than in the 
cytoplasm (Bogerd et al., 2006). Conversely, APOBEC3 proteins which are 
predominantly cytoplasmic, may be more likely to be incorporated into virions as this is 
where virus assembly takes place. From Figure 3.4, this does appear to be the case. 
Further and more intriguingly, the most anti-viral APOBEC3 proteins are also more 
effectively localised to Ago2 and DDX6 marked cytoplasmic foci (Figures 3.4 - 3.6), 
which has been previously implied (Wichroski et al., 2006). The importance of these 




However co-localisation is not indicative of an interaction as has been demonstrated for 
A3G and the P-body protein Lsm1 (Wichroski et al., 2006), and therefore the 
interactions between APOBEC3 proteins and Argonaute 2 was assessed via co-
immunoprecipitation (Figure 3.8). Previously this has been done for A3F and A3G but 
it was important to look at the whole APOBEC3 family in order to draw out 
correlations with their anti-viral phenotypes. From this analysis, it is clear that A3G, 
A3F and A3H interact with Ago2 and weak interactions were also detected with A3A 
and A3C. Since these latter APOBEC3 proteins were poorly associated with P-bodies 
(Figure 3.6), this demonstrates that the majority of these interactions are most likely 
occurring in the diffuse cytoplasm rather than at these punctate structures. In support of 
this, Leung et al (2006) have found that only ~ 2% of total cellular Ago2 is present in P-
bodies at any one time and that these foci are in fact highly dynamic structures with 
proteins continually shuttling between them and the cytoplasm. It is also formally 
possible that this interaction occurs in the nucleus, as there are some reports to suggest 
that Ago2 may localise to the nucleus (Rudel et al., 2008; Weinmann et al., 2009). 
The fact that other Argonautes were also able to interact with the APOBEC3 proteins 
(Figure 3.9) indicates that the APOBEC3 interaction with Ago2 is not dependent on the 
catalytic activity of this protein. As has been previously mentioned, the fact that these 
co-imunoprecipitation experiments cannot rule out the possibility that the APOBEC3 
proteins are directly binding to the beads means that these results must be interpreted 
with some caution. The inclusion of more stringent negative controls would help 
resolves this issue. On the other hand, the interactions between Ago2 and A3F and A3G 
have already been validated in published reports (Gallois-Montbrun et al., 2008; 
Gallois-Montbrun et al., 2007; Wichroski et al., 2006).  
Attempts to further validate the co-immunoprecipitation results using a yeast 2 hybrid 
approach proved inconclusive (Figure 3.10). This is most likely due to the poor 
expression of the Argonaute proteins in yeast cells (Figure 3.10C). However, several 
known protein - protein interactions cannot be recapitulated in yeast 2 hybrid assays 
such as the interaction between A3G and Vif. A further means of validating this 
interaction was attempted through FRET/FLIM analysis, which could also be used to 
define the sub-cellular location of this interaction (i.e in P-bodies versus the diffuse 
cytoplasm). However, due to technical issues concerning this method and specifically 
the need to significantly overexpress the proteins of interest in order to identify positive 
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interactions, it was not considered a valid means of assessing the true biological nature 
of this interaction. Overexpression of A3G and Ago2 resulted in their association with 
large protein aggregates, and possibly stress granules, which are not formed under 
normal cellular conditions (Figure 3.12). Although confirming protein interactions in 
other systems is ideal, the interactions described here via co-immunoprecipitation have 
been consistently demonstrated even when the protocol was modified to include 
formaldehyde cross-linking, thus highlighting the robustness of the interaction observed. 
Although it has been reported that the interaction between A3F/A3G and Ago2 is 
partially resistant to RNase treatment, others have claimed it is wholly dependent on 
RNA (Wichroski et al., 2006). Whether this interaction is in fact mediated by miRNA or 
mRNA remains unresolved at present. Ago2 mutants that were no longer able to bind 
miRNAs still retained their interaction with A3G, though not to the same extent as the 
wild type protein (Figure 3.11). This might suggest that a proportion of this interaction 
is dependent on miRNAs. However, the fact that the F2V2 mutant is no longer able to 
bind either GW182 or miRNAs (Eulalio et al., 2008b) implies that in fact these two 
point mutations have caused serious conformational changes in the protein which 
affects its binding interface with cellular proteins, including A3G, and nucleic acid. 
Mutations in the PAZ domain of Ago2 may similarly interfere with A3G binding. 
Although the PAZ9 and PAZ10 mutants have been claimed to still interact with Dcp1a, 
the efficiency of this interaction was not reported (Liu et al., 2005b). Therefore it is 
likely that these mutations, though not affecting expression of the protein, interfere with 
its ability to interact with cellular factors through conformational alterations. What can 
be deducted from these Ago2 mutants, however, is that the interaction with A3G 
appears to be dependent on more than one intact Ago2 domain as mutations in both the 
PAZ and Mid domains reduced the association between these two proteins.  
Overall, it can be concluded that the interaction between the APOBEC3 and Argonaute 
proteins extends beyond A3F/A3G and Ago2 for both protein families. This interaction 
did not appear to closely correlate with the anti-viral phenotypes of the APOBEC3 
proteins, however, their co-localisation to Ago2 foci/P-bodies did. Although the exact 
nature of these interactions is not yet fully understood, the Argonaute proteins may 
provide a means of gaining novel insight into APOBEC3 activity and thus the 
functional consequences of this interaction will be explored in more detail in the 
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Functional implications of the interaction between the 
APOBEC3 and Argonaute protein families. 
 
4.1 Introduction 
The discovery that certain APOBEC3 proteins were able to associate with an array of 
cellular RNA binding proteins in RNP complexes (Chiu et al., 2006; Gallois-Montbrun 
et al., 2008; Gallois-Montbrun et al., 2007; Kozak et al., 2006; Wichroski et al., 2006), 
evoked questions regarding the relevance of these interactions for APOBEC3 activity, 
not just in terms of their anti-viral capabilities but also viral target specificities and 
potential unidentified cellular functions. It has already been proposed that high 
molecular weight complex formation allows A3G to sequester away Alu elements, thus 
inhibiting their retrotransposition, and that A3G contained within these complexes is 
enzymatically inactive (Chiu et al., 2006), thereby highlighting the importance of 
cellular interactions for functional regulation. Nevertheless, the importance of specific 
associated proteins to APOBEC3 activity, either as co-factors or regulators, has 
remained largely unexplored. Further, no cellular function has yet been defined for the 
APOBEC3 family, but their association with a number of proteins relevant to RNA 
metabolism and turnover suggest that they may be involved in similar processes. The 
mouse and rat APOBEC1 proteins are able to post-transcriptionally regulate the fate of 
AU rich element (ARE) containing mRNAs (Anant and Davidson, 2000; Anant et al., 
2004) and the human APOBEC3 proteins have been reported to antagonise miRNA 
mediated translational repression (Huang et al., 2007a).  Therefore, the functional 
implications of the interaction between the APOBEC3 and Argonaute proteins was 
investigated in more detail, firstly in terms of Argonaute involvement in APOBEC3 






4.2 Ago2 overexpression and APOBEC3 anti-viral activity 
To determine whether Ago2 had any effect on APOBEC3, in particular A3G, antiviral 
activity, HeLa cells stably expressing either untagged A3G or YFP were generated by 
retroviral transduction and maintained under neomycin selection. Expression and 
functionality of the transduced proteins was evaluated before further experiments were 
performed (data not shown). These cells were then co-transfected with equivalent 
amounts of Ago2 or GFP (in both HA and myc epitope tagged expression vectors) and 
the NL43 Δvif proviral plasmid. The myc tag is at the N-terminus of the protein while 
the HA tag is at the C-terminus. The position of epitope tags can strongly influence 
protein expression and/or activity, which is why two different plasmids were used in 
this experiment. A single cycle infectivity assay was then performed, as described in 
section 3.2, but briefly viral supernatants were harvested 48 hours post transfection, 
normalized by p24Gag ELISA and used to challenge the TZM-bl reporter cell line.  
Expression of the transduced and transfected proteins was confirmed by 
immunoblotting (Figure 4.1A), with equivalent amounts of Ago2 and GFP expressed in 
both cell lines. Virus production from these cells, shown in Figure 4.1B, is fairly 
consistent between the different samples. Slightly less virus is produced from the A3G 
expressing cells (black bars) compared to the YFP control line (grey bars), especially 
evident for the GFP.HA sample, but overexpression of A3G and other APOBEC3 
proteins can sometimes be mildly inhibitory to virus production. Nevertheless, when 
identical amounts of p24Gag were used to infect TZM-bl cells, HIV-1 Δvif inhibition by 
A3G was unaffected by the presence of Ago2 as a 1.5 log decrease in viral infectivity 
was consistently observed from A3G containing samples. Accordingly, it can be 
concluded from the data presented here that overexpression of Ago2 does not appear to 








Figure 4.1: Overexpression of Ago2 does not affect A3G anti-viral activity. 
HeLa cells stably expressing either untagged A3G or YFP (as a negative control) were transfected with 
equivalent amounts of either HA or myc epitope tagged Ago2 and GFP expression vectors and an NL43 
Δvif proviral plasmid. 48 hours post transfection, viral supernatants were harvested, quantified by p24Gag 
ELISA and used to infect the TZM-bl reporter cell line. A. immunoblot analysis of transduced and 
transfected proteins with anti-GFP (which also detects YFP), anti-A3G, anti-myc, anti-HA and anti-
HSP90 (as a loading control) antibodies. B. Virion production from transfected cells. C. Infectivity of 
virions produced in B. Results are representative of 2 independent experiments. 
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4.3 Knockdown of Argonaute 2 
4.3.1 Phenotypic analysis 
Although overexpression analyses can often be informative, mostly when a protein is 
limiting in a particular process or pathway, they fail to demonstrate whether it is 
actually necessary. Thus, even though overexpression of Ago2 did not yield any 
instructive data, this is not to say that it is not important for A3G function. A more 
thorough, and nowadays obligatory, means of assessing this is through RNAi, where a 
protein of interest is depleted through the use of small, targeted RNAs (discussed in 
Chapter 1, section 1.11.2). These RNAs recruit the RISC complex to their mRNA 
targets by binding to complimentary sites in the 3’UTR of the mRNA. RISC 
components (such as the Argonaute proteins) will then induce either translational 
repression or cleavage of these targeted mRNAs, thereby significantly reducing protein 
levels.  
Lentiviral vectors expressing short hairpin RNAs (shRNAs) were used to knock down 
Ago2. These shRNAs are perfectly complimentary to their mRNA target and therefore 
knockdown is achieved through Ago2 mediated cleavage. However, unlike traditional 
siRNAs, they are not produced from long double stranded RNA but instead from 
hairpin structures, as their name would suggest. This means that they are processed like 
miRNAs, with cleavage of the hairpin by Drosha in the nucleus and subsequent export 
and processing by Dicer in the cytoplasm to yield the siRNA (see Chaper 1, section 
1.11.1). As these shRNAs are expressed in lentiviral vectors, stable cells knocked down 
for the protein of interest can be generated and maintained. They also encode GFP 
allowing transfection and transduction efficiencies to be easily assessed. Knockdown of 
Ago2 via Ago2 mediated cleavage is possible and well documented (Meister et al., 
2005; Roberts et al., 2011; Schmitter et al., 2006), as this protein is highly catalytic and 
thus even residual amounts can have some phenotypic effect.  
HeLa and 293T cells were stably transduced with either an Ago2 targeting shRNA 
(Ago2) or a non-silencing control shRNA (NSC). After transduction, cells were 
maintained under puromycin selection and subsequently harvested and lysed for 
immunoblot analysis. Knockdown of Ago2 was highly effective (Figure 4.2A), as there 
is a significant reduction of Ago2 at the protein level in the knockdown cell lines 
compared to those expressing the control shRNA. Equivalent amounts of protein were 
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loaded onto the gel as judged by the amount of β-actin. Knock down of Ago2 had no 
obvious effects on cell proliferation or morphology.  
It was also of interest to determine whether knockdown of Ago2 led to any changes in 
the size and/or number of P-bodies as has been demonstrated for other P-body 
components. For this, stable HeLa and 293T cells were plated onto coverslips and 
stained with an anti-Ge1 antibody, a well-known marker of P-bodies. This antibody was 
primarily raised against the nuclear p70 s6 kinase protein but has subsequently been 
shown to cross-react with the cytoplasmic Ge1 protein (Kedersha and Anderson, 2007). 
Cells were imaged using a Leica confocal microscope. Contrary to published reports 
(Nathans et al., 2009), knockdown of Ago2 had no detectable effect on P-body 
formation in both HeLa and 293T cells (Figure 4.2B), which illustrates that this protein 






Figure 4.2: Phenotypic analysis of Ago2 knockdown by shRNA lentiviral vectors. 
293T cells were transfected with an Ago2 (Ago2) or non-silencing control (NSC) shRNA encoded 
lentiviral vector, a Gag-Pol packaging plasmid (p8.91) and a VSVG expression plasmid (pVSVG) at a 
2:2:1 ratio. 48 hours later, virus like particles (VLPs) were harvested and equivalent amounts used to 
transduce 293T or HeLa cells seeded in 24 well plates, with the addition of polybrene. 48 hours later, 
cells were checked for transduction efficiency by assessing GFP expression and placed under puromycin 
selection. Cells were maintained under selection for at least 5 days before immunoblot and 
immunofluorescence analysis. A. Cells were harvested, lysed and subjected to immunoblotting with anti-
Ago2 and anti-β-actin (as a loading control) antibodies to check for protein expression. B. Cells were also 
plated onto coverslips and 24 hours later fixed in 4% formaldehyde. Cells were then permeablised and 
stained with a mouse anti-Ge1 primary antibody and an anti-mouse 594 secondary antibody. Coverslips 
were mounted onto slides and dried overnight before imaging using a Leica confocal microscope. Scale 
bar = 10 µm. 
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4.3.2 Functional analysis  
Ago2 has been demonstrated to be the sole mediator of siRNA mediated silencing in 
humans as it is the only Argonaute protein that has retained its catalytic activity and is 
able to cleave mRNAs (Liu et al., 2004; Meister et al., 2004). Hence, it would be 
expected that depletion of Ago2 would lead to a reduced efficiency of silencing by 
siRNAs. This would thus provide a means of validating whether knockdown of Ago2, 
as determined by protein expression, had any functional consequences, before any 
further experiments with these cell lines were performed. 
In order to test this, siRNAs targeting the ESCRT component, ALIX (ALIX), or a non-
targeting control siRNA (control), were twice transfected into HeLa and 293T cells 
stably knocked down for Ago2. 48 hours after the second siRNA transfection, cells 
were harvested, lysed and subjected to immunoblotting (Figure 4.3). Cell lysates were 
probed for the expression of both ALIX and Ago2, using protein specific antibodies. 
Levels of HSP90 and β-actin verify that equal amounts of lysate were loaded onto the 
gels. Transfection of the control siRNA into both the non-silencing and Ago2 shRNA 
expressing cell lines (lanes 1 and 2) had no effect on ALIX expression. As would be 
expected, on the other hand, transfection of the ALIX siRNA into the control cell line 
(for both HeLa and 293T cells), led to a significant reduction in ALIX protein levels. 
However, using the same siRNA in the 293T Ago2 knock down cell line (Figure 4.3A), 
resulted in a less efficient depletion of ALIX, which would imply that in these cells, 
siRNA mediated silencing had been perturbed, though not completely eliminated 
(compare ALIX protein levels in lane 4 to lanes 1 and 2). It is unlikely that a complete 
inhibition of siRNA mediated silencing could be achieved with knock down of Ago2, as 
due to its highly catalytic nature, any residual protein remaining would still be 
functional. Also, without some Ago2 endonuclease activity, knockdown of this protein 
could not be achieved in the first place. In HeLa cells, knockdown of ALIX was 
equivalent in both the control and Ago2 shRNA expressing cell lines, suggesting that in 
this case, functional impairment of Ago2 was not as effective as in 293T cells, even 








Figure 4.3: Perturbation of siRNA mediated silencing as functional confirmation of Ago2 
knockdown. 
Stable 293T (A) (seeded 24 hours before) and HeLa (B) (seeded 4 hours before) cells, expressing either a 
non-silencing control (-) or Ago2 (+) targeting shRNA, generated as in Figure 4.2, were transfected with 
50 pmol of siRNAs targeting the ESCRT component ALIX (+) or a scrambled control (-), using the 
Dharmafect transfection reagent. 48 hours later, cells were re-seeded into 24 well plates and 4 hours later 
were transfected again as before. 48 hours after the second transfection cells were washed in PBS and 
lysed in gel loading buffer. Lysates were analysed by immunoblotting using anti-ALIX and Ago2 specific 
primary antibodies. Anti-HSP90 and anti-β-actin antibodies were also included as loading controls. Data 
is representative of four independent experiments. 
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4.3.3 Ago2 knockdown and APOBEC3 anti-viral activity 
To help establish a functional basis for the interaction between the APOBEC3 proteins 
and Ago2, an infectivity assay was utilised to assess the consequences of Ago2 
depletion on both HIV-1 virion infectivity and APOBEC3 anti-viral activity. 
As previously described in section 4.2, stable 293T cells expressing either a control or 
Ago2 targeting shRNA were co-transfected with 0.5 ug each of APOBEC3.HA 
plasmids (with GFP as a negative control) and an NL43 Δvif construct. 48 hours later, 
viral supernatants were harvested, and normalised amounts were used to infect TZM-bl 
cells. In parallel, equivalent amounts of supernatant were spun through a 20% sucrose 
cushion and the pellets lysed and prepared for immunoblotting in order to check for 
virion incorporation of the APOBEC3 proteins.  
Ectopic expression of the APOBEC3 proteins led to similar levels of protein expression 
in both cell lines (Figure 4.4A), and near equivalent amounts of virus production from 
all samples tested (Figure 4.4B). This demonstrates that Ago2 neither inhibits nor 
facilitates HIV-1 particle production in 293T cells. From Figure 4.4C, it can also be 
seen that Ago2 has no significant effect on HIV-1 infectivity, as demonstrated by the 
equivalent levels of viral infectivity in the presence of GFP. Fundamentally, depletion 
of Ago2 did not alter APOBEC3 anti-viral activity (Figure 4.4C). A slight difference is 
observed for A3G inhibition in the control and knock down cell line but this is most 
likely due to these values being very close to background levels and are therefore less 
robust. These results are confirmed by the virion incorporation blots (Figure 4.4A), as 
the degree of APOBEC3 packaging is identical in both cell lines.  
In order to rule out the possibility that overexpression of the APOBEC3 proteins had 
masked any differences in viral inhibition, a titration of A3G and GFP (as a negative 
control) was carried out and virus production, anti-viral activity and virion packaging 
were examined as before (Figure 4.5). Once again, there is near equivalent expression 
of the transfected proteins (except at the lowest concentration of A3G for some reason, 
compare lanes 11 and 12, Figure 4.5A) and of virus production from both cell lines 
(Figure 4.6B).  HIV-1 infectivity is not affected by Ago2 depletion as judged by 
titration of GFP in the control and knock down cell lines. The anti-viral activity of A3G 
is also comparable between the two cell lines, even at lower amounts of input DNA, 
although as before there is slightly less inhibition in the knockdown compared to the 
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control cells (Figure 4.5C). However this does not appear to be a dramatic effect, 
though it is consistent, and the raw values in all cases were relatively low. This is 
supported by the fact that similar amounts of A3G are packaged into virions in both cell 
lines (Figure 4.5A, lower panels).  
Overall it can be concluded that depletion of Ago2 does not seem to have any 
significant consequences, either positive or negative, for APOBEC3 anti-viral activity. 
Therefore, since Ago2 is the only enzymatically active Argonaute protein, siRNA 





































Figure 4.4: Knockdown of Ago2 does not affect APOBEC3 anti-viral activity.  
293T cells stably transduced with either an Ago2 (Ago2) or non-silencing control (NSC) shRNA, as 
described in Figure 4.2, were transfected with 0.5 µg of HA-tagged APOBEC3 expression plasmids and 
an NL43 Δvif proviral plasmid. 48 hours later, viral supernatants were harvested, normalised and used to 
infect the TZM-bl reporter cell line. Normalised viral supernatants were also concentrated through a 20% 
sucrose cushion and viral pellets analysed by immunoblotting for APOBEC3 incorporation. A. 
Immunoblot analysis of cell and viral lysates with anti-HA, anti-p24Gag and anti-Ago2 antibodies. Anti-
HSP90 and anti-β-actin were included as loading controls. B. Virion production from transfected cells, 
described above. C. Infectivity of virions produced in B. Data is presented as the average of three 
independent experiments, with error bars denoting the standard deviation. All values are normalised to 































Figure 4.5: Knockdown of Ago2 does not affect A3G anti-viral activity even at lower levels of A3G 
expression 
293T cells stably transduced with either an Ago2 (Ago2) or non-silencing control (NSC) shRNA encoded 
lentiviral vector, as described in Figure 4.2, were transfected with either 0.5 µg, 0.16 µg or 0.05 µg of 
HA-tagged A3G or GFP (as a negative control) expression plasmids and 0.5 µg of an NL43 Δvif proviral 
plasmid. Total DNA concentrations were kept constant at 1 µg with the addition of an untagged luciferase 
expression plasmid. An infectivity assay was then performed as in Figure 4.4. A. Immunoblot analysis of 
cell and viral lysates with anti-HA, anti-p24Gag and anti-Ago2 antibodies. Anti-HSP90 and anti-β-actin 
were included as loading controls. B. Virion production from transfected cells, described above. C. 
Infectivity of virions produced in B. Data is presented as the average of three independent experiments, 
with error bars denoting the standard deviation. All values are normalised to GFP in the NSC cell line, 






4.4 Ago2 knockdown and miRNA mediated repression 
Although it has been demonstrated that Ago2 and siRNA mediated silencing do not 
appear to be important for APOBEC3 anti-viral activity, the role of the other Argonaute 
proteins and miRNA mediated repression, in general, has not been explored. All four 
Argonaute proteins are known to be involved in this process, yet the exact contributions 
of any one particular protein are not understood. Therefore, it was conceivable that 
knockdown of Ago2 may cause some reduction in miRNA mediated repression, though 
not abolish it completely. If true, this would help unearth any possible involvement of 
this pathway in APOBEC3 activity. To check this, a miRNA based assay was utilised 
comprising firefly luciferase reporter constructs containing four binding sites for the let-
7 miRNA (wild type/FF4LCS) or a control containing mutated binding sites 
(mutant/FFrm4LCS) (Figure 4.6A). Expression of the wild type construct should be 
repressed approximately 4 - 5 fold compared to the control due to the action of 
endogenous let-7 miRNAs (Lytle et al., 2007). These will bind to the target sites in the 
wild type construct and recruit the RISC complex, which will subsequently induce 
translational repression or degradation of the reporter (see Chapter 1, sections 1.11.1 – 
1.11.3). The mutant construct will be unaffected by the actions of these miRNAs and 
therefore should be expressed at normal levels. Renilla luciferase is also included to 
account for any differences in transfection efficiencies. Both the wild type and mutant 
constructs were transfected into HeLa Ago2 knockdown and control cell lines and 
luciferase expression was assessed by a Dual Luciferase Reporter Assay (Promega) as 
per manufacturer’s instructions. This experiment could not be performed in 293T cells 
due to the poor repression of the wild type construct, most likely due to low amounts of 
endogenous let-7 miRNA expression in these cells. In the Ago2 knock down cell line, 
repression of the wild type construct might be expected to be reduced but this was not 
the case as the level of repression was equivalent in both cell lines (Figure 4.6B). This 
indicates that miRNA repression is not dependent upon Ago2 as it occurs just as 
efficiently, mediated by the other Argonaute family members, in the presence of 








Figure 4.6: Knockdown of Ago2 does not impair miRNA mediated repression. 
A. Schematic diagram of the luciferase reporter constructs used in this study. Firefly luciferase expression 
plasmids contain either four intact (wild type/FF4LCS) or mutated (mutant/FFrm4LCS) binding sites for 
the let-7 miRNA in the 3’UTR. The inserted sequences are shown with the let-7 bind§ing sites 
highlighted in bold. B. HeLa cells stably expressing either an Ago2 (Ago2) or non-silencing control 
(NSC) shRNA encoded lentiviral vector were transfected with 0.1 µg of the wild type or mutant reporter 
plasmid, 0.4 µg of HA-tagged GFP and 0.01 µg of Renilla luciferase as a transfection control. 30 hours 
later cells were harvested, lysed and a Dual Luciferase Assay performed to measure luciferase activity. 




4.5 mlin41 overexpression and effects on Argonaute 2 
The results presented above highlight the complexities of studying a family of proteins 
with similar functional roles, as knockdown of one particular member may have no 
observable effects on the pathway of interest. In a bid to address this redundancy, the 
mouse Trim71 protein (commonly referred to as mlin41) was employed as a means to 
deplete all four Argonautes simultaneously, as it has been reported to be involved in the 
proteosomal degradation of these proteins (Rybak et al., 2009). mlin41 is a target of the 
let-7 miRNA and has been shown to interact with the Argonautes and Dicer by co-
immunoprecipitation and localise to P-bodies. Moreover, it acts as an E3 ubiquitin 
ligase, inducing the ubiquitination and hence degradation of the Argonaute proteins and 
as a result, interferes with mRNA translational repression. Overexpression of mlin41 in 
embryocarcinoma cells resulted in reduced Ago2 proteins levels to almost undetectable 
levels. More importantly, using reporter constructs in 293 cells, it led to inhibition of 
repression mediated by the let-7 and miR-124 miRNAs (Rybak et al., 2009). Thus if its 
effects could be replicated, it would be a useful tool in resolving the significance of 
miRNA repression and consequently the Argonaute proteins for APOBEC3 function. 
Therefore, FLAG-tagged mlin41 was transfected into HeLa and 293T cells at increasing 
concentrations, along with luciferase and DDX6, as negative controls. 48 hours post 
transfection, cells were harvested, lysed and prepared for immunoblotting. Lysates were 
probed for the expression of endogenous Ago2 only, as a good commercial antibody is 
available for this protein.  
From Figure 4.7, mlin41 appears to be well expressed in both HeLa and 293T cells, but 
from the Ago2 blots (bottom left and right), overexpression of mlin41 does not seem to 
have a dramatic effect on Ago2 protein levels when compared to the mock transfected 
control (compare lane 1 with lanes 4 - 6, in both cell lines). At the highest concentration 
of input DNA (lane 6), there is a moderate reduction in Ago2 expression, which is more 
evident in the 293T cells, yet a substantial amount of protein is still present. In essence, 
although mlin41 may cause a slight decrease in Ago2 protein levels when highly 
expressed, it is insufficient with which to efficiently deplete these proteins from cells 





       






Figure 4.7: mlin41 overexpression and effects on Ago2 protein expression. 
293T and HeLa cells were either untransfected (mock) or transfected with 2 µg of FLAG-tagged 
luciferase, FLAG-tagged DDX6 and increasing concentrations of FLAG-tagged mlin41 (0.5 µg, 1 µg and 
2 µg) expression plasmids in 6 well plates using either PEI (293T) or Fugene (HeLa). Total DNA 
concentration was kept constant at 2 µg with the addition of an untagged luciferase expression plasmid. 
48 hours later cells were lysed in gel loading buffer and analysed by immunoblotting using anti-FLAG 
and anti-Ago2 antibodies. Anti-HSP90 was included as a loading control. Data is representative of three 





4.6 APOBEC3 proteins and regulation of RNA 
4.6.1 miRNA mediated translational repression 
Since it was evident from the data presented thus far, that there was no apparent role for 
Ago2 in APOBEC3 mediated HIV-1 inhibition, focus then turned to a potential role of 
the APOBEC3 proteins in Argonaute function. Specifically, Huang et al (2007) have 
reported that the APOBEC3 proteins are able to inhibit both siRNA and miRNA 
mediated translational repression through an as yet unidentified mechanism. This 
assigns a cellular function to the APOBEC3 proteins but also has implications for their 
anti-viral activity as there is increasing evidence of the importance of cellular and viral 
miRNAs in both viral replication and inhibition (discussed in Chapter 1, section 1.11.4). 
It also provides functional relevance to the APOBEC3-Argonaute interaction. To verify 
these findings, a miRNA based reporter assay was employed as described in section 4.4. 
In this case, HeLa cells were co-transfected with HA-tagged APOBEC3 expression 
vectors and either the wild type or mutant luciferase reporter constructs. Renilla 
luciferase was included to account for any differences in transfection efficiencies. 24 
hours later, cells were harvested and lysed and luciferase activity measured.  
Figure 4.8 presents the raw firefly and Renilla luciferase values, with all data 
normalised to GFP co-transfected with the mutant reporter, which is set at 100%. Firstly, 
with co-transfection of the negative control, GFP, there is a four fold decrease in the 
expression of the wild type construct relative to the mutant control (Figure 4.8A), as 
would be expected from previous reports (Lytle et al., 2007). Expression of A3C 
resulted in an increase in expression of the wild-type reporter (black bar), which would 
be expected if this were indeed a miRNA mediated effect. However, this change was 
matched by a similar increase for the mutant reporter, which implies that this is not a 
result of inhibition of miRNA mediated translational repression. The remaining 
APOBEC3 proteins either caused only modest increases in the expression of both 
reporters (A3A, A3G and A3H) or resulted in decreased expression, to varying degrees, 
with A3D/E having the strongest effect. These results were confirmed when examining 
expression of Renilla luciferase (Figure 4.8B). This plasmid contains no known miRNA 
binding sites and therefore its expression should be unaffected by the APOBEC3 
proteins, if indeed their affects are miRNA dependent. Similar changes are observed for 
the expression of this protein upon co-transfection of the different APOBEC3 proteins, 
as seen for firefly luciferase. In both instances, A3C had the most dramatic effect, 
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increasing protein levels of all the constructs tested by approximately 10 fold. 
Expression of the different APOBEC3 proteins with both the wild type and mutant 
reporter was confirmed by immunoblotting (Figure 4.8C). These data indicate that the 
APOBEC3 proteins are not able to specifically suppress miRNA mediated translational 
repression and instead they act as more general modulators of protein expression. The 









Figure 4.8: APOBEC3 proteins do not inhibit miRNA mediated translational repression by the let-
7 miRNA. 
HeLa cells, seeded in 24 well plates, were transfected with 0.1 µg of wild type or mutant let-7 luciferase 
reporter plasmids (described in Figure 4.6), 0.9 µg of HA-tagged APOBEC3 expression plasmids and 
0.01 µg of a Renilla luciferase expression plasmid as a transfection control. 30 hours later, cells were 
harvested, lysed and a Dual Luciferase Assay performed to measure luciferase activity. Cells were also 
re-suspended in gel loading buffer for immunoblot analysis A. Firefly luciferase values of the wild-type 
and mutant reporter constructs co-expressed with the APOBEC3 plasmids or GFP as a negative control. 
B. Renilla luciferase values of wild type and mutant reporter constructs co-expressed with the APOBEC3 
plasmids and GFP as a negative control. For both A and B, data are the raw luciferase values presented as 
the average of four independent experiments with error bars denoting the standard deviation. All values 
are normalised to GFP co-expressed with the mutant luciferase reporter plasmid which is set at 100%. C. 
Immunoblot analysis of APOBEC3 protein expression in the presence of the wild type (left panel) and 




4.6.2 Inhibitors of miRNA mediated translational repression 
Few proteins have so far been described that are actually able to modulate miRNA 
mediated translational repression. A selection of these were tested in the miRNA system 
described in section 4.4 and 4.6.1 so as to identify possible positive controls for this 
assay.  
VA1 is a non-coding structured RNA encoded by adenovirus. It has been reported to 
specifically inhibit miRNA function, but not siRNAs, by hindering export of miRNA 
precursors from the nucleus and by directly binding to Dicer (Lu and Cullen, 2004). In 
spite of this, overexpression of VA1 failed to relieve repression of the wild type 
construct in the let-7 miRNA assay (Figure 4.9A). Although cells were harvested 48 
hours after transfection, it may take significantly longer for the effects of VA1 to be 
observed, especially when measuring let-7, which is one of the most abundant miRNAs 
expressed in HeLa cells. In support of this, it can take several days before phenotypic 
effects of Dicer depletion are manifest. 
Another protein tested was the RNA binding protein Dead end 1 (DND1), which is 
required for germ cell survival and migration in zebrafish. Kedde et al (2007) state that 
the human orthologue is capable of directly binding to mRNAs thereby interfering with 
miRNAs binding at their target sites, specifically of the LATS2 and p27 tumour 
suppressor genes. Figure 4.9B demonstrates that expression of DND1 caused significant 
decreases in both firefly and Renilla expression levels. Raw values from these 
experiments are presented to clearly highlight this. These indiscriminate effects 
therefore rule out DND1 as a possible positive control in this system.  
Finally, the HIV-1 accessory protein, Tat, was also investigated. It has been proposed 
that Tat is able to suppress global RNAi in HIV-1 infected cells by either directly 
binding to Dicer or through sequestration of the Dicer co-factor TRBCP (Bennasser et 
al., 2005; Hayes et al., 2011; Qian et al., 2009). From Figure 4.9C, although Tat does 
increase expression of the wild type construct, it has similar though not as strong effects 
on the mutant reporter as well. This fits in with the role of Tat as a general translation 
enhancer and is akin to the effects seen with the over expression of some of the 
APOBEC3 proteins. Moreover, this result supports a recent study where Tat was shown 
to have no role in inhibiting the actions of both exogenous and endogenously expressed 





Figure 4.9: Analysis of proposed inhibitors of miRNA mediated translational repression. 
A. HeLa cells seeded in 24 well plates, were transfected with 0.1 µg of wild-type or mutant let-7 
luciferase reporter plasmids (as described in Figure 4.6), 0.9 µg of a VA1 expression plasmid or empty 
vector (pBS) as a negative control and 0.01 µg of a Renilla luciferase expression plasmid as a transfection 
control. 30 hours later, cells were harvested, lysed and a Dual Luciferase Assay performed to measure 
luciferase activity. Data is presented as the ratio of firefly to Renilla values, with Renilla levels equivalent 
across samples. B. As in A, except that 0.9 µg of a DND1 expression plasmid (or the pCS2 empty vector 
as a negative control) were co-transfected with the luciferase reporter constructs. Data is presented as the 
raw firefly and Renilla values. C. As in A and B except that 0.9 µg of Tat expressed in the pCDNA3.1 
expression plasmid (or GFP as a negative control) was co-transfected with the luciferase reporter 
constructs. Data is presented as the ratio of firefly to Renilla values, with Renilla levels equivalent across 
all samples. In all cases, data is representative of at least two independent experiments.  
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4.6.3 siRNA mediated silencing 
Although VA1 had no discernable effects on the miRNA constructs used within this 
study, its ability to interfere with miRNA biogenesis has been demonstrated and 
validated in a different reporter system (Lu and Cullen, 2004). This consists of firefly 
luciferase coupled to eight binding sites for the mir30p miRNA (Figure 4.10A). The 
expression of mir30p, when transfected into cells, is as a pri-miRNA precursor and it is 
therefore processed like a miRNA (discussed in Chapter 1, section 1.11.1). However, it 
is perfectly complimentary to the binding sites contained within the luciferase reporter 
and therefore, repression is achieved via Ago2 endonucleolytic cleavage. Because of 
this, the APOBEC3 proteins were analysed for their effects on this second RNAi 
reporter system, which would evaluate their roles in miRNA biogenesis and siRNA 
mediated silencing.  Plasmids encoding the firefly luciferase reporter, the mir30p 
miRNA and either VA1 or HA-tagged APOBEC3 proteins were transfected into HeLa 
cells with Renilla luciferase also included as an internal transfection control. 48 hours 
later cells were harvested and a Dual Luciferase Assay was performed as previously 
described.  
As shown and previously reported (Lu and Cullen, 2004), co-expression of the miRNA 
and the reporter construct leads to a substantial reduction in luciferase expression 
(Figure 4.10B) of approximately 6 - 10 fold (pBS and GFP samples). Addition of VA1, 
however, restores luciferase expression to the same level as seen in the absence of the 
miRNA thereby confirming that VA1 acts as a derepressor of miRNA activity. 
Although some of the APOBEC3 proteins, namely A3A, A3B, A3C and A3D/E did 
cause a modest increase in luciferase expression in the presence of the miRNA this was 
much smaller in comparison to the effects seen with VA1. A similar increase was seen 
in the absence of the miRNA (black bars) for A3A, A3B and A3C and is an effect that 
has also been noted and reported for VA1 (Lu and Cullen, 2004). A3F actually caused a 
decrease in expression, even when no miRNA was present and A3G appeared to have 
no effect on these reporter constructs at all. This indicates that the APOBEC3 proteins 
do not affect miRNA biogenesis, as has been demonstrated for VA1. It also supports the 
work presented earlier that the APOBEC3 proteins do not interfere with miRNA and/or 











Figure 4.10: APOBEC3 proteins do not inhibit siRNA mediated silencing or affect miRNA 
biogenesis. 
A. Schematic diagram of the siRNA luciferase reporter and miRNA construct used in this study. The 
firefly luciferase reporter (top) construct contains 8 perfectly complementary binding sites for the mir30p 
miRNA (bottom) in its 3’UTR. The sequence of the mir30p miRNA is provided. B. HeLa cells seeded in 
24 well plates were co-transfected with the luciferase reporter and HA-tagged APOBEC3 expression 
plasmids in the presence (grey bars) and absence (black bars) of the mir30p miRNA. GFP is included as a 
negative control. VA1 expressed in the pBS expression plasmid is included as a positive control with the 
empty vector (pBS) included as the negative control. In all cases, a Renilla luciferase expression plasmid 
was also included as a transfection control. 48 hours later, cell lysates were harvested, lysed and a Dual 
Luciferase Assay performed to measure luciferase activity. Results are presented as the ratio of firefly to 




4.6.4 ARE mediated decay (AMD) 
Another means of RNA regulation is through AU-rich element (ARE) mediated decay 
(Chapter 1, section 1.11.6). Certain mRNAs contain AU rich sequences within their 
3’UTR which are recognised and bound by particular cellular proteins. These ARE 
binding proteins will then contribute to either the degradation or stability of these 
mRNAs via mechanisms that are not completely understood.  The mouse APOBEC1 
protein, has been identified as one such ARE binding protein as it binds and stabilises 
several ARE containing mRNAs (Chapter 1, section 1.8.1). Further, the Argonauate 
proteins and miRNAs have also been implicated in ARE regulation (Jing et al., 2005; 
Vasudevan and Steitz, 2007a; Vasudevan et al., 2007b). Thus it is conceivable that the 
APOBEC3 proteins may also be involved in this process. 
To investigate this, reporter constructs were utilised which consisted of firefly luciferase 
coupled to either the full length 3’UTR (UTR) or just the ARE binding sites (ARE) of 
TNFα, a well known AU rich RNA that is subject to ARE mediated decay. An empty 
vector (CTRL) and a construct harbouring mutated ARE binding sites (ARE mt) were 
used as the respective controls (Figure 4.11A) (Vasudevan and Steitz, 2007a). HA-
tagged APOBEC3 plasmids were co-transfected with the various constructs and Renilla 
luciferase was also included to account for differences in transfection efficiencies. 
Results in Figure 4.11B are presented as the ratio of firefly to Renilla luciferase values 
as no difference in Renilla levels were observed across all samples. Co-transfection of 
GFP results in a four fold reduction in expression of the ARE containing constructs 
compared to their controls (first four bars) as would be expected based on previous 
reports (Vasudevan and Steitz, 2007a). Addition of A3A, A3F or A3G does not alter 
this (white and dark grey bars), though with A3G and more dramatically A3A, 
expression of all the constructs is increased.  Thus it can be concluded that the 
APOBEC3 proteins are not involved in the regulation of ARE containing mRNAs but 









Figure 4.11: APOBEC3 proteins do not inhibit ARE mediated decay of TNFα. 
A. Schematic diagram of the ARE reporter constructs used in this study. Firefly luciferase reporter 
plasmids contain either the full length 3’UTR of TNFα (UTR) or just the ARE binding sites (ARE). An 
empty vector (CTRL) and a construct containing mutated binding sites (AREmt) serve as the respective 
controls. The sequences of the wild type and mutated TNFα ARE are also depicted. B. HeLa cells plated 
in 24 wells plates were co-transfected with a luciferase reporter construct and untagged A3A, A3F or 
A3G (or GFP as a negative control). A Renilla luciferase expression plasmid was also included as a 
transfection control. 30 hours later cells were harvested, lysed and a Dual Luciferase Assay performed to 
measure luciferase activity. Data is presented as the ratio of firefly to Renilla luciferase values, with 





4.6.5 ARE binding proteins (ARE-BP) 
Numerous ARE binding proteins have now been identified that are able to modulate the 
expression of ARE containing transcripts. Several of these proteins were tested against 
the reporter constructs described above in order to establish a positive control for this 
system. Firstly, and as previously mentioned, mouse and rat APOBEC1 have both been 
shown to stabilise expression of the c-myc mRNA among others, through binding to 
AU rich sequences in the 3’UTR (Anant and Davidson, 2000; Anant et al., 2004). 
Secondly, HuR has been reported to bind to ARE-containing mRNAs in the nucleus and 
protect them from degradation upon translocation to the cytoplasm (Fan and Steitz, 
1998). Finally, exogenous expression of FXR1 induces translational activation of the 
TNFα mRNA (Vasudevan and Steitz, 2007a). However, none of these effects proved to 
be reproducible in this system (Figure 4.12), as all of the proteins tested were unable to 
counteract repression of the ARE containing reporters. The underlying basis for these 


















Figure 4.12: Effects of ARE binding proteins on the TNFα ARE. 
A. HeLa cells plated in 24 wells plates were co-transfected with luciferase reporter constructs (as 
described in section 4.11) and human and rat APOBEC1 in the pCDNA3.1 expression vector, with 
Renilla luciferase included as a positive control. 30 hours later cells were harvested, lysed and a Dual 
Luciferase Assay performed to measure luciferase activity. B. As in A except in this case a HuR 
expression plasmid was co-transfected with the luciferase reporter constructs. C. As in A and B, except in 
this case an FXR1 expression plasmid was co-transfected with the luciferase reporter constructs. In all 
cases, data is presented as the ratio of firefly to Renilla values, with Renilla levels equivalent across all 





The work presented in this chapter aimed to identify functional consequences for the 
interaction between the APOBEC3 and Argonaute proteins. It has been demonstrated 
that Ago2 is dispensable for APOBEC3 antiviral activity though the effects of the other 
Argonaute proteins and miRNA repression in general requires further exploration. 
Conversely the APOBEC3 proteins are not involved in the general regulation of 
mRNAs through miRNA, siRNA or ARE containing transcripts. Thus the implications 
of the APOBEC3-Argonaute interaction may be subtler than originally envisaged.  
Cellular co-factors for both AID and APOBEC1 are essential for their activity 
(Chaudhuri et al., 2004; Mehta et al., 2000). Whether such factors exist and are 
necessary for the function of the APOBEC3 proteins is unknown at present. Conversely, 
interacting proteins may help regulate the activity of the APOBEC3 proteins, especially 
in light of their enzymatic capabilities. Whether or not Argonaute 2 fulfils either of 
these roles was investigated due to the close association of these proteins as observed 
through biochemical analysis (Chapter 3). Overexpression and knock down studies are 
now commonly used approaches to verify whether a gene of interest is necessary and/or 
sufficient for a particular biological process. These methods were used in an attempt to 
ascertain the importance of Ago2 for APOBEC3 mediated HIV-1 inhibition, and as a 
consequence, for HIV-1 replication in general (Figures 4.1 and 4.4). Nathans et al 
(2009) have reported that siRNA mediated knockdown of Ago2 leads to a 2 - 3 fold 
increase in virus production and a subsequent 2 fold increase in virus infectivity (when 
viruses are normalised), which coincides with a loss of P-bodies as marked by ectopic 
expression of an A3G-YFP fusion protein. On all accounts, the results presented here do 
not support these findings. Even with a highly efficient depletion of Ago2 at the protein 
level, DDX6 labelled P-bodies were still present in both HeLa and 293T cells. This 
discrepancy may be due to the different P-body markers used (an exogenous A3G 
fusion protein compared to endogenous Ge1), but the differences in effects in HIV-1 
replication upon Ago2 knockdown are harder to resolve and will be discussed in more 
detail in Chapter 5.  
Importantly, functional knockdown of Ago2 was confirmed in 293T cells through a 
reduction in siRNA mediated silencing of the ALIX protein (Figure 4.3). This approach 
did not work in HeLa cells, probably due to the more efficient knock down of ALIX, 
which made recovery more difficult. It was subsequently shown that in these cells there 
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was no significant impairment of APOBEC3 antiviral activity (Figures 4.4 and 4.5), 
ruling out the necessity of Ago2 and more specifically its endonuclease function for this 
process. It has been speculated that the endonuclease activity of Ago2 may be utilised 
for the degradation of A3G edited reverse transcripts (thus accounting for the lack of 
accumulation of these products associated with A3G viral inhibition), similar to the 
proposed and later discounted role of cellular repair enzymes such as UNG2 (Harris et 
al., 2003b). The data presented in this chapter fails to substantiate this hypothesis. It 
must be emphasised however that although the knockdown of Ago2 at the protein level 
was fairly substantial, the functional knockdown was only partial (Figure 4.3), which 
renders the possibility that a more stringent knockdown may be required to determine 
functional effects. A similar problem was documented with the nuclear protein 
LEDGF/p75 (Llano et al., 2006). Even though it appeared to be efficiently depleted at 
the protein level, a more rigorous knock down strategy had to be employed to 
conclusively identify its essential role in HIV-1 proviral integration. However, since 
silencing of Ago2, like all targeted mRNAs, is dependent upon the presence and 
endonuclease activity of Ago2, complete functional depletion cannot be achieved. This 
may not necessarily be a problem though as several groups have used siRNAs to target 
Ago2 with noticeable phenotypic effects (Lian et al., 2007; Meister et al., 2005; Randall 
et al., 2007; Schmitter et al., 2006; Wilson et al., 2011). This suggests that this is in fact 
a valid means of elucidating the functional requirements of Ago2 for a given process or 
pathway.  
As mentioned earlier, a major detriment to these studies is the problem of functional 
redundancy between the Argonaute proteins. Consequently the importance of the 
miRNA pathway to APOBEC3 mediated HIV-1 inhibition has not been fully addressed. 
Cellular miRNAs have been reported to target viral RNA and they may also modulate 
proteins that are required for HIV-1 to complete its life cycle [reviewed in (Houzet and 
Jeang, 2011)].  Alternatively virally encoded miRNAs may facilitate viral replication. 
Thus whether the APOBEC3 proteins depend on this pathway for possible editing 
independent means of viral inhibition is an important point to resolve. The simultaneous 
knock down of all four Argonaute proteins is possible but challenging, as the efficiency 
of the knockdown for all the proteins, potential toxicity and cell viability would have to 
be optimised. Very recently, the combined depletion of all four Argonaute proteins has 
been published (Roberts et al., 2011), but the individual knockdown efficiencies of each 
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protein at the mRNA or protein level was not reported. As an alternative approach, 
overexpression of the mlin41 protein was trialled in an attempt to deplete the whole 
Argonaute family but this yielded an insufficient knockdown of Ago2 (Figure 4.7). 
Therefore, to comprehensively explore whether the miRNA pathway is involved in 
APOBEC3 antiviral activity, it may be more amenable to knock down other essential 
components, such as Dicer or GW182, both of which have been successfully knocked 
down by a number of different groups (Chable-Bessia et al., 2009; Jakymiw et al., 2005; 
Lian et al., 2007; Meister et al., 2005; Nathans et al., 2009; Roberts et al., 2011; 
Schmitter et al., 2006; Triboulet et al., 2007). Even though three orthologues of GW182 
exist in mammals and all can mediate translational repression, knockdown of any one 
protein markedly affects miRNA mediated repression (Zipprich et al., 2009), 
demonstrating a lack of functional overlap. This may be due to their recruitment of and 
interaction with distinct complexes of Argonaute proteins (Baillat and Shiekhattar, 
2009). In essence it has been established that Ago2 and siRNA mediated silencing are 
not required for APOBEC3 inhibition of HIV-1. Whether the miRNA pathway is 
important will require alternative means of investigation that may not necessarily 
include the Argonaute proteins.  
The APOBEC3-Argonaute interaction may not have direct consequences on APOBEC3 
anti-viral activity but may be more important for other functions of this protein family. 
Although the APOBEC3 proteins target single stranded DNA they are RNA binding 
proteins and associate with a variety of proteins involved in RNA metabolism and 
turnover. Therefore it is possible that they may also have a role to play in RNA 
regulation, especially as a cellular function for these proteins has not yet been identified. 
Whether the APOBEC3 proteins are able to regulate the miRNA pathway, for example, 
would also help address how important this process may be to its anti-viral phenotype. 
On this note, it has been reported that the APOBEC3 proteins act as inhibitors of 
miRNA mediated translational repression (Huang et al., 2007a) and thus are antagonists 
of Argonaute protein function. The data presented here fail to support these findings as 
the APOBEC3 proteins affected protein expression regardless of miRNA or siRNA 
inhibition in two separate reporter systems (Figures 4.8 and 4.10). The relevance of 
these general effects on protein levels, particularly for A3C, which had the most 
dramatic phenotype, is currently unknown. In order to decipher the mechanism behind 
this, it must first be established whether these changes are occurring at the protein or 
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RNA level. The specificity of this effect as well as its biological relevance must also be 
investigated. The fact that viral protein production (p24Gag) was not upregulated upon 
overexpression of the APOBEC3 proteins (see Figures 4.4 and 4.5) reinforces the 
notion that there may be some specificity involved and also that this is not just an 
overexpression artefact. As the APOBEC3 proteins appear to have differing effects and 
because this phenotype does not correlate with their anti-viral status makes it especially 
intriguing and may help identify novel functions for some of the less well studied 
APOBEC3 proteins.  
The reasons why the work of Huang et al could not be replicated in this study are 
unclear but a large part of this is most likely due to differences in experimental methods. 
Also, results from these types of experiments are typically presented as the ratio of 
firefly to Renilla levels but this makes it difficult to evaluate exactly where changes are 
taking place and thus compare results from different groups. Since the APOBEC3 
proteins caused substantial changes in Renilla levels as well as the control construct this 
information may be lost if the values are normalised and may lead to inaccurate 
conclusions being drawn. Because of this, the raw luciferase values from all constructs 
were presented from the experiments in this study but are therefore not directly 
comparable with the data presented by Huang and colleagues. On the other hand, 
although the authors reported that the APOBEC3 proteins could hinder the action of the 
let-7 miRNA, it may not necessarily be their natural target. The identification of 
APOBEC3 associated RNAs, both miRNA and mRNA may help elucidate more 
specific and biologically relevant targets of these proteins. Identification of APOBEC3 
associated RNAs has already been initiated (Kozak et al., 2006), and these RNAs may 
also contribute to the functional regulation of these proteins, as has already been 
determined for APOBEC1 and AID (Bransteitter et al., 2003; Sowden et al., 1996). 
Thus although the APOBEC3 proteins had no effect in the reporter systems tested here, 
a potential role for them in RNAi cannot yet be conclusively ruled out.  
Finally, the APOBEC3 proteins were also tested for their involvement in ARE mediated 
repression (Figure 4.11), in light of what has been reported for both mouse and rat 
APOBEC1, which can stabilise the expression of several ARE containing mRNAs, 
including c-myc and Cox-2, that would otherwise be rapidly degraded (Anant and 
Davidson, 2000; Anant et al., 2004).  Once again, they were not found to modulate this 
process with the caveat that proteins that have been shown to influence ARE mediated 
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repression also did not produce any positive results (Figure 4.12). As before, this could 
be explained, in part, by the fact that APOBEC1 and potentially the other APOBEC3 
proteins do not naturally target the TNFα transcript. To address this numerous ARE 
containing mRNAs would have to be tested. However HuR and FXR1 have both been 
reported to affect the stability of TNFα mRNAs and so the lack of an effect observed in 
this system is somewhat unexpected. However, in the case of HuR, only effects at the 
level of the RNA were reported (Fan and Steitz, 1998), so it is not clear how these 
changes would be manifested at the protein level, as was measured here. Further the 
destabilisation of the luciferase reporter containing the TNFα ARE binding sites, which 
leads to its reduced expression, may be the result of degradation of the transcript rather 
than repression. In that case, its expression may not be able to be rescued, regardless as 
to the effects of the co-expressed protein. Therefore whether in fact this is repression or 
decay needs to be firmly established and perhaps a more flexible reporter system needs 
to be utilised, which would be able to address these effects. So, although the APOBEC3 
proteins did not appear to modulate AMD of the TNFα ARE, a more thorough 
investigation of their role in this process is required in order to draw any firm 
conclusions.  
In sum, APOBEC3 mediated HIV-1 inhibition is not dependent on the presence of 
Ago2. Whether this interaction is essential for the restriction of other viruses and viral 
elements is worth investigating, as is the importance of other cellular factors that could 
potentially affect APOBEC3 function. Although the APOBEC3 proteins did not appear 
to have an inhibitory role in either miRNA mediated repression or siRNA mediated 
silencing a detailed analysis of the RNA composition of their cellular complexes would 
provide a more focused approach in identifying their involvement in RNA regulatory 
processes. The work presented in this chapter serves to illustrate that individual proteins 
may not make substantial contributions to APOBEC3 activity, whereas certain cellular 
pathways, processes or complexes may be more relevant. Therefore, one such 







































As discussed in Chapter 1, section 1.10.1, mRNA Processing Bodies (P-bodies) are 
non-membraned cytoplasmic foci that are sites for the storage and/or degradation of 
untranslated mRNA. They are characterised by the presence of proteins involved in 
mRNA turnover such as the decapping enzymes Dcp1a and Dcp2, the decapping 
activators, DDX6 and Lsm1 and the 5’ – 3’ exoribonuclease Xrn1 among others [for a 
comprehensive list see (Kulkarni et al., 2010) and (Eulalio et al., 2007a)]. Consequently, 
they are the endpoints for various mRNA regulatory pathways including NMD, AMD 
and RNAi. More recently, the role of P-bodies in viral life cycles, particularly RNA 
viruses and retroviruses, has been under intense scrutiny as they represent convenient 
cytoplasmic compartments within which these viruses can segregate translation and 
replication or packaging of their genetic material. However, the role of P-bodies in viral 
replication is complex, as they have also been shown to be inhibitory for virus 
production and infectivity, most notably for HIV-1 (Chable-Bessia et al., 2009; Nathans 
et al., 2009). In Chapter 3 it was demonstrated that several APOBEC3 proteins localised 
to P-bodies and this correlated with their anti-viral phenotypes. However, the functional 
significance of this has yet to be explored. If indeed P-bodies are sites of viral assembly, 
it is tempting to speculate that this is also where APOBEC3 proteins are packaged into 
HIV-1 virions. In yeast, P-bodies are necessary for efficient retrotransposition of the 
Ty1 and Ty3 retroelements and have been proposed to be sites of virus like particle 
(VLP) assembly (Beliakova-Bethell et al., 2006; Dutko et al., 2010). A3G co-
localisation to P-bodies with the Gag protein and genomic RNA of the Ty1 retroelement 
appears to be important for its inhibition of this retrotransposon, most probably because 
it is within these foci that A3G is incorporated into Ty1 VLPs (Dutko et al., 2010; 
Dutko et al., 2005; Esnault et al., 2005). Therefore the conservation of A3G localisation 
to P-bodies and retroelement restriction, from yeast to humans, implies that these 
phenotypes may be functionally linked. In a bid to address these issues, therefore, the 
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importance of P-bodies for APOBEC3 anti-HIV-1 activity and HIV-1 replication in 
general was examined in more detail.  
 
5.2 A3G packaging defective mutants and localisation to P-bodies 
5.2.1 Expression of A3G mutants 
In order to establish a more definitive link between virion incorporation and P-body 
localisation, A3G packaging defective mutants were assessed for their ability to localise 
to these foci (Figure 5.1A). These N-terminal point mutants show reduced anti-viral 
activity due to inefficient virion incorporation as compared to wild type A3G (Huthoff 
et al., 2009; Huthoff and Malim, 2007). However, whether the subcellular localisation 
of these proteins, specifically localisation to P-bodies, is also altered has not yet been 
investigated but has been speculated to contribute to their packaging defect (Huthoff 
and Malim, 2007). The expression levels of the mutant proteins compared to wild type 
A3G was first established. 2 µg of each mutant A3G plasmid and between 2 - 0.125 µg 
of wild-type A3G plasmid, in HA-tagged pCMV4 expression vectors, were transfected 
into HeLa cells. 24 hours later, cells were harvested, lysed and subjected to 
immunoblotting. Figure 5.1B displays the immunoblots along with quantification of 
band intensities by Licor-Odyssey software. As can be seen, the R24A, R30A, Y124A 
and W127A mutants were roughly 2 fold less well expressed than wild type A3G at the 
same concentration of DNA (compare lane 1 with lanes 6 - 9). The double mutants, 
R24+R136A and R30+R136A (lanes 10 and 11) showed slightly poorer expression than 
the single mutants but not dramatically so. These data are in keeping with the original 
reports describing these mutants (Huthoff et al., 2009; Huthoff and Malim, 2007). Thus 
even though the mutant proteins are not as efficiently expressed as their wild type 
counterpart, the level of expression is still reasonable enough with which to conduct 







Figure 5.1: Expression of A3G packaging defective mutants. 
A. Schematic diagram of the A3G protein with positions of the mutations indicated. CDM = cytidine 
deaminase motif. B. HeLa cells seeded in 12 well plates were transfected with 2 µg of plasmids encoding 
HA-tagged A3G single mutants, R24A, R30A, Y124A and W127A and the double mutants 
R24A+R136A and R30A+R136A or a titration of HA-tagged wild type A3G (A3G WT) expression 
plasmid at 0.125 µg, 0.25 µg, 0.5 µg, 1 µg and 2 µg. 30 hours later cells were harvested and lysed in gel 
loading buffer and analysed by immunoblotting with anti-HA and anti-HSP90 (as a loading control) 





5.2.2 Localisation of A3G mutants at P-bodies  
In order to verify whether the mutant proteins could still co-localise with Ago2 and 
hence P-bodies, HeLa cells plated on coverslips were co-transfected with either 1 µg of 
each mutant plasmid (except for the R30A mutant, which was not included in this 
analysis) or wild-type A3G at the indicated amounts and 0.2 µg of myc-tagged Ago2. 
24 hours later, cells were fixed, permeablised and stained with anti-HA and anti-myc 
primary antibodies and appropriate secondary antibodies. Coverslips were then mounted, 
dried and imaged using a Leica confocal microscope.  
Even at the lowest amount of input DNA for wild type A3G (Figure 5.2, panel 4) 
localisation with Ago2 marked bodies is still clearly evident. All of the mutants 
displayed some degree of co-localisation with Ago2 and in all cases foci are clearly 
visible though not as bright as for wild type A3G, even at similar expression levels 
(compare panel 2 with panels 5 - 7). Thus it can be concluded that the inability of these 
mutant proteins to be packaged into virions does not correlate with loss of association 
with P-bodies. Although the mutants showed reduced efficiency of localisation to Ago2 
foci compared to wild type A3G, this could potentially be a result of their impaired 
cellular RNA binding capabilities, which does not affect their ability to assemble into 
RNP complexes (Huthoff et al., 2009). These results have failed to support the 
correlation observed in Chapter 3, section 3.4, of a link between P-body localisation and 




































Figure 5.2: A3G packaging defective mutants can still localise to P-bodies. 
HeLa cells seeded on to coverslips in 12 well plates were co-transfected with 1 µg of the HA-tagged A3G 
mutants or a titration of HA-tagged wild type A3G (WT) at 0.125 µg, 0.25 µg, 0.5 µg and 1 µg with 0.2 
µg of a myc-tagged Ago2 expression plasmid. 30 hours later cells were fixed in 4% formaldehyde and 
permeabilised. Cells were then stained with rabbit anti-HA and mouse anti-myc primary antibodies and 
then anti-rabbit 488 and anti-mouse 594 secondary antibodies, plus DAPI for visualisation of the nucleus. 
Coverslips were mounted onto slides and dried overnight before imaging on a Leica confocal microscope. 
Merged images are displayed on the right. Data is representative of 2 independent experiments. Scale bar 
= 10 µm. 
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5.3 DDX6 mutant proteins and HIV-1 infectivity 
5.3.1 Phenotypic analysis of DDX6 mutants 
A more direct way of investigating the importance of P-bodies for HIV-1 infectivity and 
possibly assembly is through targeted disruption of these foci. DDX6 is a member of 
the DEAD box family of helicases and is known to be a general translational repressor 
(Coller and Parker, 2005). It regulates RNA through its roles in decapping and miRNA 
mediated translational repression (Chu and Rana, 2006). It is also essential for P-body 
formation as depletion of DDX6, unlike other proteins, prevents the re-establishment of 
P-bodies in arsenite treated and hence translationally inhibited cells (Serman et al., 
2007). Therefore overexpression of DDX6 dominant negative proteins was employed as 
a first attempt at depleting P-bodies from cells as these should interfere with 
endogenous DDX6 function and thus inhibit P-body formation. Several such dominant 
negative proteins have been described in the literature and three of these were generated 
for use in this study. Site directed mutagenesis by overlapping PCR was used to 
introduce the desired mutations into the wild-type protein sequence (Figure 5.3A). 
Mutants A (R89A + K91A) and B (G346A) are based on studies in yeast where these 
mutations caused defects in RNA binding due to conformational changes between the 
two domains of the protein (Cheng et al., 2005). Mutant C (R423Q/HRIGQ) has been 
proposed to abrogate RNA binding, ATP binding and helicase activity and importantly 
the authors demonstrate a 98% reduction in the number of cells with P-bodies upon 
expression of this dominant negative protein (Minshall et al., 2009). Confirmation that 
these mutant proteins did in fact disrupt P-body formation was obtained by 
immunofluorescence analysis. HeLa cells, plated on coverslips, were transiently 
transfected with each DDX6 dominant negative protein, along with wild-type DDX6 for 
comparison, expressed in HA-tagged expression vectors. 24 hours later, cells were fixed, 
permeablised and stained with antibodies recognising the Ge1 P-body protein and the 
HA epitope tag. From Figure 5.3B, it can be seen that wild type DDX6 localises to P-
bodies and co-localises with the Ge1 P-body protein. However, not only do the mutant 
proteins A and C no longer localise to P-bodies (panels 2 and 4), they also prevent P-
body assembly as illustrated by the lack of Ge1 marked foci in transfected cells. This is 
most evident when comparing transfected and untransfected cells side by side as in 
panel 4. The mutations introduced into mutant protein B appear not to affect either P-
body localisation or formation (panel 3). Therefore overexpression of certain DDX6 
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dominant negative mutants is one method of successfully disrupting endogenous P-body 
formation. 
5.3.2 DDX6 dominant negative mutants and HIV-1 infectivity 
Subsequently, DDX6 wild-type and dominant negative proteins were transiently 
transfected into 293T cells at both a 3:1 and a 1:3 ratio of plasmid DNA to an NL43 
proviral plasmid. 48 hours later viral supernatants were harvested, quantified by p24Gag 
ELISA and used to challenge TZM-bl reporter cells. Cell lysates from the virus 
producer cells were prepared for immunoblot analysis. From Figure 5.4A, the dominant 
negative DDX6 proteins are expressed just as well and sometimes even better than the 
wild-type protein. p24Gag production from cells transfected with the mutant proteins was 
equivalent to that seen with overexpression of wild-type DDX6 (which induces P-body 
formation) and the negative control, GFP, at both concentrations of input DNA (Figure 
5.4B). Importantly, infectivity of the virions produced in the presence of the dominant 
negative proteins was analogous to that produced with the controls (Figure 5.4C), 
implying that loss (with mutant DDX6 proteins) or overexpression (with wild-type 
DDX6 protein) of P-bodies does not substantially impact upon HIV-1 virus production 












Figure 5.3: DDX6 mutant proteins disrupt P-body formation. 
A. Schematic diagram of the DDX6 protein with domains and positions of mutations indicated. B. HeLa 
cells seeded onto coverslips in 12 well plates were transfected with 0.4 µg of HA-tagged DDX6 wild type 
or mutant (A = R89A+K91A, B = G346A, C = R423Q/HRIGQ) expression plasmids. 30 hours later cells 
were fixed in 4% formaldehyde and permeabilised. Cells were then stained with rabbit anti-HA and 
mouse anti-Ge1 primary antibodies and anti-rabbit 488 and anti-mouse 594 secondary antibodies, plus 
DAPI for visualisation of the nucleus. Coverslips were then mounted onto slides and dried overnight 
before imaging on a Lecia confocal microscope. Merged images are displayed on the right. Data is 




Figure 5.4: Overexpression of DDX6 mutant proteins does not affect HIV-1 infectivity 
293T cells, seeded in 6 well plates were co-transfected with either 0.16 µg or 1.5 µg of HA-tagged DDX6 
wild type or dominant negative expression plasmids and 0.5 µg of an NL43 Δvif proviral plasmid giving a 
ratio of 1:3 or 3:1 of DDX6 protein to provirus. Total DNA was kept constant at 2 µg with the addition of 
an untagged Luciferase expression plasmid. 48 hours later, viral supernatants were harvested and 
quantified by p24Gag ELISA. Normalised amounts were then used to infect TZM-bl reporter cells which 
were harvested 30 hours post infection and assayed for β-galactosidase activity. A. Immunoblot analysis 
of virus producer cells with anti-HA, anti-p24Gag and anti-HSP90 (as a loading control) antibodies. B. 
Virus production from transfected cells as determined by p24Gag ELISA. C. Infectivity of virions 
produced in B as determined by TZM assay. 
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However a major drawback to this type of analysis, especially in HeLa cells, is that not 
every cell will be transfected with the dominant negative protein nor co-transfected with 
both the protein and the viral DNA. The use of 293T cells for the infectivity assay 
sought to partially address this issue but it still means that a proportion of cells will 
contain P-bodies. This may not be an issue if the phenotypes are dramatic but more 
subtle differences may be overlooked. Originally it was hoped that stable cell lines 
could be generated to overcome this problem. However cells stably expressing YFP 
tagged versions of these proteins (both wild type and dominant negative), when 
transfected with the NL43 Δvif provirus failed to produce sufficient amounts of virus 
with which to conduct infectivity assays (data not shown). The reasons behind this 
remain unclear. Therefore, although no effects on HIV-1 infectivity and virus 
production were observed in the presence of the DDX6 mutant proteins, further 

















5.4 Infection of P-body depleted cells  
5.4.1 Phenotypic analysis of DDX6 knockdown by shRNA 
To convincingly and more thoroughly deplete P-bodies from cells, knockdown of 
DDX6 by RNAi was utilised. It has been demonstrated that knockdown of DDX6, by 
this method, leads to a significant reduction of visible P-bodies (Chu and Rana, 2006). 
Lentiviral vectors encoding shRNAs (as described in Chapter 4, section 4.3) targeting 
either DDX6 or a non-silencing control were used to transduce HeLa cells. 48 hours 
post transduction, cells were maintained under puromycin selection for between 5 - 7 
days before they were either lysed and subjected to immunoblotting, to check for DDX6 
protein levels, or plated onto coverslips for immunofluorescence analysis. In this case 
cells were then fixed, permeablised and stained with an anti-Ge1 antibody (as a marker 
for P-bodies) to evaluate P-body knockdown.  
From Figure 5.5A, cells stably expressing the DDX6 shRNA show an approximate 80% 
reduction in DDX6 protein levels compared to control cells (quantified by Licor-
Odyssey software), when equal amounts of lysate were loaded onto gels (as judged by 
the HSP90 loading control). Importantly, expression levels of a second P-body protein, 
Lsm1, are unchanged, proving that the knockdown is specific to DDX6. It was also 
observed that efficient knockdown of DDX6 resulted in reduced cell proliferation, with 
cells growing almost twice as slowly as the control cell line. 
Pertinent to these studies, a reduction in DDX6 protein levels also led to a substantial 
depletion of P-bodies, both in terms of the number of cells containing P-bodies and the 
average number of P-bodies per cell, as presented in Figure 5.5B. Compared to the 
control cells, which on average harbour approximately 5 P-bodies per cell, the DDX6 
shRNA expressing cells contained either 0 or 1 of these foci, on average. Representative 
images are displayed in Figure 5.5C. This dramatic loss of microscopically visible P-
bodies makes these cells a useful tool for studying the effects of P-body depletion on 







Figure 5.5: Phenotypic analysis of DDX6 knockdown by shRNA lentiviral vectors. 
293T cells were co-transfected with a Gag-Pol packaging plasmid, a DDX6 (DDX6) targeting or non-
silencing (NSC) shRNA encoded lentiviral vector and a VSVG expression plasmid at a 2:2:1 ratio. 48 
hours later, VLPs were harvested and equivalent amounts used to transduce HeLa cells seeded in 24 well 
plates, with the addition of polybrene. 48 hours later transduction efficiencies were determined by 
analysis of GFP expression and cells were placed under puromycin selection and maintained in this way 
for at least 5 days before immunoblot and immunofluorescence analysis. A. Immunoblot analysis of 
protein expression in transduced HeLa cells with anti-DDX6, anti-Lsm1 and anti-HSP90 (as a loading 
control) antibodies. Protein bands were quantified using Licor-Odyssey software. B. Quantification of the 
number of knockdown and control cells containing Ge1 marked foci (top) and the average number of 
these foci per cell (bottom) (n=95). C. Immunofluorescence analysis of transduced cell lines to check for 
P-body depletion. Cells were plated onto coverslips, 24 hours later, fixed, permeabilised and stained with 
a mouse anti-Ge1 primary antibody and an anti-mouse 594 secondary antibody. Coverslips were mounted 




5.4.2 Functional analysis of DDX6 knockdown 
As for Ago2 (Chapter 4, section 4.4), it was also useful to determine whether 
knockdown of DDX6 had any functional consequences, besides the phenotypic effects 
observed through P-body loss. DDX6 has been reported to be necessary for miRNA 
mediated translational repression and specifically that mediated by the let-7 miRNA 
(Chu and Rana, 2006). The authors note a 1.5 fold decrease in repression of reporter 
constructs upon DDX6 depletion. In an attempt to reproduce this modest effect, the 
luciferase reporter system described in Chapter 4, section 4.4 was employed. Briefly 
two luciferase reporter constructs, one containing 4 binding sites for the let-7 miRNA 
(wild-type) and the other containing mutated binding sites (mutant) are separately 
transfected into HeLa cells, along with Renilla luciferase as a transfection control. 
Expression of the wild type reporter should be reduced 4 - 5 fold compared to the 
mutated control due to the action of endogenous let-7, which recruits the RISC complex 
to instigate translational repression. If there is inhibition of this repression, expression 
of the wild type and mutant constructs should be roughly equivalent. When these 
constructs were transfected into the DDX6 knockdown HeLa cells, no difference in 
expression of the wild type construct was observed compared to the control cell line 
(Figure 5.6) and the level of repression in both cases was approximately 4 fold, as 
would be expected. Expression of both reporters was increased in the DDX6 shRNA 
expressing cells indicating that general translational repression upon DDX6 knockdown 
may have been somewhat relieved. However these results would imply that DDX6 is 
not necessary for miRNA mediated translational repression or at least not to any 
substantial effect. They also confirm the finding that microscopically visible P-bodies 

























Figure 5.6: Knockdown of DDX6 does not impair miRNA mediated translational repression.  
HeLa cells stably expressing either a control (NSC) or DDX6 targeting (DDX6) shRNA (generated as 
described in section 5.4) were co-transfected with 0.1 µg of luciferase reporter constructs containing 
either wild type (wt) or mutated (mt) binding sites for the let 7 miRNA (as described in Chapter 4), 0.4 µg 
of a HA-tagged GFP expression plasmid and 0.01 µg of a Renilla expression plasmid, as a transfection 
control. 24 hours later cells were harvested, lysed and luciferase levels measured. Data is presented as the 
ratio of firefly to Renilla values, with Renilla equivalent across all samples, and is representative of 2 





5.4.3 Generation of DDX6 knockdown and A3G expressing stable cell lines 
Since knockdown of DDX6, using shRNAs, proved to be highly effective at disrupting 
P-bodies (section 5.4.1), this was used as a basis to evaluate HIV-1 infectivity and A3G 
anti-viral activity in the absence of these foci. Rather than conducting these experiments 
by transient transfection, as performed in Chapter 4, section 4.3.3, an infection based 
approach was used instead, which is considered to be more physiologically relevant. 
This is also the method used by two groups who found that P-bodies/P-body 
components were inhibitory to HIV-1 infectivity (Chable-Bessia et al., 2009; Nathans et 
al., 2009), thereby making results obtained here more comparable with published work.  
Stable HeLa cells were generated expressing either untagged A3G or YFP as described 
in Chapter 4, section 4.2. These cells were then transduced again with either a DDX6 
targeting or a non-silencing control shRNA encoded lentiviral vector. This led to the 
production of four separate stable cell lines, expressing either A3G or YFP and then 
either a control or DDX6 shRNA. Efficient knockdown of DDX6 and hence P-bodies 
and expression of A3G and YFP was first confirmed by immunoblot (Figure 5.7A) and 
immunofluorescence analysis (Figure 5.7B). Compellingly depletion of DDX6 bodies 
also led to a removal of A3G marked foci (Figure 5.7B) demonstrating that the 





Figure 5.7: Generation of stable DDX6 knockdown and A3G expressing cell lines. 
HeLa cells were first transduced with either untagged A3G or YFP by retroviral transduction and 
maintained under neomycin selection for approximately 10 days. They were subsequently transduced 
with either a DDX6 (DDX6) or non-silencing (NSC) shRNA by lentiviral transduction. Cells were then 
maintained under puromycin and neomycin selection for at least 5 days before immunoblot and 
immunofluorescence analysis. A. Immunoblot analysis of doubly transduced cells to check protein 
expression with anti-A3G, anti-GFP (which recognises YFP), anti-DDX6 and anti-HSP90 (as a loading 
control) antibodies. B. Immunofluorescence analysis of transduced cells to check for P-body depletion. 
Cells were plated onto coverslips and 24 hours later were fixed, permeabilised and stained with mouse 
anti-Ge1 or rabbit anti-A3G primary antibodies and appropriate Alexa Fluor 594 conjugated secondary 
antibodies. Coverslips were mounted onto slides, dried overnight and imaged using a Lecia confocal 
microscope. Scale bar = 10 µm.  
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5.4.4 HIV-1 infectivity and A3G anti-viral activity in shRNA mediated DDX6 
knockdown cells 
The cells described in section 5.4.3 were then infected with either 50 ng or 100 ng of 
VSV-G pseudotyped wild-type and Δvif viruses. Virus stocks were produced by co-
transfection of 293T cells with an NL43 proviral plasmid (either wild-type or Δvif) and 
a VSV-G expression plasmid at a 3:1 ratio. Supernatants were harvested and quantified 
by p24Gag ELISA. The number of infected cells was determined by p24 intracellular 
staining and subsequent FACS analysis. Approximately 30% and 60% of cells were 
infected with 50 ng and 100 ng of input virus, respectively (data not shown). Cells were 
infected for 4 hours, before virus was removed by extensive washing and replaced with 
fresh media. 48 hours post-infection, viral supernatants were collected, normalised by 
p24Gag ELISA and used to infect TZM-bl cells. 20 ng was spun through a 20% sucrose 
cushion to check for virion incorporation of A3G. Corresponding cell lysates were also 
obtained to check for protein expression in producer cells.    
From Figure 5.8A it can be seen that virus production from the wild-type and Δvif 
viruses is roughly equivalent, though in general slightly more is produced with the latter 
virus. There does not appear to be any consistent nor specific effect of DDX6 depletion 
on HIV-1 particle production (Figure 5.8A), which is in contrast to reported work 
(Nathans et al., 2009). When the infectivity of the viruses produced in Figure 5.8A was 
measured, it appeared to decrease slightly rather than increase in the DDX6 knockdown 
cell lines (Figure 5.8B), implying that DDX6 does not inhibit HIV-1 infectivity, which 
is in disagreement with reports from two groups (Chable-Bessia et al., 2009; Nathans et 
al., 2009). Also, knockdown of DDX6 and hence loss of P-bodies had no effect upon 
A3G mediated inhibition of HIV-1 as a consistent 1.5 log decrease in Δvif viral 
infectivity is observed in the A3G expressing cell lines. It is also clear from Figure 5.8C, 
that packaging of A3G, which only occurs in the absence of Vif, as would be expected, 
is not impaired by knockdown of DDX6. These infection-based experiments thus 
provide evidence that DDX6 and/or P-bodies are not relevant to A3G anti-viral activity 

























Figure 5.8: Infection of DDX6 shRNA depleted cells does not affect A3G anti-viral activity or 
negatively regulate HIV-1 infectivity. 
Doubly transduced HeLa cells expressing either A3G or YFP and then either a DDX6 targeting (DDX6) 
or non-silencing control (NSC) shRNA (generated as described for Figure 5.7) were infected with 50 ng 
or 100 ng of VSV-G pseudotyped wild-type or Δvif NL43 virus. 4 hours later cells were extensively 
washed to remove any input virus and incubated in complete DMEM. 48 hours later viral supernatants 
were harvested and quantified by p24Gag ELISA. Normalised amounts were used to infect TZM-bl 
reporter cells which were harvested 30 hours post-infection and assayed for β-galactosidase activity. 
Equivalent amounts of viral supernatant was also concentrated through a 20% sucrose cushion and viral 
pellets along with cell lysates were subjected to immunoblot analysis. A. Virus production from infected 
cells as determined by p24Gag ELISA. B. Infectivity of virions produced in A, as determined by TZM 
assay. C. Immunoblot analysis of cell lysates from virus producer cell to check protein expression and 
viral pellets to check virion incorporation, with anti-A3G, anti-GFP, anti-DDX6, anti-p24Gag and anti-








5.4.5 HIV-1 infectivity and A3G anti-viral activity in siRNA mediated DDX6 
knockdown cells 
Although use of the DDX6 shRNA consistently gave a knockdown of DDX6 protein 
levels of between 70 - 80%, a siRNA oligonucleotide was tested to determine whether 
an even more efficient reduction could be achieved. This would also help rule out 
knockdown efficiency as the basis for the discrepancy with published reports (Chable-
Bessia et al., 2009; Nathans et al., 2009), as both of these groups used siRNAs to 
deplete P-bodies from cells. Further, any differences in cell proliferation rates, 
associated with depletion of DDX6 in stable cell lines, would also be eliminated. 
Knockdown of DDX6 by siRNA was first verified by immunoblot and 
immunofluorescence analysis before further experiments were conducted. The DDX6 
siRNA oligonucleotide used led to an approximate 93% reduction in protein levels 
(Figure 5.9A), and a significant depletion of P-bodies from these cells when compared 
to either a non-targeting scrambled or luciferase targeted control, respectively (Figure 
5.9B). Stable A3G and YFP expressing HeLa cells were then twice transfected with 
either the DDX6 or non-targeting control siRNA. 12 hours after the second siRNA 
transfection, cells were infected with 50 ng of virus and assayed as previously described. 
Results are presented in Figure 5.10. Even by this method, no increase in p24Gag 
production was observed from cells knocked down for DDX6 (Figure 5.10A). 
Subsequent infection of TZM-bl cells led to equivalent levels of HIV-1 infectivity and 
A3G anti-viral activity regardless as to whether cells were transfected with the control 
or DDX6 targeting siRNA (Figure 5.10B). Packaging of A3G also remained unaffected 
by DDX6 depletion (Figure 5.10C). Expression of the stably transduced proteins and 
knockdown of DDX6 was comparable between the different cell lines and samples 
(Figure 5.10C). Therefore, from the data presented in sections 5.4.4 and 5.4.5, it would 
appear that knockdown of DDX6 and hence loss of P-bodies does not positively or 
negatively influence HIV-1 virus production and infectivity. Additional work would be 
required to establish the basis for the discrepancies with published reports claiming that 
P-bodies are in fact inhibitory to HIV-1 particle production and production of infectious 
virions. Further to this, A3G anti-viral activity and incorporation into virions was also 
unperturbed by P-body depletion which implies that these foci are not relevant to the 
anti-viral phenotypes of the APOBEC3 proteins and are not sites for packaging of these 






Figure 5.9: Phenotypic analysis of DDX6 knockdown by siRNA oligonucleotides. 
HeLa cells, seeded in 24 well plates, were transfected with 50 pmol of either a DDX6 targeting (DDX6) 
or a scrambled control (con) siRNA oligonucleotide. 48 hours later, cells were split and re-seeded into 24 
wells plates for immunoblot analysis or into 12 well plates plus coverslips for immunofluorescence 
analysis and 2 hours later transfected as before. Cells were harvested 48 hours later. A. Immunoblot 
analysis of siRNA transfected cells with anti-DDX6 and anti-HSP90 (as a loading control) antibodies. B. 
siRNA transfected cells were fixed, permeabilised and stained with a mouse anti-Ge1 primary antibody 
and an anti-mouse 488 secondary antibody. Coverslips were mounted onto slides, dried overnight and 




Figure 5.10: Infection of DDX6 siRNA depleted cells does not affect A3G anti-viral activity or 
negatively regulate HIV-1 infectivity. 
HeLa cells, stably expressing either untagged A3G or YFP, seeded in 24 well plates 2 hours prior, were 
first transfected with 50 pmol of either a DDX6 targeting (DDX6) or a scrambled control (con) siRNA. 
48 hours later, cells were re-seeded into 6 well plates and 2 hours later transfected as before. 12 hours 
after the 2nd transfection, cells were infected with 50 ng of either VSV-G pseudotyped wild-type (wt) or 
Δvif virus. Cells were then assayed as described in Figure 5.8. A. Virus production from infected cells as 
determined by p24Gag ELISA. B. Infectivity of virions produced in A, determined by TZM assay. C. 
Immunoblot analysis of cell lysates from virus producer cell to check protein expression and viral pellets 
to check virion incorporation, with anti-A3G, anti-GFP, anti-DDX6, anti-p24Gag and anti-HSP90 (as a 
loading control) antibodies. Data is representative of 2 independent experiments. 
  
  201 
5.5 Transient transfection of P-body depleted cells 
5.5.1 HIV-1 infectivity and APOBEC3 anti-viral activity in DDX6 knockdown 
cells   
Since the results presented in section 5.4 do not support the conclusions drawn by 
Chable-Bessia et al and Nathans et al of an inhibitory effect of P-bodies on HIV-1 virus 
production and infectivity, a transient transfection based approach was utilised to try 
and address this discrepancy. Both groups have shown that ectopic expression of a 
proviral plasmid should increase viral production in the absence of P-body proteins, 
such as DDX6. This method was also used to further confirm the finding that P-bodies 
are not required for A3G mediated viral restriction, as concluded from the infection 
based assays.  
HeLa cells stably transduced with either a non-silecning control or DDX6 targeting 
shRNA, were co-transfected with 1 µg of a HA-tagged APOBEC3 plasmid and 1 µg of 
an NL43 Δvif proviral construct. 48 hours later, viral supernatants were harvested and 
quantified by p24Gag ELISA. 5 ng was then used to infect TZM-bl reporter cells. To 
check for virion incorporation of the APOBEC3 proteins, 20 ng of viral supernatant was 
concentrated through a 20% sucrose cushion and pellets lysed and subjected to 
immunoblotting. Corresponding cell lysates were also prepared in parallel for 
immunoblot analysis. Results are presented in Figure 5.11. As shown, virus production 
from the DDX6 knock down cells is generally 2 - 4 fold higher than that obtained from 
the control cells and this is consistently observed across each sample (Figure 5.11A). 
This is in contrast to what was found by infection of virus producer cells but would 
suggest that DDX6 and/or P-bodies are mildly inhibitory for virus production as has 
been previously reported (Nathans et al., 2009). However, when normalised amounts of 
virus were used to challenge TZM-bl indicator cells, no difference in virus infectivity is 
observed (Figure 5.11B, compare first two bars, GFP samples). Moreover, knockdown 
of DDX6 had no obvious consequences for APOBEC3 anti-viral activity, as the level of 
viral inhibition was roughly equivalent in both cell lines, for all APOBEC3 proteins 
tested. There is slightly higher infectivity observed in the DDX6 depleted cells for A3F, 
A3G and A3H, which are the APOBEC3 proteins that most strongly associate with P-
bodies, however this effect is very modest. This is further confirmed when assessing 
virion incorporation (Figure 5.11C). Expression of the different APOBEC3 proteins in 
the cell lysates is relatively similar in the two cell lines and packaging of the different 
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APOBEC3 proteins appears to be just as efficient in the control and knock down cell 
lines. These results validate the data presented earlier, that knockdown of DDX6 does 
not affect APOBEC3 anti-viral activity or virion incorporation. However, although 
HIV-1 viral infectivity was unperturbed by DDX6 depletion, a modest increase in virus 
production was observed from those cells expressing the DDX6 shRNA compared to 
the control cell line. As this effect is not seen when infecting cells, its relevance to HIV-
1 replication will require further investigation. 
5.5.2 DDX6 knockdown and A3G virion incorporation 
As both infection and transfection based assays failed to demonstrate an influence of P-
bodies on A3G anti-viral activity, a titration of A3G and GFP, as a negative control, 
was carried out to determine if at lower concentrations of A3G, any differences in virion 
incorporation could be detected. This was important to establish as overexpression of 
proteins can sometimes lead to artificial virion encapsidation (as noted in Chapter 3, 
section 3.3). Therefore to conclusively confirm that A3G packaging is not dependent on 
the presence of DDX6 and hence P-bodies, this protein was expressed at more 
physiologically relevant levels and virion incorporation was assessed (Figure 5.12), as 
described for Figure 5.11. Decreasing amounts of input DNA led to less protein 
expression in the cell lysate but even at the lowest concentration of DNA (0.1 µg, lanes 
11 and 12), virion incorporation of A3G is clearly visible and is unaffected by P-body 
loss. This would indicate that P-bodies are not sites at which the APOBEC3 proteins, 
particularly A3G, are packaged into virions as this occurs just as efficiently in the 



























Figure 5.11: Knockdown of DDX6 leads to an increase in HIV-1 virus production by transient 
transfection. 
HeLa cells stably expressing either a control (NSC) or DDX6 targeting (DDX6) shRNA (generated as 
described in section 5.4) were co-transfected with equivalent amounts of HA-tagged APOBEC3 or GFP 
(as a negative control) expression plasmids and an NL43 Δvif proviral plasmid. 48 hours later viral 
supernatants were harvested and quantified by p24Gag ELISA. Normalised amounts were used to infect 
TZM-bl reporter cells which were assayed 30 hours post infection for β-galactosidase activity. Equivalent 
amounts of viral supernatant was also concentrated through a 20% sucrose cushion and viral pellets as 
well as corresponding cell lysates were analysed by immunoblotting. A. Virus production from 
transfected cells as determined by p24Gag ELISA. B. Infectivity of virions produced in A as determined by 
TZM assay. Data is presented as the average of three independent experiments with error bars denoting 
the standard deviation. All values are normalised to GFP expressed in the NSC cell line, which is set at 
100% C. Immunoblot analysis of virus producer cells to check for protein expression. D. Immunoblot 
analysis of viral pellets to check for virion incorporation with anti-HA, anti-p24Gag, anti-DDX6 and anti-
























Figure 5.12: A3G is efficiently packaged, even at lower expression levels, in cells depleted of DDX6. 
HeLa cells stably expressing either a control (NSC) or DDX6 targeting (DDX6) shRNA (generated as 
described in section 5.4) were co-transfected with decreasing amounts of HA-tagged A3G or GFP, 
included as a negative control (1 µg, 0.3 µg and 0.1 µg) and 1 µg of an NL43 Δvif proviral plasmid. Total 
DNA concentration was kept constant at 2 µg with the addition of an untagged luciferase expression 
plasmid. Cells were then assayed for virion incorporation as described for Figure 5.11. Immunoblot 
analysis of virus producer cells to check for protein expression and viral pellets to check for virion 
incorporation with anti-HA, anti-p24Gag, anti-DDX6 and anti-HSP90 (as a loading control) antibodies. 
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5.5.3 Pulse labelling analysis in DDX6 knockdown cells 
As observed here by transient transfection (section 5.5.1) and noted by other groups 
(Chable-Bessia et al., 2009; Nathans et al., 2009), depletion of certain P-body 
components results in a modest increase in HIV-1 particle production. It has been 
suggested that this effect is specific to HIV-1 virus production and is not the result of a 
more general effect on protein translation due to relief of translational repression upon 
DDX6 knockdown (Nathans et al., 2009). Whether this is indeed the case requires 
further investigation and so a preliminary pulse labelling experiment was performed, 
comparing levels of protein synthesis for both a full-length proviral plasmid and a 
codon-optimised Gag construct, in control and DDX6 knock down cell lines. 
HeLa cells were twice transfected with siRNAs targeting DDX6 (DDX6) or a non-
targeting scrambled control siRNA (con). 12 hours after the second siRNA transfection, 
cells were transfected with either GFP (mock control), codon-optimised Gag or NL43 
Δvif proviral expression plasmids. 48 hours later, viral supernatants were harvested and 
quantified by p24Gag ELISA. Subsequently, cells were incubated in cysteine and 
methionine depleted (-Cys, -Met) media before the addition of [35S]cysteine/methionine. 
All newly synthesized proteins containing cysteine and methionine thus become 
radiolabelled. Cells were then lysed before immunoprecipitation with a p24Gag specific 
antibody (UP598, see Table 2.3). Samples were subjected to SDS-PAGE before 
visualisation by autoradiography. As shown in Figure 5.13A, a highly efficient 
knockdown of DDX6 at the protein level is achieved through siRNA transfection of 
HeLa cells and this leads to an approximate 2 fold increase in virus production, 
compared to control cells, when transfected with a proviral plasmid (Figure 5.13B). 
This appears to be matched with an increase in Gag synthesis from the DDX6 siRNA 
transfected compared to control transfected cells (Figure 5.13C, lanes 5 and 6). 
However, increased expression of Gag, in the absence of DDX6, is also observed for the 
codon-optimised Gag construct (Figure 5.13C, lanes 3 and 4) which suggests that these 
effects are not specific to HIV-1 and may instead be the consequence of general effects 














Figure 5.13: Increase in p24Gag levels, upon DDX6 depletion, is not specific to HIV-1. 
HeLa cells were twice transfected with siRNAs targeting either DDX6 (DDX6) or a non-targeting 
scrambled control (con). 12 hours after the second transfection, cells were transfected with either GFP, 
codon-optimised Gag or an NL43 Δvif proviral plasmid and viral supernatants were harvested 48 hours 
later for quantification of virus production by p24Gag ELISA. siRNA transfected cells were then incubated 
for 20 minutes in -Cys, -Met depletion media, with [35S]cysteine/methionine added for an additional 5 
minutes. Cells were then lysed and subjected to immunoprecipitation for 1 hour using a p24Gag specific 
antibody and G protein coupled Agarose. Samples were loaded onto gels, transferred onto membranes 
and exposed to a phosphoimager screen overnight. Membranes were also transferred onto film at -80°C 
for 5 days and developed. A. Immunoblot of cell lysates (prior to immunoprecipitation) to check for 
DDX6 knockdown using anti-DDX6 and anti-HSP90 (as a loading control) antibodies. B. HIV-1 particle 
production in DDX6 siRNA transfected cells. C. Immunoprecipitation of p24Gag following 
35S[methionine] labelling in DDX6 knockdown and control cell lines. Data is representative of 2 




5.6 P-body depletion by knockdown of Lsm1 
5.6.1 Phenotypic analysis of Lsm1 knockdown by shRNA 
In order to determine whether the increase in virus production observed with 
knockdown of DDX6 was a specific effect of this protein or a feature of P-bodies in 
general and to validate the findings that P-bodies do not negatively regulate HIV-1 nor 
affect APOBEC3 anti-viral activity, knockdown of a second P-body protein was utilised. 
This time Lsm1 was targeted, which is part of a heptameric complex involved in 
decapping that associates with P-bodies (Ingelfinger et al., 2002). Like DDX6, this 
protein has also been demonstrated to be inhibitory to HIV-1 particle production and 
infectivity (Chable-Bessia et al., 2009; Nathans et al., 2009).  
Knock down of Lsm1 was achieved as described for DDX6 (section 5.4.1) and Ago2 
(Chapter 4, section 4.3) with the use of lentiviral encoded shRNAs to generate stable 
HeLa cell lines. Knockdown of the protein was confirmed by immunoblot analysis 
(Figure 5.14A) with expression of DDX6 remaining constant in both cell lines. Notably, 
this resulted in a significant depletion of P-bodies in the knock down cells as the 
number of cells containing P-bodies as well as the average number of foci per cell was 
substantially reduced in the absence of Lsm1 (Figure 4.14B). Representative examples 
of the knockdown and control cell lines are presented in Figure 5.14C. However, unlike 
with DDX6, no effects upon cell growth were observed. This validates the use of these 













Figure 5.14: Phenotypic analysis of Lsm1 knockdown by shRNA lentiviral vectors. 
293T cells were co-transfected with a Gag-Pol packaging plasmid, an Lsm1 (Lsm1) targeting or non-
silencing (NSC) shRNA encoded lentiviral vector and a VSVG expression plasmid at a 2:2:1 ratio. 48 
hours later, VLPs were harvested and equivalent amounts used to transduce HeLa cells seeded in 24 well 
plates, with the addition of polybrene. 48 hours later transduction efficiencies were determined by 
analysis of GFP expression and cells were placed under puromycin selection and maintained in this way 
for at least 5 days before immunoblot and immunofluorescence analysis. A. Immunoblot analysis of 
protein expression in transduced HeLa cells with anti-Lsm1, anti-DDX6 and anti-HSP90 (as a loading 
control) antibodies. B. Quantification of the number of knockdown and control cells containing DDX6 
foci (top) as well as the average number of these foci per cell (bottom), (n=65). C. Immunofluorescence 
analysis of transduced cell lines to check for P-body depletion. Cells were plated onto coverslips, 24 
hours later, fixed, permeabilised and stained with either a mouse anti-Ge1 or rabbit anti-DDX6 primary 
antibody and then the appropriate Alexa-Fluor 594 conjugated secondary antibody. Coverslips were 
mounted onto slides, dried overnight and imaged using a Leica confocal microscope. Scale bar = 10 µm. 
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5.6.2 HIV-1 infectivity and APOBEC3 anti-viral activity in Lsm1 knockdown 
cells, by transient transfection 
As before (section 5.5.1) cells were transfected with equivalent amounts of HA-tagged 
APOBEC3 and NL43 Δvif proviral plasmids. Virus production and infectivity were 
subsequently assessed as described in section 5.5.1. Virion incorporation was not 
assayed for these cell lines. The results, displayed in Figure 5.15A, demonstrate that 
knockdown of Lsm1 had no discernable effects on HIV-1 virus production, in contrast 
to what was seen with knockdown of DDX6. This would imply that enhanced virus 
production is specific to DDX6 depletion and not P-bodies in general. The infectivity of 
the virions produced in the presence of GFP did appear to be slightly higher in the 
knockdown compared to the control cells lines (Figure 5.15B), implying that HIV-1 
infectivity may have been inhibited in the presence of Lsm1. However this was not seen 
with depletion of DDX6, is quite a modest effect and is not consistently observed across 
all samples. Once again, loss of P-bodies had no impact upon APOBEC3 anti-viral 
activity (Figure 5.15B). The expression of the transfected proteins was equivalent in 
both cell lines and the level of Lsm1 knockdown was consistent for all samples (Figure 
5.15C).  
These findings were further supported when A3G and GFP, as a negative control, were 
titrated down to more physiologically relevant expression levels. No differences in 
p24Gag production were observed between the cells lines (Figure 5.16A) and the 
observed increase in HIV-1 infectivity upon Lsm1 depletion was not replicated in two 
other samples (Figure 5.16B, titration of GFP), confirming that this is not a robust 
phenotype. Importantly, A3G viral inhibition was comparable even at lower amounts of 
DNA input demonstrating that lack of differences between the two cell lines is not due 
to gross overexpression of the APOBEC3 proteins. Expression of the transfected 
proteins was equivalent for both cell lines except at the lowest concentration of A3G 
(Figure 5.16C, lanes 11 and 12) where slightly more protein is expressed in the control 
compared to the Lsm1 knockdown cell line. The reason for this is unclear but has been 
consistently observed with knockdown of both Lsm1 and Ago2 (Chapter 4, Figure 4.5), 






























Figure 5.15: Knockdown of Lsm1 does not affect HIV-1 virus production, infectivity or APOBEC3 
anti-viral activity, by transient transfection. 
HeLa cells stably expressing either a control (NSC) or Lsm1 targeting (Lsm1) shRNA (generated as 
described in section 5.4) were co-transfected with equivalent amounts of HA-tagged APOBEC3 or GFP 
(as a negative control) expression plasmids and an NL43 Δvif proviral plasmid. 48 hours later viral 
supernatants were harvested and quantified by p24Gag ELISA. Normalised amounts were then used to 
infect TZM- bl reporter cells, which were assayed 30 hours post infection for β-galactosidase activity. A. 
Virus production from transfected cells as determined by p24Gag ELISA. B. Infectivity of virions 
produced in A as determined by TZM assay. Data is presented as the average of three independent 
experiments with error bars denoting the standard deviation. All values are normalised to GFP expressed 
in the NSC cell line, which is set at 100%. C. Immunoblot analysis of virus producer cells to check for 































Figure 5.16: Knockdown of Lsm1 does not affect A3G anti-viral activity even at lower levels of 
protein expression. 
HeLa cells stably expressing either a control (NSC) or Lsm1 targeting (Lsm1) shRNA (generated as 
described in section 5.4) were co-transfected with decreasing amounts (1 µg, 0.3 µg and 0.1 µg) of HA-
tagged A3G or GFP, included as a negative control, and 1 µg of an NL43 Δvif proviral plasmid. Total 
DNA concentration was kept constant at 2 µg with the addition of an untagged luciferase expression 
plasmid. Cells were then assayed as described for Figure 5.15. A. Virus production from transfected cells 
as determined by p24Gag ELISA. B. Infectivity of virions produced in A as determined by TZM assay. 
Data is presented as the average of three independent experiments with error bars denoting the standard 
deviation. All values are normalised to GFP expressed in the NSC cell line, which is set at 100%. C. 
Immunoblot analysis of virus producer cells to check for protein expression with anti-HA, anti- p24Gag, 







Overall, the data from transient transfection experiments, in sections 5.5 and 5.6, show 
that APOBEC3 anti-viral activity is unaffected by the absence of the P-body proteins 
DDX6 and Lsm1 in virus producer cells, similar to the findings reported for the 
infection based assays (section 5.4). The incorporation of these proteins into HIV-1 
virions was similarly unperturbed demonstrating that P-bodies do not represent sites of 
APOBEC3 packaging. P-body depletion also had no effect upon HIV-1 infectivity, 
which is in disagreement with recently published findings (Chable-Bessia et al., 2009; 
Nathans et al., 2009). Knockdown of DDX6, but not Lsm1, did lead to a modest 
increase in virus production, which may be attributable to relief of general translational 
repression due to loss of DDX6 (section 5.5). However, the exact causes of this effect 
would require further experimental investigation, particularly as it was only observed 






















5.7 Lsm1 knockdown and HIV-1 replication 
5.7.1 Phenotypic analysis of Lsm1 and DDX6 knockdown in a T cell line 
All of the experiments conducted thus far, to ascertain whether P-bodies are influential 
in HIV-1 infectivity and APOBEC3 anti-viral activity, have centred on single cycle 
infectivity assays. Although these experiments are useful, they do not actually address if 
HIV-1 replication is affected, which would need to be monitored over several days.  
In light of this, the Hut78 T cell line was employed, which naturally expresses A3G and 
potentially other anti-viral APOBEC3 proteins, to assess the effects of P-body loss on 
HIV-1 replication and endogenous A3G activity. These cells were transduced with 
either a DDX6 or Lsm1 targeting lentiviral encoded shRNA or a non-silencing control. 
Following transduction, immunoblot and immunofluorescence analyses were performed 
to verify the extent of the knockdown. Figure 5.17A demonstrates that a very efficient 
knockdown of Lsm1 is achieved at the protein level. However only a moderate 
reduction (approximately 30 - 50%) in the number of P-bodies (marked by the anti-
DDX6 and anti-Ge1 antibodies) is observed, which is contrary to what is seen in HeLa 
cells, where P-bodies are more extensively depleted upon Lsm1 knockdown (section 
5.6). On the other hand, use of the DDX6 targeting shRNA resulted in only a 50% 
knockdown of DDX6 (Figure 5.17A, shRNA 5). Several other DDX6 shRNAs were 
also trialled but reduction in protein expression was never greater than 2 fold (Figure 
5.17A, shRNAs 1 - 4). Despite this, a more substantial P-body depletion is still 
observed than that obtained with knockdown of Lsm1 (Figure 5.17B). This reinforces 
the notion that DDX6, unlike other P-body proteins, is essential for formation of these 
foci. However, these cells could not be used for further replication studies, as their rate 
of growth was significantly slower than the control cell line, making direct comparisons 
difficult. Because of this the Lsm1 knockdown cells were used instead. Although the P-
body phenotype was not as extensive as would be required to determine the effects of 
these foci on HIV-1 replication, the extent of the protein knockdown itself was 
considerable. Two groups have claimed that loss of Lsm1 leads to an increase in both 
virus production and infectivity (Chable-Bessia et al., 2009; Nathans et al., 2009), 








Figure 5.17: Phenotypic analysis of Lsm1 and DDX6 knockdown in Hut78 cells.  
Hut78 cells were transduced with lentiviral vectors encoding shRNAs targeting either DDX6 (1 - 5), 
Lsm1 or a non-silencing control (NSC). Transduction efficiencies were determined by analysis of GFP 
expression and cells were maintained under puromycin selection for 5 - 7 days before immunoblot and 
immunofluorescence analysis. A. Immunoblot analysis of transduced cells to check levels of protein 
expression, with anti-Lsm1 (left panel) or anti-DDX6 (right panel) antibodies. An anti-HSP90 antibody is 
included in both cases as a loading control. B. Immunofluorescence analysis of transduced cells to check 
levels of P-body depletion. Coverslips were coated in Poly-L-lysine and dried overnight. Hut78 cells 
were then plated onto coverslips and 24 hours later were fixed, permeabilised and stained with either a 
mouse anti-Ge1 or a rabbit anti-DDX6 primary antibody and then appropriate Alexa-Fluor 594 
conjugated secondary antibodies. Coverslips were mounted, dried overnight and imaged using a Leica 
confocal microscope. Scale bar = 10 µm. 
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5.7.2 Lsm1 knockdown and effects on HIV-1 replication and A3G anti-viral 
activity 
The cell lines described in Figure 5.17 were infected with p24Gag corresponding to 25 ng 
of either wild-type or Δvif virus, produced in 293T cells. The cells were then 
extensively washed to remove any input virus and re-suspended in fresh medium. 
Supernatant was harvested every two days post infection and quantified by p24Gag 
ELISA. Cell lysates were collected in parallel and subjected to immunoblotting to 
determine protein expression levels. 
Virus production steadily rose, peaked at days 4 - 6 and then began to decline at day 8 
(Figure 5.18A). The replication kinetics of both the Lsm1 knockdown and control cell 
lines was nearly identical when infected with wild-type virus. Similarly, A3G inhibition 
of the replication of the Δvif virus appears to be unperturbed by Lsm1 depletion as a 2 
log decrease in p24Gag production is observed for both cell lines over the course of the 
assay. These results were reproducible even when cells were infected with higher (125 
ng) and lower (5 ng) virus titres (Figure 5.18B). Immunoblots confirm that knockdown 
of Lsm1 was maintained throughout the replication cycle (Figure 5.18C). This indicates 
that in ongoing replication, as well as single cycle infectivity assays, Lsm1 is neither 








Figure 5.18: Knockdown of Lsm1 does not affect HIV-1 replication or endogenous A3G anti-viral 
activity. 
Hut78 cells transduced with either an Lsm1 targeting (Lsm1) or non-silencing control (NSC) shRNA 
encoded lentiviral vector (generated as described for Figure 5.17) were infected with p24Gag 
corresponding to 5 ng, 25 ng or 125 ng of either wild-type (wt) or Δvif NL43 virus produced in 293T cells. 
4 hours later cells were extensively washed and re-suspended in complete RPM1. Every 2 days, cells 
were pelleted and a sample of supernatant collected for analysis of virus production by p24Gag ELISA and 
fresh media added. Cell lysates were also collected for immunoblot analysis. A. Virus production from 
transduced cells infected with 25 ng of input virus, monitored over 8 days, as determined by p24Gag 
ELISA. B. Virus production from transduced cells infected with 5 ng (left graph) or 125 ng (right graph) 
of input virus, monitored over 8 days, as determined by p24Gag ELISA. C. Immunoblot analysis of protein 
expression from transduced cells described in A at days 2 and 6 post infection. * denotes the position of a 
background band. Data are representative of two independent experiments. 
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5.8 Sub-cellular localisation of HIV-1 genomic RNA and Gag 
5.8.1 Assessment of HIV-1 genomic RNA localisation to P-bodies 
In support of claims as to the relevance of P-bodies to HIV-1 infectivity and virus 
production, both Nathans et al and Chable-Bessia et al report that HIV-1 genomic RNA 
(gRNA) is found to localise to P-bodies. Since the data presented thus far fails to 
substantiate their initial findings, it was important to determine whether viral 
components could be detected at these cytoplasmic foci. To investigate this, a proviral 
construct was created based on the MS2-bacteriophage tethering system (Bertrand et al., 
1998; Jouvenet et al., 2009). A wild-type NL43 construct was engineered so as to 
contain 24 binding loops from the bacteriophage MS2 coat protein. These loops were 
introduced at the end of the Gag reading frame (Figure 5.19A). Co-expression of an 
MS2-YFP fusion protein then allows HIV-1 gRNA to be tracked in cells through 
detection of YFP fluorescence. The high affinity between the MS2 protein and the 
binding loops has made this system remarkably useful for visualising RNA in both 
living and fixed cells.  
HeLa cells were thus co-transfected with equal amounts of the 24xMS2 NL43 construct 
and the MS2-YFP plasmid. 24 hours later cells were fixed, permeablised and stained 
with anti-GFP (to enhance the YFP signal) and anti-DDX6 (as a marker for P-bodies) 
primary antibodies and appropriate secondary antibodies. Coverslips were then mounted, 
dried and imaged using a Leica confocal microscope. As shown (Figure 5.19B), 
expression of the MS2-YFP fusion protein alone displayed a characteristic nuclear 
localisation due to the presence of a nuclear localisation signal (NLS). With co-
expression of the NL43 proviral construct however, a more cytoplasmic distribution 
was evident along with significant particle formation and a more elongated morphology 
of the infected HeLa cell (Figure 5.19C). However, no localisation with DDX6 foci (in 
red) was observed in any of the cells imaged. This implies that HIV-1 gRNA does not 









Figure 5.19: MS2 tethered HIV-1 genomic RNA does not co-localise with the P-body protein DDX6. 
A. Schematic diagram of the MS2 tethered proviral construct used in this study to visualise HIV-1 
genomic RNA. 24 MS2 binding loops from the coat protein of the MS2 bacteriophage were introduced at 
the end of the Gag reading frame in an NL43 proviral plasmid. Expression of Pol is disrupted and thus 
some experiments were also performed with complementation using wild-type virus. Co-expression of an 
MS2-YFP fusion plasmid, which binds with high affinity to the MS2 binding loops, allows visualisation 
of the HIV-1 viral RNA. B. HeLa cells were co-transfected with equivalent amounts of an MS2-YFP 
expression plasmid and an untagged Luciferase plasmid as a control. C. HeLa cells were co-transfected 
with equivalent amounts of an NL43 provirus containing 24xMS2 binding loops (as described in A) and 
an MS2-YFP fusion plasmid. For both B and C, cells were fixed 24 hours after transfection, 
permeabilised and stained with a mouse anti-GFP and a rabbit anti-DDX6 primary antibody and then 
anti-mouse 488 and anti-rabbit-594 secondary antibodies. Cells were also stained with DAPI for 
visualisation of the nucleus. Coverslips were then mounted, dried overnight and imaged using a Leica 
confocal microscope. Images are compilations of between 6-10 z-stacks, with merged images presented 




5.8.2 Assessment of HIV-1 Gag localisation to P-bodies  
Following this, a second construct, this time containing both the MS2 binding loops and 
Cherry fluorescent protein fused in frame with Gag (Figure 5.20A), was used in order to 
determine localisation of the viral Gag protein. In this case, co-localisation with both the 
DDX6 (Figure 5.20B) and Ge1 (Figure 5.20C) P-body proteins was evaluated. Gag 
localisation showed a characteristic cytoplasmic distribution with more intense staining 
at the plasma membrane. This is consistent with data detailing the plasma membrane as 
the main site of Gag driven viral assembly. Once again, no localisation of Gag was 
observed at either DDX6 or Ge1 marked foci (Figures 5.20A and B). In sum, HIV-1 
viral components, neither gRNA nor Gag, are found to co-localise with two different P-



















Figure 5.20: HIV-1 Gag does not co-localise with the P-body proteins DDX6 and Ge1. 
A. Schematic diagram of the Gag-Cherry fusion proviral plasmid used in this study. The NL43 provirus is 
the same as that described in Figure 5.19 containing 24xMS2 binding loops but it also contains an 
additional sequence encoding Cherry fluorescent protein, fused in frame with Gag. Expression of Pol is 
disrupted and thus some experiments were performed with complementation using wild-type virus. B and 
C. HeLa cells were transfected with 0.5 µg of an NL43 24xMS2 Gag-cherry proviral plasmid, as 
described in A and 0.5 µg of a myc-tagged luciferase expression plasmid. 24 hours later, cells were fixed, 
permeabilised and stained with either a rabbit anti-DDX6 (B) or a mouse anti-Ge1 (C) primary antibody 
and then the appropriate Alexa-Fluor 488 conjugated secondary antibody. Cells were also stained with 
DAPI for visualisation of the nucleus. Coverslips were then mounted, dried overnight and imaged using a 
Leica confocal microscope. Images are compilations of between 6-10 z-stacks, with merged images 






Results presented in Chapter 3, section 3.4 revealed that several APOBEC3 proteins 
localised with Ago2 to cytoplasmic P-body structures. Since this correlated with their 
anti-viral phenotypes, it was important to determine the functional implications of this 
localisation. Here it is shown that disruption of P-bodies has no observable impact upon 
APOBEC3 mediated viral inhibition. Further, P-bodies and P-body components do not 
appear to regulate HIV-1 replication and viral components could not be detected at 
these foci, as has been previously proposed. Therefore the relevance of APOBEC3 
localisation to these structures remains unresolved and requires further investigation. 
It is clear from the results presented in this study that HIV-1 replication is not 
influenced by P-bodies. It is important to make the distinction between the effects of 
individual proteins and P-bodies in general because as shown, knockdown of DDX6 but 
not Lsm1 led to a modest increase in virus production in certain experimental settings 
(section 5.5). This suggests that this effect is specific to loss of DDX6. Other groups 
have noted similar but weaker effects on HIV-1 particle production with knockdown of 
Lsm1 and Ago2 (Chable-Bessia et al., 2009; Nathans et al., 2009), which was not 
observed here. The reason for this discrepancy as well as the failure to reproduce this 
effect in a slightly different experimental context (section 5.4) is unclear but it does 
point to a possible weakness of the observed phenotype. An alternative explanation is 
that the efficiency of infection is altered in the knockdown cell lines. However, the 
increase in p24Gag production in the DDX6 knockdown cell lines in transient 
transfection experiments, though modest, was consistently observed (Figure 5.11). 
Nathans et al argue that this effect is specific to HIV-1 protein production as they only 
see a very slight change in GFP protein levels, with no change in mRNA levels for both 
constructs. Preliminary results from pulse labelling experiments (section 5.5.3) seem to 
indicate that this phenotype is most likely due to the general stimulation of global 
cellular translation upon reduction of the DDX6 protein, which is a known translational 
repressor (Coller and Parker, 2005). This is supported by the fact that certain plasmids 
appear to be slightly better expressed in the DDX6 depleted cell lines (Figure 5.6). 
Jangra et al also noted an increase in cellular translation rates upon DDX6 knockdown, 
though not in HeLa cells, as were tested here (Jangra et al., 2010). It is important to note 
however, that this apparent increase in protein synthesis is not accompanied by an 
increase in steady state levels of intracellular Gag as determined by western blot (see 
  
  225 
Figures 5.11 and 5.12). Therefore a pulse chase analysis to track the fate of the RNA 
and Northern blot analysis to determine whether the RNA produced is more stable or 
whether translation is more efficient in the absence of DDX6 would be required to fully 
understand the nature of this phenotype. In essence, although an increase in p24Gag 
production was consistently observed in transient transfection experiments, the fact that 
it could not be observed in the more physiologically relevant context of infection based 
methods implies that it may not be relevant in vivo.  
Viral infectivity was also assessed and in all methods tested, no influence of P-bodies, 
either positive or negative was observed. This is in disagreement with two recently 
published reports. However when Chable-Bessia et al conducted these experiments by 
transient transfection they also failed to see an effect of DDX6 or Lsm1 knockdown on 
HIV-1 infectivity. Nathans et al looked in target, not producer cells and the magnitude 
of the effects found in this case was only two fold. The work described here also 
specifically looked at HIV-1 replication in the context of Lsm1 depletion (section 5.7). 
It would be expected that any small differences in viral production and the quality of the 
viruses produced would be magnified when monitoring p24Gag production over several 
days. However no such effects were observed, even when a very efficient depletion of 
Lsm1 protein levels was obtained. This once again questions the validity of the 
phenotypes reported by both groups.  
Finally, viral localisation to P-bodies was also evaluated as several groups have reported 
that viral RNA can localise to P-bodies (Chable-Bessia et al., 2009; Martin et al., 2011; 
Nathans et al., 2009). It is generally believed that the majority of virion assembly takes 
place at the plasma membrane and that Gag and gRNA must traffic to these sites in 
order to form particles. However, how they are directed there and whether they pass 
through cytoplasmic foci, such as P-bodies, beforehand is unknown. In yeast, P-bodies 
have been found to be associated with the plasma membrane (Beckham et al., 2007), 
thus linking them to sites of viral assembly. Whether the same is true in human cells 
remains to be determined but it is interesting to note that Ago2 was originally reported 
to localise to the plasma membrane (Cikaluk et al., 1999). Also, localisation of viral 
RNA and Gag to P-bodies would provide an opportunity for A3G to interact with these 
components, which is necessary for its virion encapsidation. However, it was 
discovered that neither HIV-1 gRNA nor Gag localised with endogenous P-body 
proteins using an MS2 tethering system (section 5.8). This lack of co-localisation is in 
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keeping with the data presented thus far in this study relating to the role of P-bodies in 
HIV-1 replication, and is also supported by other published reports (Abrahamyan et al., 
2010; Burnett and Spearman, 2007). This is, however, in contrast to the work of both 
Chable-Bessia et al and Nathans et al. In the former study although they also use an 
MS2 tethering system, they do so in the context of a HIV-1 vector, rather than in the 
more biologically relevant context of a proviral plasmid, as was used here. Nathans et al, 
on the other hand, used fluorescent in situ hybridisation (FISH) and determined 
localisation with ectopic expression of an A3G-YFP construct, rather than with 
endogenous P-body markers. However only one representative example is shown of co-
localisation at a P-body structure and therefore the generality of this finding cannot be 
determined. Also a FISH/IF co-analysis of HIV-1 RNA by Levesque et al (2006) did 
not produce the same punctate distribution described by Nathans et al. Differences in 
experimental procedure may account for the discrepancy in results but it is unclear why 
co-localisation would not be observed with an MS2 tethering system as it has been 
successfully used by others to track HIV-1 gRNA and Gag localisation (Jouvenet et al., 
2009). Alternatively, viral RNA may be localising to other punctate foci in the cell that 
may potentially partially overlap with P-bodies and stress granules. Abrahamyan et al 
have reported that Staufen RNP complexes, formed in response to HIV-1 infection, 
contain both Gag and gRNA. They also claim that depletion of Staufen leads to a 
reduction in viral RNA encapsidation, hence highlighting a role for these foci in 
infectious particle production. The authors do note that these structures are distinct from 
P-bodies and stress granules but Staufen is able to localise to stress granules and A3G 
has been reported to partially overlap with Staufen (Martin et al., 2011). Therefore the 
conflicting findings relating to gRNA and Gag localisation to P-bodies may be 
complicated by the nature of the foci that are under observation. Various different P-
body markers should therefore be used to formally verify that the foci are in fact mRNA 
Processing bodies and not other types of RNA granules with which P-body components 
may partially associate (Kedersha et al., 2005; Kulkarni et al., 2010).  
The role of P-bodies and P-body components in the anti-viral action of the APOBEC3 
proteins was investigated by numerous different approaches in terms of P-body 
depletion (shRNAs and siRNAs), virus input (transfection and infection based assays) 
and measure of outcome (single cycle infectivity assays and ongoing replication). Since 
all of these methods yielded the same conclusion, that APOBEC3 anti-viral activity was 
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unperturbed by P-body protein knockdown, it strongly reinforces the point that P-bodies 
are not necessary for this aspect of APOBEC3 function. This is supported by the work 
of Chable-Bessia et al who also found that knockdown of DDX6 and Lsm1 had no 
effect on A3G anti-viral activity. Here, the whole APOBEC3 family was investigated as 
well as specifically determining that these proteins were still packaged in the absence of 
P-bodies and conversely that A3G packaging defective mutants could still localise to 
these foci (section 5.2). This latter finding is corroborated by a recently published report 
(Martin et al., 2011). This refutes speculation that P-bodies are sites of APOBEC3 
virion incorporation and potentially viral assembly. This is also in agreement with the 
work of Soros et al, who found that it is newly synthesised A3G that is specifically 
incorporated into HIV-1 particles and not that which is associated in high molecular 
weight RNP complexes (Soros et al., 2007). Intriguingly, another cellular protein 
known to regulate HIV-1 replication, Mov10, has also been found to associate with P-
bodies. Mov10 is a putative RNA helicase which interacts with components of the RISC 
complex (Meister et al., 2005) as well as A3F and A3G in an RNA dependent manner 
(Gallois-Montbrun et al., 2007; Kozak et al., 2006). Its overexpression has been shown 
to potently inhibit wild type HIV-1, as well as SIV and MLV, by an as yet unidentified 
mechanism, though it has been reported to associate with viral cores and is packaged 
into virions (Chertova et al., 2006; Furtak et al., 2010; Wang et al., 2010). Therefore it 
remains to be determined why such modulaters of HIV-1, as well as other viruses, 
localise to these structures. The anti-viral protein Trim5α is also known to associate 
with cytoplasmic bodies (Stremlau et al., 2004). The nature of these bodies, which are 
distinct from P-bodies (Campbell et al., 2007), appears to be dependent on Trim5α 
oligomerisation rather than on protein-RNA complexes. Whether these bodies are 
important for Trim5α mediated restriction is the subject of much debate but it has been 
reported that pre-existing bodies are not required for this activity (Song et al., 2005). 
Others have shown that Trim5α aggregates form in response to viral infection 
(Campbell et al., 2008), which adds to the mystery surrounding the significance of foci 
formation for cellular restriction factors. A recent publication has claimed that A3G 
complex formation inhibits HIV-1 viral particle production and that dissolution of these 
foci, which partially overlap with P-bodies, increases virus output from these cells 
(Martin et al., 2011). However, these A3G ‘complexes’ are dependent on the presence 
of DDX6, which when knocked down itself can result in an increase in virus production 
(Figure 5.11). Therefore the distinction between A3G and DDX6 foci appears to be 
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strained and in the data presented in Chapter 3, section 3.4 these two proteins show 
significant overlap. The fact that in this study HIV-1 Gag failed to accumulate at DDX6 
marked bodies further disagrees with the conclusions of Martin et al. Also 
overexpression of A3G, and more prominently other APOBEC3 proteins such as A3C 
(for example see Figure 5.11), is slightly inhibitory to virus production and thus is not 
likely the result of foci formation.  In sum, the localisation of A3G and other APOBEC3 
proteins does not appear to be relevant to their anti-viral phenotypes, yet the association 
of viral inhibitors with cytoplasmic foci is intriguing and merits further investigation.  
It is conceivable that APOBEC3 localisation to these structures may be more relevant to 
restriction of other viruses and endogenous retroelements. Several P-body components 
have been implicated in the replication of a diverse array of viruses as discussed in 
Chapter 1, section 1.9. Significantly, in yeast, A3G localisation to P-bodies appears to 
be important for its packaging and hence restriction of the Ty1 retrotransposon (Dutko 
et al., 2010; Dutko et al., 2005; Esnault et al., 2005).  However no correlation has been 
found in human cells between APOBEC3 inhibition of retrotransposition and P-body 
association for example (Niewiadomska et al., 2007). On the other hand it has been 
reported that A3G restricts Alu retrotransposition by sequestering these elements away 
in high molecular weight complexes (Chiu et al., 2006). Thus similar results may be 
achieved if the APOBEC3 proteins are able to recruit these transcripts to P-bodies.  
Additionally P-body localisation may be a result of a more general involvement of the 
APOBEC3 proteins in cellular RNA regulation, rather than being related to their anti-
viral activity. Other P-body components have fundamental roles in the metabolism and 
turnover of RNA, thus implying that the APOBEC3 proteins could also be part of such 
processes. As discussed in Chapter 4, though no specific role of the APOBEC3 proteins 
in RNAi and ARE mediated decay was revealed, description of APOBEC3 associated 
RNAs, both mRNA and small RNAs, including miRNAs, may provide insight into 
potential targets. This can be achieved through techniques such as cross-linking 
combined with co-immunoprecipitation (CLIP). Preliminary work by Kozak et al has 
already identified several mRNA species that interact with A3G, including its own 
mRNA, indicating a degree of self-regulation (Kozak et al., 2006). Several small RNAs 
such as Alu, 7SL and Y RNAs are also known to interact with A3G (Gallois-Montbrun 
et al., 2007). 7SL, for instance, has been postulated to mediate A3G virion incorporation. 
Thus the identification of associated RNAs can provide greater insight into A3G 
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activity and functional control. Further examination of the possible role of APOBEC3 
proteins in the control of RNA is required to address these points and how this may 
impact upon their sub-cellular localisation.  
Furthermore APOBEC3 localisation to P-bodies may be a means of regulating their 
function and preventing them from editing cellular DNA targets as proposed for A3G 
recruitment into high molecular weight RNP complexes (Chiu et al., 2006). Several 
APOBEC3 proteins may be able to target DNA viruses such as herpes viruses and 
human papilloma virus (Suspene et al., 2011b; Vartanian et al., 2008) as well as other 
types of foreign DNA (Stenglein et al., 2010). What regulates their enzymatic activities 
such that they do not hypermutate genomic DNA remains to be determined. Recently 
A3A alone has been reported to edit nuclear DNA (Stenglein et al., 2010; Suspene et al., 
2011a), and it is interesting to note that it is the only APOBEC3 protein that does not 
associate with P-bodies (Chapter 3, section 3.4). 
Finally, it has also been suggested that smaller P-body structures exist within the cell, 
not visible by light microscopy that can persist after the dissolution of larger visible foci 
by targeted protein knock down. This means that although microscopically visible P-
bodies may have been eliminated, the APOBEC3 proteins may still be interacting with 
P-body proteins in smaller, less visible foci. This has been used as an explanation as to 
why the disappearance of P-bodies does not appear to impact on RNA regulatory 
processes such as miRNA mediated repression, siRNA silencing, NMD or AMD. 
However these effects can also be explained by the fact that RNA decay can occur co-
translationally and thus separate from that which occurs in P-bodies (Hu et al., 2010). 
The existence of smaller, microscopically undetectable P-body structures is obviously 
difficult to verify and therefore remains undetermined at present. Whether these foci 
would actually be classified as P-bodies is also a matter of debate (Eulalio et al., 2007b). 
Overall, the relevance of APOBEC3 localisation to P-bodies in terms of functional 
significance requires further exploration.  
In summary, P-bodies and P-body components do not appear to influence APOBEC3 
anti-viral activity. They are also unlikely to be the sites of APOBEC3 virion 
incorporation or viral assembly as efficient packaging was maintained in the absence of 
these foci and HIV-1 viral components were not found to localise to them. Loss of P-
bodies and associated proteins also failed to have any impact upon HIV-1 infectivity 
and only modestly influenced virus production in certain circumstances. This would 
  
  230 
argue against microscopically visible P-bodies being inhibitory to HIV-1 replication. 
Therefore, the relevance of APOBEC3 association with P-bodies and related proteins is 

















































6. DISCUSSION AND FUTURE WORK 
 
6.1 Outstanding questions concerning the APOBEC3 family  
The discovery of the antiviral protein, APOBEC3G, and its family members, nearly ten 
years ago, unearthed a previously unknown mechanism of host mediated innate 
resistance against invading pathogens. It had been well established that viruses, such as 
HIV-1, utilised cellular factors for their own benefit and often to the detriment of the 
host, but cells have evolved multiple means of limiting their replication at various 
stages of their life cycle. It is clear that co-evolution between host and pathogen has 
dramatically shaped both genomes, and in trying to understand these evolutionary 
pressures we have gained a better understanding not just of the biology of the pathogen, 
and what it must do in order to survive and propagate, but also that of the cell. Research 
into HIV-1 and other viruses has provided invaluable insight into processes such as 
reverse transcription, nuclear trafficking and oncogenesis to name a few, which has 
subsequently enabled targeted and effective drug development. It is well known that 
A3G and other APOBEC3 proteins induce mutations into the HIV-1 cDNA during 
reverse transcription via their cytidine deaminase capabilities. This compromises the 
production of replication competent progeny virions and thus impedes further 
replication of the virus. In defence of its own genome, the viral protein Vif has evolved 
to target these proteins for degradation, thereby preventing their incorporation into 
nascent virions and repressing their anti-viral effects. However, there is still much to be 
learnt and the work presented in this study aimed to further characterise the APOBEC3 
family as both viral restriction factors and as cellular proteins. 
The APOBEC3 proteins differentially regulate the fate of a diverse range of exogenous 
viruses and endogenous retroelements but the factors that contribute to their target 
substrate specificities have not yet been determined. The association of A3F and A3G, 
the two most potent anti-HIV-1 proteins, in large ribonucleoprotein complexes and their 
localisation to discrete cytoplasmic foci, implicates both interacting cellular proteins 
and sub-cellular localisation as influencing functional activity. Further, these factors 
have also postulated a potential cellular role for the APOBEC3 proteins, which remains 
largely undefined, in the regulation of RNA. However, their contribution to this process 
has not been fully explored. Therefore, the data presented in the preceding chapters has 
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sought to address some of these outstanding issues with an attempt to gain new insight 
into APOBEC3 activity. 
 
6.2 Importance of cellular factors for APOBEC3 anti-viral activity 
6.2.1 APOBEC3 interaction with Argonaute 2 
Research is often focused on A3G, as it is the most potent anti-HIV-1 APOBEC3 
protein. However, in order to better understand functional differences between the 
different family members, the whole family needs to be assessed in the same 
experimental context. This was an important and necessary feature of the work 
presented in this study. The APOBEC3 proteins do not all inhibit HIV-1 infectivity and 
neither do they do so to the same extent (Chapter 3, Figure 3.2), but their anti-HIV-1 
phenotypes do positively correlate with their packaging into virions (Chapter 3, Figure 
3.3). Identification of factors that regulate virion encapsidation, and hence anti-viral 
activity, is therefore crucial to comprehend their differential phenotypes.  An important 
contributory factor to these differences may be their interactions with cellular 
components, which could potentially act as co-factors or regulators of their anti-viral 
activity. Although A3F and A3G associate with a diverse array of RNA binding 
proteins (Chiu et al., 2006; Gallois-Montbrun et al., 2008; Gallois-Montbrun et al., 
2007; Kozak et al., 2006; Wichroski et al., 2006), the Argonaute proteins, in particular, 
make attractive candidates for this role as they are closely associated with A3F and 
A3G in a partially RNase insensitive manner (Gallois-Montbrun et al., 2007). Across 
the whole APOBEC3 family, however, interactions with Ago2 did not precisely 
correlate with anti-viral phenotypes, although the most inhibitory APOBEC3 proteins, 
A3F, A3G and A3H, did interact most strongly with Ago2 (Chapter 3, Figure 3.4). This 
would suggest that APOBEC3 anti-viral function is independent of Ago2. More 
definitive confirmation of this was obtained when it was shown that knockdown of 
Ago2 had no effect on APOBEC3 mediated HIV-1 inhibition (Chapter 4, Figures 4.4 
and 4.5). More importantly it rules out the necessity of Ago2’s endonuclease activity, 
which is not shared by the other Argonaute proteins, for APOBEC3 function.  
An important point to note is that results from natural endogenous reverse transcription 
(NERT) reactions demonstrate that no target cell factors are required for A3G inhibition 
of HIV-1 and thus any required cellular proteins would have to be encapsidated, along 
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with A3G, into HIV-1 particles from virus producer cells (Bishop et al., 2008). It has 
been determined that it is newly synthesised A3G which is incorporated into virions and 
not the cellular pool that is contained within high molecular mass RNP complexes 
(Soros et al., 2007). This means that cellular proteins that may regulate APOBEC3 anti-
viral activity are not necessarily dependent on A3G for their virion incorporation.  Ago2 
was originally identified as a membrane associated protein (Cikaluk et al., 1999) and 
recent reports have localised Ago2, and more prominently GW182, to endosomes and 
multi-vesicular bodies (MVBs), which appears to be important for miRNA mediated 
repression (Gibbings et al., 2009; Lee et al., 2009). These data indicate that Ago2 has 
the potential to be incorporated into viral particles. However, to date, no such reports 
have been published and preliminary work, not presented here, suggests that Ago2 is 
not packaged into virions at detectable levels. In combination this data would lead to the 
conclusion that Ago2, specifically, is not required for the restriction of HIV-1 as 
mediated by the APOBEC3 proteins.  
6.2.2 APOBEC3 interaction with PIWI proteins 
Whether the Argonaute proteins are required for APOBEC3 inhibition of other viruses 
or viral elements has not been addressed. It has been found that A3F and A3G (and 
potentially other APOBEC3 proteins) are highly expressed in the testis and ovary 
(Koning et al., 2009) and so they may act to protect the germline from the potentially 
deleterious effects of endogenous retroelements. The Argonuate family members, the 
PIWI proteins, are similarly expressed in the germline and are actively involved in 
inhibiting retrotransposition events by RNA silencing. Whether the APOBEC3 proteins 
interact with the PIWI proteins and can co-ordinate with them to defend the germline is 
currently unknown but would be an interesting issue to resolve, especially as several 
APOBEC3 proteins can very effectively restrict retrotransposition events in somatic 
cells. In fact, in Drosophila, PIWI interacting small RNAs (piRNAs) have been found 
in cytoplasmic foci that contain proteins normally associated with P-bodies in somatic 
cells, such as Dcp1a, Dcp2 and ME31B (the Drosophila homologue of DDX6), 
implying that the PIWI proteins may engage a similar set of proteins as their Argonaute 
counterparts (Lim et al., 2009). Similar results have also been reported in mice (Aravin 
et al., 2009).  Alternatively the APOBEC3 and PIWI proteins may invoke distinct 
mechanisms of inhibition that may target different types of retrotransposons or that may 
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be utilised under different circumstances. Further work will be required to clarify these 
issues.  
6.2.3 APOBEC3 interaction with other identified cellular proteins 
Although Ago2 may not be involved in APOBEC3 anti-viral activity, other cellular 
factors may contribute to this function. One interesting candidate is the anti-viral zinc 
finger protein ZAP1, which has been shown to interact with A3G in a partially RNase 
independent manner (Kozak et al., 2006), akin to the Argonaute proteins. ZAP1 was 
first identified as inhibiting the replication of MLV, through depletion of viral 
messenger RNA from the cytoplasm of infected cells (Gao et al., 2002; Guo et al., 
2004). Subsequently it has been reported that ZAP1 interacts with and utilises both the 
3’ - 5’ and 5’ - 3’ mRNA degradation pathways to mediate a similar effect against HIV-
1 (Guo et al., 2007; Zhu et al., 2011). Its interaction with Dcp1a, Dcp2 and Xrn1 is 
particularly interesting as, along with A3G, these proteins localise to P-bodies. Whether 
ZAP1 displays a similar subcellular localisation remains to be determined, as does the 
functional relevance of its interaction with A3G, with particular focus on anti-viral 
defence. In light of this it is important to note that the anti-viral factor Mov10 interacts 
and co-localises with A3G and is packaged into HIV-1 virions (Chertova et al., 2006; 
Gallois-Montbrun et al., 2007; Kozak et al., 2006; Wichroski et al., 2006). Yet these 
proteins do not work in tandem to mediate HIV-1 inhibition and instead represent 
independent modes of viral resistance (Burdick et al., 2010).  
Upf1, which mediates NMD, is another potential candidate as it is necessary for A3G 
directed inhibition of the Ty1 retroelement in yeast (Dutko et al., 2010). It has been 
identified in A3G containing RNP complexes (Kozak et al., 2006) and localises to P-
bodies but further work would be required to establish whether it is involved in the anti-








6.3 APOBEC3 proteins and the miRNA pathway 
Although the relevance of the miRNA pathway to APOBEC3 anti-viral activity was not 
specifically addressed in this study it is important to determine the role this pathway 
may play in their function. This can be achieved by targeted knockdown of essential 
components of this pathway, such as Dicer and GW182, or else simultaneous 
knockdown of all four Argonaute proteins, which has recently been reported (Roberts et 
al., 2011). This is of interest as there is increasing evidence to suggest that the miRNA 
pathway may be an important regulator in the control of virus replication in mammals, 
as it is in plants and invertebrates. Several groups have now shown that virally encoded 
miRNAs can be processed by cellular machinery to yield short noncoding RNAs that 
can be utilised by either the virus or the cell [reviewed in (Umbach and Cullen, 2009)]. 
This is especially true for DNA viruses such as herpes virus where a large number of 
miRNAs have now been identified (see Chapter 1, section 1.11.4). These results thus 
implicate miRNAs and the Argonaute proteins in the regulation of a number of different 
viruses, including HIV-1 although this remains controversial at present. However, the 
absence of an RNA dependent RNA polymerase in human cells means that the effects 
of individual miRNAs may be relatively inconsequential to viral replication. On the 
other hand, miRNAs and the Argonaute proteins can mediate the upregulation of protein 
expression as well as its downregulation (Vasudevan et al., 2007b). This is most evident 
for the replication of hepatitis C virus (HCV) which is dependent on the expression of 
the miR122 miRNA in liver cells for its replication (Jopling et al., 2005), and 
knockdown of the Argonaute proteins and/or Dicer leads to a decrease in HCV 
replication due to reduced HCV translation (Randall et al., 2007). These effects on HCV 
replication are also observed for other P-body and miRNA associated proteins (Scheller 
et al., 2009). This demonstrates that the miRNA pathway is not just involved in anti-
viral defence but can be co-opted by viruses for their own benefit. In these cases, 
normally repressive translation machinery may be hijacked by the virus to instead 
promote translation. It has also been proposed that the subcellular localisation of Ago2 
contributes to its dual functioning. Promotion of HCV replication is dependent upon 
recruitment to lipid droplets whereas suppression of this virus is associated with 
interactions with P-bodies (Berezhna et al., 2011).  Whether the APOBEC3 proteins 
mediate a similar effect and whether they can work in conjunction or in opposition to 
these other proteins for HCV replication, for example, remains to be determined. An 
intriguing observation is that A3G expression appears to be elevated in the hepatocytes 
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and lymphocytes of infected HCV patients (Komohara et al., 2006). Thus it would be of 
relevance to determine firstly the role of the miRNA pathway in APOBEC3 function 
and secondly how these proteins may be involved in the restriction of other viruses, 
such as HCV, which appear to be heavily regulated by miRNAs and associated protein 
factors.  
 
6.4 Importance of sub-cellular localisation for APOBEC3 anti-viral 
activity 
6.4.1 P-bodies and APOBEC3 anti-viral activity 
Another factor, which may influence APOBEC3 virion incorporation and hence anti-
viral activity, is their subcellular localisation, and specifically localisation to P-bodies. 
In yeast, for example, A3G incorporation into Ty1 VLPs and hence restriction of Ty1 
retrotransposition appears to be dependent upon its P-body localisation (Dutko et al., 
2010). There does appear to be a positive correlation between anti-viral activity of the 
APOBEC3 proteins and localisation to these foci (Chapter 3, Figure 3.6). However, 
depletion of P-bodies through knockdown of DDX6 and Lsm1 did not substantially 
affect APOBEC3 virion incorporation or inhibition of HIV-1 (Chapter 5, sections 5.4 – 
5.7). This indicates that microscopically visible P-bodies are not required for 
APOBEC3 packaging. Recently, it has also been reported that formation of A3G 
‘complexes’, which substantially overlap with P-bodies, contribute to inhibition of HIV-
1 virus production (Martin et al., 2011). Similar to the findings presented in Chapter 5, 
Figure 5.7, these A3G foci are dependent on the presence of DDX6 for their formation. 
Coupled with the fact that A3G and DDX6 foci show considerable overlap (Chapter 3, 
Figures 3.5 and 3.6), indicates that these A3G ‘complexes’ are in fact P-bodies. 
However, the authors conclude that it is the specific depletion of these A3G foci which 
mediates the effect on HIV-1 virus production. This is in opposition to what has been 
observed in this study as knockdown of DDX6, in a transient transfection system, 
consistently led to a modest increase in HIV-1 virus production regardless as to the 






6.4.2 P-bodies and APOBEC3 functional regulation 
Although there did not appear to be a role for P-bodies in the antiviral activities of the 
APOBEC3 proteins, they may instead be required for alternative functions. An 
important question regarding the APOBEC3 family is whether they have other targets 
besides viral nucleic acid, and if so, how their function may be regulated such that they 
do not detrimentally mutate cellular genomic DNA, especially those proteins which 
localise to the nucleus. The regulation of APOBEC3 activity has already been 
documented in terms of high molecular weight RNP complexes and specific RNAs 
(Chiu et al., 2006; McDougall and Smith, 2011; Soros et al., 2007). Recently, Stenglein 
et al reported that several APOBEC3 proteins were capable of mutating foreign DNA 
species, thus preventing their accumulation and consequent deleterious effects. In this 
instance, editing of nuclear DNA was not observed, highlighting a degree of specificity 
in the actions of the APOBEC3 proteins (Stenglein et al., 2010). However, Suspene et 
al have since reported that A3A can deaminate nuclear DNA, particularly of genes 
implicated in cancers, with mutations subjected to cellular mismatch repair machinery 
(Suspene et al., 2011a). This demonstrates that nuclear DNA can be targeted by 
APOBEC3 proteins. On the other hand, only A3A has been reported to have this effect 
even though several APOBEC3 proteins localise to the nucleus and all have cytidine 
deaminase activity. With this in mind, it is especially intriguing that although A3A does 
localise to the cytoplasm, it is the only APOBEC3 protein which shows no association 
with P-bodies (Chapter 3, Figure 3.6). Therefore these foci could potentially be 
involved in limiting APOBEC3 enzymatic activity directed at nuclear DNA. Further 
work would be required to conclusively substantiate this theory.  
6.4.3 APOBEC3 proteins and stress granules 
As well as P-bodies, A3F and A3G are known to localise to stress granules in response 
to cellular stress. Other Argonaute interacting factors such as GW182, which is essential 
for miRNA mediated translational repression, does not relocate in this way (Kedersha et 
al., 2005). This demonstrates that the complex of proteins that shuttle between P-bodies 
and stress granules is specific and indicates that A3G may be involved in the regulation 
of translation related to the stress response. Stress granules are known to form in 
response to viral infection and thus APOBEC3 trafficking to these structures may be 
important for its anti-viral activity. It may be of significance that the ORF1p and 
ORF2p proteins of the LINE-1 retrotransposon accumulate in foci that overlap with 
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stress granules (Goodier et al., 2007). Thus they may be sites within which the 
APOBEC3 proteins interact with these retroelements. However, since viral infection 
stimulates the formation of stress granules, they may be more relevant to the control of 
exogenous viruses rather than endogenous retroelements. It would therefore be of 
interest to explore the movement of the APOBEC3 proteins between these foci in 
response to HIV-1 infection using real time imaging techniques. It has been reported 
that A3F can actually stabilise P-bodies and stress granules (Marin et al., 2008). Further, 
although several APOBEC3 proteins are resistant to Vif mediated degradation, namely 
A3A, A3B and A3C, their subcellular localisation appears to be altered by this viral 
protein (Marin et al., 2008). The reasons behind this are not clear but other groups have 
shown that Vif can localise to P-bodies but only when bound to an APOBEC3 protein. 
It may move with them to these sites before targeting them for degradation (Wichroski 
et al., 2005). Thus a complex interplay appears to exist between the cellular localisation 
of the APOBEC3 proteins, P-bodies and HIV-1 infection, which necessitates further 
investigation. 
 
6.5 Cytoplasmic foci formation and anti-viral defence  
6.5.1 P-bodies and HIV-1 replication 
The hypothesis that P-bodies were sites of APOBEC3 virion incorporation relied on the 
assumption that these foci were also sites of viral assembly, or at least that viral 
components could traffic through them. Chable-Bessia et al and Nathans et al both 
reported the localisation of HIV-1 gRNA and/or Gag at P-bodies using MS2 tethering 
constructs and FISH respectively. It still remains unclear as to how these viral 
components are trafficked to the plasma membrane to initiate viral assembly and 
whether they may be spatially segregated within the cytoplasm. However, it seems 
unlikely that viral components transit through P-bodies or even that these foci are sites 
of viral assembly as neither Gag nor gRNA co-localised with DDX6 or Ge1, two well 
known P-body markers (Chapter 5, Figures 5.19 and 5.20). Other groups using slightly 
different experimental setups have reported similar findings (Abrahamyan et al., 2010; 
Burnett and Spearman, 2007). If HIV-1 viral components did not localise to P-bodies it 
would also have to be determined how they are protected from degradation. 
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An alternative possibility is that HIV-1 gRNA and/or Gag may localise to related 
cytoplasmic structures that may partially overlap with P-bodies. One example may be 
stress granules as these foci share several protein components (Kedersha et al., 2005). 
Also, viral RNA has been proposed to localise to Staufen containing RNP complexes, 
distinct from P-bodies and stress granules, which are important for its virion 
encapsidation (Abrahamyan et al., 2010). Therefore, from the data presented in this 
study, it does not appear to be the case that viral components localise to P-bodies 
though they may localise to related foci. Precise differentiation between these different 
subcellular foci is required to effectively address these issues.  
6.5.2 Anti-viral proteins and cytoplasmic foci formation 
An interesting point to note is the localisation of proteins, which influence viral 
replication, to discrete subcellular compartments. Although knockdown of the P-body 
proteins Ago2, DDX6 and Lsm1 did not substantially affect HIV-1 infectivity (Chapter 
4, section 4.2.3 and Chapter 5, sections 5.4 – 5.7), these proteins have been more 
conclusively implicated in the control of other viruses, such as hepatitis C, as discussed 
earlier. Also, as has already been described, the recently identified antiviral factor, 
Mov10, which significantly compromises HIV-1 infectivity when overexpressed, 
localises to P-bodies and stress granules (Burdick et al., 2010; Furtak et al., 2010; Wang 
et al., 2010). It has also been reported that poliovirus infection causes the 
downregulation of both P-bodies and stress granules, with the specific degradation of 
key proteins (Dougherty et al., 2011; White et al., 2007). Stress granules have also been 
implicated in both the inhibition and promotion of a diverse range of viral life cycles, 
including West Nile virus, herpes simplex virus-1, Semliki Forest Virus, vesicular 
stomatitis virus and Sendai virus (Umbach and Cullen, 2009).  Thus P-body and stress 
granule components may be influential in controlling the replication of certain viruses. 
Aside from P-body proteins, the antiviral protein Trim5α also accumulates in 
cytoplasmic bodies when ectopically expressed. Although pre-existing Trim5α bodies 
appear to be dispensable for its inhibitory phenotype (Song et al., 2005), the use of 
fluorescently labelled viral particles has demonstrated the formation of these foci 
around viral complexes and their association in response to proteosomal inhibition 
(Campbell et al., 2008). Whether this is a true reflection of the localisation of the 
endogenous protein and the exact cellular components of these cytoplasmic bodies has 
yet to be determined. However, the formation of subcellular protein aggregates in 
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response to viral infection has also been observed for vaccinia virus, where foci with a 
similar but not identical protein content to stress granules, function to block virus 
replication (Simpson-Holley et al., 2011). Whether these and other foci act to sequester 
away cellular proteins required by the virus or else directly recruit antiviral proteins is 
unresolved at present. Thus cytoplasmic foci formation may be a significant factor in 
cellular antiviral defence strategies but their exact relevance and mechanism of action in 
most cases is unknown, representing important areas of future research.  
 
6.6 APOBEC3 proteins and the regulation of RNA 
6.6.1 APOBEC3 proteins and effects on RNA 
P-body localisation of the APOBEC3 proteins may be related to an as yet unidentified 
cellular function. It has been speculated that the APOBEC3 family may be involved in 
the regulation of RNA, which would support their subcellular localisation. However, 
contrary to a published report, (Huang et al., 2007a), the APOBEC3 proteins were not 
able to specifically regulate miRNA mediated repression or siRNA mediated silencing 
(Chapter 4, sections 4.7 and 4.9). Nor were they involved in the related RNA regulatory 
pathway of AMD (subject to caveats, see Chapter 4, section 4.11). However, the 
APOBEC3 proteins do appear to have some influence in regulating protein expression 
(Chapter 4, section 4.7). An important point to resolve is the specificity of this effect 
against different substrates, whether cellular and/or viral, and its in vivo relevance. A3C, 
which had the dramatic phenotype, is expressed in a wide variety of different tissues 
and has moderate inhibitory effects against certain viruses, not including HIV-1, and 
retrotransposons (see Chapter 3, Table 3.1). Also, it is not induced by interferon alpha 
stimulation (Koning et al., 2009). From the results presented in Chapter 4 and 5 it would 
appear that the APOBEC3 proteins, if anything, decrease viral protein expression upon 
overexpression, at least for p24Gag (see effects of A3B, A3C and A3H). Nevertheless, as 
has been observed, overexpression systems in cell lines can sometimes produce artifacts 
or results that are not representative of endogenous function. Thus these effects of the 
APOBEC3 proteins would have to be more rigorously explored. To specifically address 
the effects of the APOBEC3 proteins on RNA translation, direct tethering assays could 
be utilised. Reporter constructs containing 5 BoxB hairpins in their 3’UTR are co-
transfected with the protein of interest fused to a twenty-two amino acid λN peptide, 
which binds to the BoxB sites with high affinity (Gehring et al., 2003). Direct effects of 
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the protein on RNA translation can then be measured via expression of the reporter 
plasmid. This type of assay has successfully been used to determine that the Argonaute 
proteins and GW182 can repress translation of mRNAs, independently of each other 
and of their interactions with miRNAs (Pillai et al., 2004; Zipprich et al., 2009).  
These results of an upregulation of protein expression are also somewhat contradictory 
to recent reports claiming that the APOBEC3 proteins are able to mediate the clearance 
of foreign DNA and thus reduce the expression level of co-transfected proteins, such as 
GFP (Stenglein et al., 2010). While this effect may be evident for certain APOBEC3 
proteins in the luciferase reporter assays used in this study, it was not observed for A3A 
and A3C, which were both identified by Stenglein et al (2010) as mediating this 
phenotype. Therefore these discrepancies need to be addressed. As has been discovered 
for Ago2, which can act to both repress and enhance translation, dependent on the 
cellular context and potentially its cellular location (Berezhna et al., 2011; Vasudevan 
and Steitz, 2007a), regulatory proteins can have dual roles in the control of translation. 
This may make it easier for cells to rapidly respond to changing environmental 
circumstances and this could be the case for the APOBEC3 proteins as well.  
6.6.2 Identification of APOBEC3 associated RNAs 
As has already been discussed, the involvement of APOBEC3 family members in other 
processes relating to RNA metabolism and turnover is still a possibility. Identification 
of the repertoire of RNAs, both mRNA and miRNA, that associate with these proteins is 
of paramount importance. Several A3G associated cellular and viral RNAs have already 
been documented including the mRNA of A3G itself and the 7SL, Alu and Y RNAs 
(Kozak et al., 2006). Differential binding of certain small RNAs has been reported for 
A3F and A3G (Gallois-Montbrun et al., 2008), and these may potentially contribute to 
differences in virion encapsidation and hence the anti-viral activities of these proteins. 
Further, they may help elucidate other functions of the APOBEC3 family and also 
cellular contributions to the regulation of these proteins. The activities of APOBEC1 
and AID, for example, are known to be regulated by cellular RNAs (Bransteitter et al., 
2003; Sowden et al., 1996). Interaction of HIV-1 viral RNA with A3G in virus particles 
has been proposed to prevent its editing activity until the process of reverse 
transcription has been initiated in the infected target cell (Soros et al., 2007). Work is 
presently underway to identify these RNA species using techniques such as in vivo 
cross-linking combined with co-immunoprecipitation (CLIP). Similar studies have 
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already been carried out for the Argonaute proteins to identify miRNA targeted mRNAs. 
A comparison of CLIP data from Argonaute and APOBEC3 proteins as well as between 
the APOBEC3 proteins themselves, in both a cellular and viral context, will help 
identify shared and differential RNA interacting factors, which may yield clues as to 
functional activity and regulation.  
 
6.7 Summary 
In summary, it can be concluded that although several APOBEC3 proteins were able to 
interact and/or co-localise with Ago2, this protein did not appear to influence 
APOBEC3 mediated anti-viral activity. Although the role of miRNAs and miRNA 
mediated repression to APOBEC3 HIV-1 inhibition has not been directly addressed, the 
APOBEC3 proteins were not able to specifically regulate this process. The fact that the 
APOBEC3 family associates with a multitude of proteins related to RNA metabolism 
suggests that they may be involved in RNA regulatory pathways, but this would require 
further formal testing. Identification of the RNA components of their cellular complexes 
would greatly assist in this matter as well as provide insight into possible mechanisms 
of functional regulation. Whether any of these other associated cellular proteins have 
roles in APOBEC3 function, either cellular or anti-viral, remains to be seen. Finally the 
localisation of APOBEC3 proteins at mRNA processing bodies did not appear to be 
necessary for their anti-viral phenotype. The mechanisms that direct these proteins to 
these cytoplasmic foci as well as the relevance of this localisation to functional activity 
has yet to be elucidated. Further, knockdown of the P-body proteins, Ago2, DDX6 and 
Lsm1, did not affect HIV-1 replication indicating that this virus is neither dependent 
upon nor inhibited by these proteins. This highlights the complex interplay between 
cellular and viral factors in both the promotion and inhibition of viral replication. 
Greater knowledge of the latter, with regards to natural restriction factors such as the 
APOBEC3 proteins, is the power with which to more effectively target viruses such as 
HIV-1, which threaten the health and economies of some of the most vulnerable 
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Name Sequence Vector Gene Restriction 
Site 
Opp24 GATCGGATCCATGTACTCGGGAGCCGG pCMV4.HA Ago2 BamH1 (3’) 
 
Opp25 GATCTCTAGAAGCAAAGTACATGGTGC pCMV4.HA Ago2 Xba1 (5’) 
 










































 DDX6-A (3’) 
Opp91 CCGCTCTTGCCTGTTCCATTGGCTGCTG
CAGCTAAGATATCCCTACCAG 
 DDX6-A (5’) 
Opp92 GATCTGTTTACCCGAGCAATTGATATAC
AAGC 
 DDX6-B (3’) 
Opp93 GCTTGTATATCAATTGCTCGGGTAAACA
GATC 
 DDX6-B (5’) 
Opp135 GATCAAGCTTACCATGGCTCTGTTAACA
GCCG 
pCMV4.HA A3H HindIII (3’) 
Opp136 GATCTCTAGACTGCTTTATCCTCTCAAG 
 











pNG72 A3G Xho1 (5’) 
Opp190 GATCCCTATCTCCATCGTATTGGACAAT
CAGGT CGCTTTGGTCATCTTG 
 DDX6-C (3’) 
Opp191 GATCCAAGATGACCAAAGCGACCTGATT
GTCCAAT ACGATGGAGATAGG  


















pCMS309 Vif EcoR1 (5’) 
Opp201 GATCCACATGGAAAAGATTAGTATAATA
GCATATGTTATTTCAAGG 
NL43 Δvif  
Opp202 GATCCCTTGAAATATACATATGCTATTA
TACTAATCT TTTCCATGTG 
NL43 Δvif  
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p3xFLAG DDX6 HindIII (3’) 
Opp233 GATCGAATTCATGAAGCCTCACTTCAGA
AAC  
pNG72 A3G EcoR1 (3’) 
     
